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Abstract 
Gram-positive pathogens are responsible for a wide range of global diseases, including 
nosocomial infections. The increasing incidence of antibiotic-resistant strains warrants 
the development of novel therapeutic strategies to combat these organisms. Novel 
potential targets for vaccine development are antigens, which are expressed during 
infection. Identification of in vivo-expressed proteins which are conserved amongst 
several Gram-positive pathogens provides the possibility of producing 
immunotherapeutics to target a range of diseases. Using a direct screening technique, 48 
in vivo-expressed antigen-encoding loci were identified in Streptococcus pyogenes. 
Analysis of these loci along with those identified in screens of Staphylococcus aureus, 
Staphylococcus epidermidis, Streptococcus agalactiae and Streptococcus pneumoniae 
resulted in the identification of 13 families of conserved domains. Three highly 
conserved S. aureus protein domains were selected for analysis, IsdA-c (amino acids 215- 
310), SdrD-n (amino acids 30-200) and ScaB-c (amino acids 156-265). Antibodies 
against these domains were opsonic during infection by S. aureus and S. agalactiae, and 
IsdA C-terminus polypeptide showed promise in protecting against infection by these 
pathogens in a mouse model of septic arthritis. Thus these protein domains may represent 
cross-protective targets for vaccine development. 
Also identified during the immunoscreening was a family of ten surface proteins in S. 
aureus and S. epidermidis, named the Staphylococcal conserved antigens (Sca). These 
proteins contain a conserved C-terminal -110 amino acid CHAP (cysteine, histidine- 
dependent amidohydrolases/peptidases) domain. Analysis of the Sca proteins in S. aureus 
identified the whole family as peptidoglycan hydrolases with ligand binding capabilities. 
Functional analysis of ScaD revealed that this enzyme may have a key role in cell 
separation. ScaD was expressed early during exponential growth and overproduction of 
the protein in S. aureus complemented the essentiality of the two-component regulator 
YycG/YycF. Overproduction of ScaD in wild-type S. aureus resulted in defective growth, 
increased resistance to lysis and a disrupted autolytic profile, indicating that unregulated 
expression of this putatively important enzyme may be hazardous to the cell. 
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Introduction 
Chapter 1 
Introduction 
1.1 The Staphylococci 
Consisting of 32 different species, the staphylococci are spherical bacteria approximately 
0.5 - 1.5 µm in diameter, predominantly associated with skin, skin glands and mucous 
membranes. The name Staphylococcus was chosen by the Scottish surgeon Sir Alexander 
Ogdson, and is derived from the Greek words staphyle, meaning bunch of grapes, and 
kbkkos, meaning grain, due to the cellular arrangement of the bacteria. Staphylococcal 
cell division is in more than one plane, hence cells are arranged in grape-like clusters 
(Wilkinson, 1997). This is a distinguishing feature from the closely related streptococci, 
which are slightly ovoid cells dividing in only one plane, resulting in chain formation. 
Staphylococci are facultatively anaerobic, capable of generating energy by respiratory or 
fermentative pathways. They are chemo-organotrophs and are catalase-positive but 
oxidase-negative. Staphylococci are commonly halo-tolerant, with most species able to 
withstand concentrations of up to 1.7M (10% w/v) NaCI (Wilkinson, 1997). The 
staphylococcal genome consists of a single circular chromosome, along with prophages, 
plasmids, transposons and insertion sequences. They are classified within the Bacillus- 
Lactobacillus-Streptococcus cluster, defining Gram-positive bacteria with a low G+C 
content of DNA, ranging from 30-39%. The staphylococci are divided into two major 
groups, the coagulase-positive and coagulase-negative (CoNS) staphylococci, based on 
their ability to clot blood plasma. The most prominent pathogen of the Staphylococcus 
species, and indeed the most studied, is Staphylococcus aureus. 
1.2 Staphylococcus aureus 
S. aureus colonies can be distinguished from those of other staphylococci, e. g. S 
epidermidis by the golden yellow colour, which is a result of carotenoid production, 
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specifically staphyloxanthin, in stationary phase cells. This differs considerably from the 
pale, translucent, white colonies of S. epidermidis. A further distinguishing trait is the 
ability of S. aureus to produce coagulase (Wilkinson, 1997). 
The genome of S. aureus is approximately 2.8 Mb and has a low G+C content. The whole 
genome of S. aureus was originally sequenced from the Japanese-derived methicillin- 
resistant strain N315 and the vancomycin-resistant strain Mu50 (Kuroda et al. 2001). 
There are now several sequenced and annotated strains of S. aureus, including S. aureus 
COL at The Institute for Genomic Research (TIGR) database (www. tigr. org/tdb) and the 
widely used laboratory strain S. aureus NCTC8325 at Oklahoma University 
(www. genome. ou. edu/staph. html). 
1.2.1. S. aureus diseases and infections 
S. aureus is a virulent pathogen and is currently the most common cause of infections in 
hospitalised patients (Archer, 1998). It is a common commensal of humans, inhabiting 
the squamous epithelium of the anterior nares. Approximately 20% of the population are 
colonised with S. aureus, 60% are intermittent carriers and 20% are non-carriers (Foster, 
2004). The organism can be carried asymptomatically on mucous membranes but is only 
transiently carried on the skin. Colonisation provides the pathogen with the opportunity 
to infect skin sites, with the potential to cause serious diseases and conditions. 
Approximately half of all skin infections are caused by S. aureus, including folliculitis, 
mastitis, pyodermas and impetigo. However, most commonly, skin infections result in 
absesses or furuncles (boils) (Tenover and Gaynes, 2000). 
Five stages of infection have been identified in the pathogenesis of S. aureus: 
colonisation, local infection, systematic dissemination and/or sepsis, metastatic infection, 
and toxinosis (Archer, 1998). Infections spread locally (e. g. carbuncle, cellulitis, impetigo 
bullosa, wound infection) or can gain access to the blood. Once in the blood, the bacteria 
are able to spread widely to distant infection sites, causing diseases such as endocarditis, 
osteomyelitis, renal carbuncle and septic arthritis. The success of S. aureus as a pathogen 
2 
Introduction 
and its ability to cause a wide spectrum of diseases can be attributed to an extensive array 
of virulence factors (Chapter 1.3). 
In the UK, 20,000 cases of S. aureus bacteraemia are reported each year and S. aureus is 
the leading potentially lethal cause of hospital-acquired infections (Garcia-Lara et al. 
2005; Archer, 1998). The presence of an indwelling medical device, such as an 
intravascular or urinary catheter, represents a significant risk factor for staphylococcal 
bacteraemia and a high proportion of these infections progress to the more serious 
endocarditis. S. aureus is also a common cause of nosocomial pneumonia, most often 
following the onset of influenza, and it is the most common cause of empyema (infection 
of the pleural space) (Tenover and Gaynes, 2000). Furthermore, S. aureus is the most 
common cause of surgical site infections, largely due to the presence of the bacteria on 
the skin and mucous membranes. 
Staphylococcal osteomyelitis can be either acute, most often occurring in children, or 
chronic, which is more common in adults. Acute osteomyelitis affects the long bones of 
the lower extremity and is treatable with antimicrobial therapy (Tenover and Gaynes, 
2000). In addition, S. aureus is responsible for a range of toxin-mediated diseases, 
including impetigo, food poisoning, toxic shock syndrome (TSS) and scalded skin 
syndrome (SSS). 
1.2.2. Antibiotic resistance in S. aureus 
The prevalence of strains of S. aureus resistant to multiple antibiotics has dramatically 
increased over recent years. Occurrence of resistance first began in the 1940s, soon after 
the introduction of penicillin (Wilson and Cockcroft, 1952). This was due to the 
production of ß-lactamase (penicillinase), a serine protease that hydrolyses ß-lactam rings 
rendering the antibiotic inactive. In 1960, a semi-synthetic penicillinase-resistant ß- 
lactam was developed, methicillin. However, the first clinical isolate of methieillin- 
resistant Staphylococcus aureus (MRSA) was reported in 1961, just a year after the 
introduction of the antibiotic (Jevons, 1961). The mechanism of methicillin resistance 
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involves the acquisition of the mecA gene, which encodes a unique penicillin-binding 
protein PBP2a. PBPs are transpeptidases which catalyse the formation of cross-bridges in 
bacterial cell wall peptidoglycan (Hiramatsu et al. 2001). PBP2a has a low affinity for ß- 
lactam antibiotics, allowing the staphylococci to survive at high concentrations (de 
Lencastre et al. 2007). PBP2a is intrinsically insensitive not only to methicillin, but to all 
ß-lactams developed, including isoxazoyl penicillins (e. g. oxacillin), cephalosporins, 
cefamycins and carbapenems (Foster, 2004). mecA is acquired by S. aureus via 
incorporation of a large genetic element known as the staphylococcal cassette 
chromosome mec (SCCmec), which integrates into the S. aureus chromosome at a 
specific location (attBscc), located near the origin of replication (Hiramatsu et al. 2001). 
One of the last available drugs to which S aureus remained sensitive was the 
glycopeptide vancomycin. However, the first clinical isolate with decreased susceptibility 
to this antibiotic (MIC =8 Vg/nil) was isolated in Japan in 1997 (Hiramatsu et at 1997). 
Several strains with increased vancomycin resistance were also identified in other 
countries, and these strains were designated vancomycin-intermediate S. aureus (VISA), 
with MICs ranging from 8-16 pg/ml. Analysis of 48 VISA isolates revealed a common 
thickening of the cell wall and it was proposed that this resulted in the trapping of 
vancomycin molecules, preventing them from reaching the cytoplasmic membrane where 
the functional targets of the antibiotic are located (Cui et at 2003). In June 2002, a high- 
level vancomycin-resistant S. aureus (VRSA) strain was isolated, with an MIC of 1024 
pg/ml (Chang et at 2003). Analysis of this isolate identified an in vivo, interspecies 
transfer of the vanA operon from vancomycin-resistant E. faecalis (VRE) to a multi- 
resistance conjugative plasmid in an MRSA, resulting in the formation of cell wall 
precursors to which vancomycin cannot bind (Weigel et at 2003). 
MRSA strains were primarily associated with hospital-acquired infections, however, the 
emergence of highly invasive staphylococcal strains occurred in the USA in 1999 when 
four fatal community-based MRSA infections in children were reported (Lowy, 2007). 
Further outbreaks of community-associated MRSA (CA-MRSA) were seen in patients 
without any of the usual hospital-associated risk factors. Initially, these CA-MRSA 
4 
Introduction 
strains showed diverse genetic backgrounds, however, unique clonal lineages emerged, 
often carrying the genetic determinant of the PVL toxin (Chapter 1.4.2), which may make 
effective chemotherapy more complex (de Lencastre et al. 2007). 
13 Virulence factors of S. aureus 
The success of S. aureus as a pathogen and its ability to cause a wide range of diseases 
can be attributed to its extensive array of virulence determinants, some of which are 
summarised in Figure 1.1 and Table I. I. These include surface proteins, toxins and 
exoenzymes, which are coordinately regulated to be expressed when needed during 
infection. These virulence factors promote the key stages of infection: 1) attachment of 
bacteria to host cells or extracellular matrices; 2) evasion of host defences; 3) invasion 
and spread of bacteria to new sites. A hypothetical model of the coordinated expression 
of virulence factors is shown in Figure 1.2. Surface proteins are primarily produced 
during the exponential phase of growth, allowing the attachment of infecting bacteria 
during the initial stages of infection. Extracellular toxins and exoenzymes are produced 
during the post-exponential (PXP) phase due to crowding, allowing bacteria to spread to 
new sites during stationary (STA) phase to repeat the cycle (Projan and Novick, 1997). 
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Figure 1.1: Virulence factors of S. aureus. Virulence factors are labelled in black, host 
components are labelled in pink. Adapted from Nizet (personal communication). 
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Virulence Factor Gene Growth phase of expression 
Attachment 
Clumping factors A, B cl A, cl Exponential 
Fibronectin-binding roteins A, B fnbA, fnbB Exponential 
Collagen-binding protein can Post-exponential 
Coagulase ca Exponential 
Host defence evasion 
Enterotoxin A sea Constitutive 
Enterotoxins A, B, C1-3, D, E, H seb-h Post-exponential 
Toxic shock syndrome toxin-I Ist Post-exponential 
Exfoliative toxins A, B eta, etb Post-exponential 
Protein A sp a Exponential 
V8 protease sspA Post-exponential 
Fatty acid modifying enzyme FAME me Post-exponential 
Panton-Valentine leukocidin lukS-PV Post-exponential 
Capsular polysaccharide types 1,5,8 cap], 5,8 Post-exponential 
Sta h lokinase sak Post-exponential 
CHIPS ch Exponential 
SCIN scn Exponential 
Invasion / tissue penetration 
a-toxin hla Post-exponential 
-haemolysin hlb Post-exponential 
y-haemolysin hlgA-C Post-exponential 
S-haemol sin hld Exponential 
Aureolysin (metal lo rotease our Post-exponential 
Cysteine protease sspB Post-exponential 
Sta ho ain scpA Post-exponential 
Table 1.1: Virulence factors of S. aureus. Adapted from Projan and Novick (1997). 
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Figure 1.2: Synthesis of staphylococcal virulence factors in relation to growth. Surface 
proteins are produced during the exponential phase. Extracellular toxins and exoenzymes 
are produced during the post-exponential (PXP) phase due to crowding, allowing bacteria 
to spread to new sites during stationary (STA) phase to repeat the cycle (reproduced from 
Projan and Novick, 1997). 
8 
Introduction 
1.3.1. Adhesins 
Attachment of staphylococci to host cells is essential for colonisation and subsequent 
dissemination. S. aureus expresses an array of adhesins which promote the attachment of 
bacteria to extracellular matrix components (ECM) of host epithelial and endothelial 
surfaces. Several adhesins are anchored covalently to the bacterial cell wall and are 
termed MSCRAMMs (microbial surface components recognising adhesive matrix 
molecules). These proteins are composed of an N-terminal signal sequence, which is 
cleaved during Sec-dependent secretion across the cytoplasmic membrane, and a 
conserved C-terminal cell wall sorting signal comprising an LPXTG motif followed by a 
hydrophobic stretch of amino acids and a positively charged tail located on the 
cytoplasmic side of the membrane (Roche et al. 2003; Marraffini et al. 2004). The 
enzyme sortase A (SrtA), an extracellular transpeptidase, recognises these surface 
proteins and cleaves them between the threonine and glycine residues of the LPXTG 
motif. This liberates the carboxyl of the threonine to form an amide bond with the amino 
group of the pentaglycine crossbridge, hence the C-terminal end is tethered to the cell 
wall peptidoglycan of the staphylococci (Ton-That et al. 1999). In S. aureus, the surface 
protein becomes linked to lipid II, and this product of the sorting reaction is incorporated 
into the cell wall envelope via the transglycosylation and transpeptidation reactions of 
cell wall biosynthesis (Marraffini et al. 2004). The product can only be released from the 
cell by cleavage by a murolytic enzyme, such as lysostaphin in S. aureus. 
Protein A (Spa) is present in over 90% of S. aureus strains and can interact with several 
host components, including immunoglobulins G, A and E, platelets and von Willebrand 
factor (Fournier and Klier, 2004). The 42 kDa surface protein binds IgG molecules by 
their Fc portion or, alternatively, it can bind the Fab domains (Jansson et al. 1998). 
Protein A is suggested to have a role as a virulence factor and studies in animal models 
have shown that spa mutants caused less severe infections than wild-type strains 
(Palmqvist et al. 2002). It is predicted that the binding of protein A to IgG antibodies is 
involved in the evasion of the immune response, possibly by preventing opsonisation 
(Projan and Novick, 1997), and protein A competes with phagocytic cells for IgG-Fc 
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sites, hence reducing IgG-mediated opsonisation (Hartleib et al. 2000). In addition, the 
binding of the Fab domain induces the activation of B cells, conferring superantigenicity 
to protein A. 
S. aureus expresses two closely-related fibronectin (Fn)-binding proteins, FnBPA and 
FnBPB (Foster and Höök, 1998), encoded by the genes fnbA and fnbB. It has been 
suggested that these two genes, separated by 682 bp, probably arose by gene duplication 
(Greene et al. 1995). Fibronectin plays an essential role in S. aureus infections of both 
implanted devices and human infections and the FnBP proteins were identified as 
sufficient for binding and invasion of host cells by S. aureus (Sinha et al. 2000). 
Furthermore, interactions between fibronectin and Fn-binding proteins have been 
implicated in the invasion of non-professional phagocytes (Joh et al. 1999). Studies with 
sera from convalescent patients has shown that antibodies against the FnBPs do not block 
fibronectin binding (Casolini et al. 1998), suggesting that the immune response against 
these virulence factors in S. aureus only produces antibodies that recognise FnBPs after 
they have bound to their ligand, hence, bacterial adhesion is not blocked. 
The Sdr family of proteins comprises six proteins characterised by the presence of a 
domain containing Ser-Asp dipeptide repeats (Josefsson et al. 1998; Clarke et al. 2006). 
CIfA and C1fB, two structurally similar fibrinogen-binding proteins, are both associated 
with virulence. C1fA is an important virulence factor in infective endocarditis and 
staphylococcal arthritis (O'Brien et al. 2002) and has been demonstrated to inhibit 
phagocytosis (Higgins et al. 2006). CUB has been suggested to contribute to the 
pathogenicity of biomaterial-related infections by promoting adherence to immobilised 
fibrinogen (Ni Eidhin et al. 1998) and, along with C1fA, mediates the binding and 
activation of platelets (O'Brien et al. 2002). SdrC, SdrD and SdrE have a similar 
structural organisation to CIfA and C1fB. sdrC is present in all strains of S. aureus and 
SdrD is associated with bone infections, osteomyelitis and methicillin resistance 
(Labandeira-Rey et al. 2007). 
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Collagenous proteins constitute a major component of the ECM and adherence to these 
ligands is mediated by the collagen-binding adhesin Cna. Although Cna has been shown 
to be a virulence factor in an experimental model of septic arthritis (Xu et al. 2004), 
vaccination of mice with a DNA vaccine encoding Cna did not protect against intra- 
peritoneal infection by S. aureus, despite inducing a strong antibody response (Therrien 
et al. 2007). 
The iron-regulated surface determinant (Isd) proteins are a family of proteins in S. aureus 
which are involved in iron transport. IsdA is able to bind transferrin and is regulated by 
exogenous iron levels via the Fur protein, only being expressed under iron-limited 
conditions (Clarke et al. 2004). In addition to binding transferrin, IsdA is a broad 
spectrum adhesin able to bind both fibrinogen and fibronectin via a NEAT domain. IsdA 
contributes significantly to virulence of S. aureus and recently, it has been shown that 
IsdA binds lactoferrin, an anti-staphylococcal polypeptide found in human nasal 
secretions, hence increasing resistance of S. aureus to its killing (Clarke and Foster, 
2008). IsdA is also required for nasal colonisation and confers resistance to antimicrobial 
peptides found on the skin (Clarke et al. 2006; 2007). 
In addition to the covalently anchored adhesins, S. aureus also expresses several adhesins 
which are ionically associated with the cell wall, known as SERAMs (secretable 
expanded repertoire adhesive molecules) (Chavakis et al. 2005). Emp (extracellular 
matrix protein-binding protein) is expressed during stationary growth and binds to several 
host extracellular matrix molecules, including fibronectin, fibrinogen, collagen and 
vitronectin (Hussain et al. 2001). Eap (extracellular adherence protein) can bind several 
plasma proteins, including fibronectin, fibrinogen and prothrombin. This adhesin causes 
agglutination of S. aureus cells and significantly enhances bacterial adherence and 
internalisation into eukaryotic cells (Haggar et al. 2003). Ebh (ECM-binding protein 
homologue) binds fibronectin and may be involved in adhesion to endothelial cells (Sinha 
and Herrmann, 2005). Notably, the presence of anti-Ebh antibodies in the serum of S. 
aureus-infected patients indicates that this protein is expressed during infection (Clarke et 
al. 2002). Efb (extracellular-fibrinogen binding protein) was shown to be important for 
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pathogenesis in a rat wound model and antibodies against this adhesin protected against 
infection in a mouse mastitis model (Palma et al. 2001). 
S. aureus capsular polysaccharides, representing 11 serologically distinct capsule types, 
have been identified in more than 90% of clinical isolates, and serotype 5 and 8 strains 
are the most predominant (Thakker et al. 1998; Watts et al. 2005). Although the role of 
these polysaccharides remains unclear, it has been demonstrated that optimal expression 
of capsule enhances bacterial virulence by increasing resistance to phagocytic killing by 
leukocytes (Thakker et al. 1998; Luong and Lee, 2002; Kampen et al. 2005). 
The surface polysaccharide PNAG (poly-(1,6)-N-acetylglucosamine), also known as 
polysaccharide-adhesin (PS/A) and polysaccharide intercellular adhesin (PIA), promotes 
adhesion of bacteria and is implicated in biofilm formation (Projan and Novick, 1997; 
Maira-Liträn et al. 2002). Deletion of the intercellular adhesin (ica) locus, which encodes 
the biosynthetic enzymes for PNAG production, resulted in strains with decreased 
virulence in murine models and increased susceptibility to antibody-independent opsonic 
killing (Kropec et al. 2005). 
1.3.2. Toxins and invasins 
In order to allow dissemination of infection, a pathogen must be able to invade host 
tissues and virulence factors involved in this process in S. aureus include cytolytic toxins, 
exfoliative toxins, TSST-1 and staphylococcal enterotoxins. 
Haemolysins are cytotoxic agents which have a role in the invasion of bacteria during 
infection. One of the most well-studied members of this group is a-toxin (a-haemolysin), 
a pore-forming toxin encoded by the gene hla (Rohach and Foster, 2000). This 293 
residue monomer is secreted extracellularly by S. aureus and binds to the host membrane, 
oligomerising to form a ring-shaped pore. The toxin can lyse red blood cells in this 
manner, as well as mononuclear immune cells, epithelial and endothelial cells, and 
platelets. Death of these cells is attributed to disrupted osmoregulation, the influx and 
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efflux of cations and cell apoptosis. Several studies have shown that a-toxin acts as a 
virulence factor, as h1 strains were significantly less virulent in experimental infections 
of keratitis, mastitis and peritonitis (Projan and Novick, 1997; Bayer et al. 1997). 
However, Bayer et al. (1997) also found that hyperproduction of a-toxin by S aureus, as 
well as non-production of the toxin, resulted in reduced virulence in a model of 
endocarditis. 
ß-haemolysin is an enzyme that acts as a sphingomyelinase, encoded by the gene hlb. 
The action of ß-haemolysin is antagonistic to that of a-toxin because ß-haemolysin 
disrupts the membranes of erythrocytes, hence a-toxin cannot attach and multimerise 
(Projan and Novick, 1997). 6-haemolysin, a 26 residue peptide, has surfactant-like 
properties and is lytic towards many types of membranes, forming channels. Therefore, 
this toxin may be cytotoxic to tissues and may have an adverse effect on leukocytes 
(Bohach and Foster, 2000). 6-haemolysin has been observed to enhance the action of ß- 
haemolysin, increasing its haemolytic properties (Projan and Novick, 1997). However, 
the specific role of this toxin in virulence is yet to be established. 
S. aureus can produce four antigenically distinct exfoliative toxins, known as ETA, ETB, 
ETC and ETD (Ladhani, 2003). These toxins are responsible for a range of diseases, 
including localised blisters, extensive exfoliation and staphylococcal scalded skin 
syndrome (SSSS). ETA and ETB, predominant in Europe/USA and Japan respectively, 
are responsible for most human cases of SSSS. They are able to target and destroy 
specific proteins of the host epidermis. It has been suggested that ETD may play a wider 
role in staphylococcal infections as it is not strongly associated with SSSS. This protein 
may be important in allowing the organism to spread and invade local tissue (Ladhani, 
2003). The role of exfoliative toxins as superantigens remains controversial. A study by 
Plano et al. (2000) concluded that the proteins did not exhibit superantigenic activity, but 
this conclusion is disputed elsewhere (Ladhani, 2003). Furthermore, exfoliative toxins 
have been shown to possess serine protease activity and share 25% homology with 
staphylococcal V8 protease (Chapter 1.3.3). 
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S. aureus produces several extracellular proteins with superantigenic properties, 
including enterotoxins and toxic shock syndrome toxin 1 (TSST-1). These are known as 
the pyrogenic toxin superantigens (PTSAgs). These superantigens directly cross-link 
certain T-cell receptor domains on major histocompatibility complex class 11 (MHC 11) 
proteins, activating specific subsets of T cells (Holtfreter et al. 2004). This results in the 
proliferation of T cells and the release of cytokines and lymphokines, for example, 
tumour necrosis factor (TNF), interleukins and interferon-y (Projan and Novick, 1997). 
This large systemic release of cytokines can lead to symptoms of toxic shock syndrome. 
Seventeen staphylococcal enterotoxins (SEs) have been identified, encoded on mobile 
genetic elements. These toxins are known as SEs A-E and G-Q, and are recognised to 
cause staphylococcal food poisoning syndrome (Akineden et al. 2001). Loss of 
superantigen activity, for example due to a genetic mutation, also results in loss of 
enterotoxic activity, confirming the correlation of these two factors (Balaban and 
Rasooly, 2000). Nearly all clinical isolates of S. aureus contain enterotoxin genes, with 
extensive variation occurring between strains (Holtfreter et al. 2004). In general, S 
aureus isolates have several of these genes, most often five. Furthermore, a correlation 
exists between the presence of enterotoxin genes in S. aureus and the ability of the 
organism to elicit T cell proliferation, substantiating the superantigenicity of these 
proteins and their roles as virulence factors involved in evading the host immune 
response. However, it has been proposed that the amounts and spectrum of superantigens 
secreted may differ between S. aureus carriage and S. aureus infection. Importantly, 
antibodies which neutralise these superantigens are highly specific and this lack of cross- 
inhibition is an important consideration in the design of superantigen vaccines (Holtfreter 
et al. 2004). 
S. aureus expresses a bi-component pore-forming exotoxin that specifically acts on 
polymorphonuclear leukocytes, disrupting phagocytosis, an important defence against 
bacterial infection (Bohach and Foster, 2000). This toxin is known as Panton-Valentine 
leukocidin (PVL) and is encoded by the Iuk-PV locus, requiring assembly of two 
polypeptdies, LukS-PV and LukF-PV, into a heterooligomeric pore (Labandeira-Rey et 
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al. 2007). Presence of PVL has been strongly associated with strains of community- 
associated methicillin-resistant S. aureus (CA-MRSA), although it was established that 
the toxin was not the major determinant of disease caused by these strains (Voyich et al. 
2006). However, expression of the luk-PV operon results in altered regulation of cell 
wall-anchored and secreted protein production, including upregulation of both SdrD and 
protein A (Spa) (Chapter 1.4.1), which may enhance tissue adherence and colonisation, 
thereby contributing to the virulence of PVL-positive strains (Labandeira-Rey et al. 
2007). 
13.3. Other extracellular enzymes 
S. aureus expresses several extracellular proteases, which are predicted to act as virulence 
factors by several mechanisms, e. g. inactivation of antimicrobial peptides, cleavage of 
human IgG molecules and allowing dissemination of bacteria by tissue destruction (Reed 
et at. 2001). The serine protease V8 protease, also known as SspA, can cleave and 
inactivate IgG antibodies and it has been proposed that it functions, along with other 
proteases, to block the action of these antibodies (Projan and Novick, 1997). sspA is 
transcribed in an operon along with sspB, a cysteine protease, and sspC, which encodes 
staphostatin B (Rice et al. 2001; Shaw et al. 2005). S. aureus also expresses a cysteine 
protease called staphopain (ScpA) and a metalloprotease called aureolysin (Aur) 
(Arvidson, 2000). SspA is required for proteolytic maturation of SspB and is itself 
activated by Aur (Shaw et al. 2004). The temporal coordination of expression of these 
proteases through the quorum-sensing system agr is believed to enable S. aureus to 
switch from the expression of adhesive molecules to the expression of extracellular toxins 
and enzymes that damage host tissues and the immune system, allowing dissemination of 
infection (Shaw et al. 2005). This change from an adhesive to invasive phenotype 
requires the degradation of adhesins post-exponentially, which is contributed to by these 
proteases (McGavin et al. 1997; Shaw et al. 2004). Indeed, a S. aureus strain lacking 
SspA was severely attenuated in virulence in mouse abscess, bacteraemia and wound 
infection models, highlighting the contribution of this serine protease to bacterial 
pathogenesis (Coulter et al. 1998). 
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Staphylokinase (Sak) is a 136 amino acid serine protease-like molecule produced by S. 
aureus. It is a plasminogen activator, converting the precursor plasminogen to the 
fibrinolytic protease plasmin, which degrades proteins of the extracellular matrix. It has 
been demonstrated that staphylokinase interacts with a-defensins, almost completely 
inhibiting their bactericidal effects (Jin et al. 2004). Staphylokinase induces the secretion 
of these defensins from polymorphonuclear cells and complex binds them, neutralising 
their effects. This represents a mechanism by which S. aureus evades killing by the host 
innate immune system. The majority of staphylococci isolated from the nasal mucosa 
produce staphylokinase, further supporting the suggestion that the production of this 
surface protein increases bacterial survival in the host. In addition, it has been suggested 
that staphylokinase may enable S. aureus to bind host plasminogen via cell surface 
receptors, hence, promoting bacterial invasion (Jin et al. 2004). 
S. aureus, along with most other strains of staphylococci of human origin, produce 
lipases. In response to bacterial infection, the host produces a variety of fatty acids and 
lipid molecules, which act as surfactants to disrupt the bacterial membrane. The lipases 
produced by S. aureus have been shown to have a negative effect on the immune system 
(Projan and Novick, 1997). Furthermore, an enzyme produced by S. aureus, fatty acid 
metabolising enzyme (FAME), is proposed to detoxify bactericidal fatty acids at the site 
of an infection. 
Chemotaxis inhibitory protein of staphylococci (CHIPS) and Staphylococcal complement 
inhibitor (SCIN) are small, excreted molecules that play a crucial role in the defence 
against the innate immune system (Rooijakkers et ai. 2006). CHIPS is a 14 kDa protein 
produced by 65% of clinical S. aureus strains which blocks neutrophil chemotaxis by 
binding neutrophil receptors (De Haas et al. 2004). SCIN is a 10 kDa protein that inhibits 
the central complement convertases, reducing opsonisation and subsequent phagocytosis 
(Rooijakkers et al. 2005; 2007). SCIN and CHIPS are produced early during exponential 
growth, allowing efficient modulation of the early immune response to infection. 
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1.4 The Streptococci 
Streptococci are round/ovoid cocci, 0.6 - 1.0 µm in diameter. These bacteria divide in 
one plane, hence occur in pairs or chains. Streptococci are fermentative and, similar to 
the staphylococci, are facultative anaerobes. They are catalase-negative and oxidase 
positive. The streptococci are classified according to the Lancefield serological grouping 
system, based on immunological differences in cell wall polysaccharides (A, B, C, F, G) 
and lipoteichoic acids (D) (Cunningham, 2000). 
1.5 Streptococcus pyogenes 
Streptococcus pyogenes is a group A streptococcus (GAS) and is a frequent pathogen of 
humans. The major reservoir of S. pyogenes is the human oral-nasal mucosa and it has 
been estimated that 5-15% of individuals carry the bacterium as part of the normal flora 
of the respiratory tract with no symptoms of disease (Cue et al. 2000). The genome of S. 
pyogenes is approximately 1.89 Mb and over 150 M-protein (Chapter 1.6.1) genotypes 
exist (Park and Cleary, 2005). 
1.5.1. S. pyogenes diseases and infections 
Acute S. pyogenes diseases primarily occur in the respiratory tract or on the skin, and 
generally, isolates from the former do not infect the latter. The most common disease 
caused by S. pyogenes infection is pharyngitis, however, there has been a recent increase 
in systemic S. pyogenes disease worldwide (Cue et al. 2000). Streptococcal pharyngitis, 
commonly known as "strep throat", is treatable using ß-lactam antibiotics. However, if 
left untreated this condition can lead to rheumatic fever and possible heart disease. 
As mentioned in Chapter 1.2.1, impetigo, a localised infection of the skin, can be caused 
by infection with S. aureus. However, this condition is also a consequence of S. pyogenes 
infection. In its severe form, this can lead to the acute invasive disease, necrotising 
fasciitis, leading to the labelling of S. pyogenes as "flesh-eating bacteria". Other invasive, 
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toxigenic infections caused by this pathogen are myositis and streptococcal toxic shock 
syndrome (TSS). Streptococcal TSS involves bacteraemia, shock and, in approximately 
30% of cases, death (Fischetti, 2000b). 
Puerperal fever, sepsis occurring after childbirth, and scarlet fever, a disease of 
childhood, were formerly diseases of S. pyogenes which claimed many lives. Now, due to 
antibiotic therapy, these conditions are rare. Studies have shown that S. pyogenes 
infections are significantly more common in children compared to adults, suggesting 
multiple infections during childhood results in the development of protective antibodies 
(Cunningham, 2000). 
1.5.2. Antibiotic resistance in S. pyogenes 
Penicillin and related ß-lactam antibiotics are the primary choice for the treatment of 
infections by S. pyogenes and currently, no resistance to penicillin has developed despite 
several years of exposure to this antibiotic (Albrich et al. 2004; Robinson et al. 2006). 
Patients with hypersensitivity to ß-lactam antibiotics are generally treated with 
macrolides, including erythromycin and clindamycin, and macrolide-resistant GAS 
(MRGAS) is increasingly being recognised as a problem in many parts of the world 
(Robinson et al. 2006). Macrolides such as erythromycin inhibit protein synthesis by 
binding to 23S rRNA of the 50S bacterial ribsome subunit (Richter et al. 2008) and most 
of the resistance to these antibiotics occurs via one of two mechanisms. Macrolide efflux 
(M phenotype) by MefA results in resistance to 14- and 15-membered ring macrolides 
but not 16-membered ring macrolides, lincosamides and streptogramin B (MLSa). 
Resistance may also be due to methylation of the ribosomal drug binding site by 
methylases encoded by ermA or ermB, resulting in resistance to all MLS8 antibiotics 
(Desjardins et al. 2004; Richter et al. 2008). These three major resistance genes (R genes) 
found in S. pyogenes are associated with mobile genetic elements and were acquired via 
horizontal gene transfer (Robinson et al. 2006). A study by Desjardins et al. (2004) 
identified the efflux (mefA) as the more common mechanism of resistance, particularly in 
pediatric GAS isolates (72% of isolates). 
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An almost linear association was identified between use of macrolide antibiotics and 
resistance in S. pneumoniae, and although weaker, a similar significant correlation was 
observed for macrolide-resistant S. pyogenes (Albrich et al. 2004). Erythromycin 
resistance was identified in 6% of adult GAS isolates and 10% of pediatric GAS isolates 
in 2004 (Desjardins et al. 2004). In a study in 2007,16% of GAS isolates studied were 
erthromycin-resistant and 27% were resistant to tetracycline (Lloyd et al. 2007). It was 
reported that rates of resistance to macrolides, tetracycline and quinolones were rising, 
most likely due to extensive use of these antibiotics. Indeed, it was suggested that 
macrolides have replaced penicillin in the treatment of S pyogenes infections due to 
favourable pharmacokinetics, despite maintained susceptibility of streptococci to 
penicillin, amoxycillin, cephalosporins and linezolid. 
Emergence of resistance to macrolides led to the development of ketolides, a new class of 
antimicrobials derived from erythromycin, which have a 10-fold greater ribosomal 
binding affinity. However, the first available antibiotic, telithromycin, has variable 
activity against macrolide-resistant S. pyogenes and resistance to this antibiotic amongst 
European strains of S. pyogenes significantly increased from 2002/03 to 2004/05 (Richter 
et al. 2008). 
1.6 Virulence factors of S. pyogenes 
Similar to S. aureus (Chapter 1.3), S. pyogenes expresses an array of virulence 
determinants enabling the pathogen to infect and cause disease. A summary of these 
virulence factors is shown in Figure 1.3 and Table 1.2. 
19 
Introduction 
Breakdown 
of NETs Phagocyte lysis 
SLS 
`. 
" SLO 
. ,f 
Sdal 
Chemokine 
degradation 
ScpA (C5a) 
" C 
Interference with 
complement 
deposition 
C3b 
Fibrinogen 
t 
complement 
deposition 
C3b 
C"; BPL_f_(ýº 
M protein 
Group A Streptococcus 
Hyaluronic 
acid 
capsule 
Cloaking of 
opsonins 
M protein 
M-like proteins 
Sfb1 
, 3b Resistance to 
antimicrobial 
peptides 
C3b 
SIC 
M protein 
Protein H 
Stb1 SpeB 
pectin 
N 
Fibrinogen \/0 
_ Albumin i SpeB 
Nonopsonic binding EndoS 
or degradation of 
immunoglobulins 
Figure 1.3: Virulence factors of Group A Streptococcus. Virulence factors are labelled in 
black, host components are labelled in pink. Adapted from Nizet (personal 
communication). 
20 
Introduction 
Virulence Factor Gene Growth phase of expression 
Attachment 
Lipoteichoic acid Ita Exponential 
Protein F s1 Post-exponential 
Host defence evasion 
M proteins emm Exponential 
Streptococcal pyrogenic exotoxins Spe Post-exponential 
Streptococcal su eranti en ssa Post-exponential 
Streptococcal mitogenic exotoxin Z smez Post-exponential 
Sic sic Exponential 
C5a peptidase scpA Exponential 
Invasion / tissue penetration 
Serum opacity factor so Exponential 
_Streptococcal 
pyrogenic exotoxin B speB Post-exponential 
Stre tol sins 0, S slo, sagA Post-exponential 
Enolase eno Post-exponential 
Streptokinase ska Post-exponential 
Table 1.2: Virulence factors of S. pyogenes. Data adapted from Kreikemeyer et al. 
(2003). 
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1.6.1. Adhesins 
The cell surface proteins of S. pyogenes are similar in structure to those of other Gram- 
positive pathogens, including S. aureus (Chapter 1.3.1). S. pyogenes expresses 
MSCRAMMs, constituting a charged C-terminus, followed by a hydrophobic domain and 
a conserved LPXTG motif, which allows covalent linkage to the bacterial peptidoglycan 
via sortase activity. The M proteins of S. pyogenes are a family of cell wall-anchored 
proteins and with more than 100 variants these surface proteins are expressed by all 
isolates of S. pyogenes (Rivera et at. 2007). The proteins, encoded by emm genes, extend 
from the surface as alpha-helical coiled-coil dimers, appearing as fibrils on the bacterial 
surface (Cunningham, 2000). The M proteins represent key virulence factors associated 
with both colonisation and resistance to phagocytosis. They have important roles in 
evading the immune response by conferring resistance to phagocytosis by human 
neutrophils (Fischetti, 1989). This antiphagocytic effect is due to the binding of the M 
protein to factor H and fibrinogen. Factor H is a regulatory component of the complement 
pathway, which inhibits the deposition of soluble C3b, hence reducing opsonisation of 
the bacteria. Binding fibrinogen to the streptococcal surface also blocks activation of 
complement via the alternate pathway, hence the amount of C3b which can bind to S. 
pyogenes cells is greatly reduced. This therefore reduces phagocytosis by 
polymorphonuclear leukocytes (Cunningham, 2000). The M protein family also contains 
proteins that can bind IgG and IgA molecules, including Arp, protein H and Sir, and it is 
likely that these proteins facilitate the evasion of the host defence mechanisms (Stenberg 
et aL 1994). 
Lipoteichoic acid (LTA) is an amphipathic molecule which can bind to a variety of host 
cell types and receptor molecules, including both fibrinogen and fibronectin. The 
negatively charged polyglycerol phosphate backbone of LTA allows it to react with the 
positively charged residues of streptococcal surface proteins (Cunningham, 2000). It has 
been proposed that LTA plays a critical role in the initial, reversible, interactions between 
streptococci and epithelial cells, facilitating the interaction of a second adhesin to result 
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in a high-affinity, host-cell specific attachment (Courtney et al. 1994). This second 
adhesin varies according to the type of host cell or tissue involved in the attachment 
process. 
Protein F (Sfbl) binds Ibronectin at its amino terminal and is expressed by 50-70% of 
clinical isolates of S. pyogenes (Kreikemeyer et al. 2004). It is involved in binding to the 
dermis and Langerhans cells, and it is regulated by a superoxide signal (Cunningham, 
2000). As well as being an adhesin, protein F mediates internalisation of S. pyogenes into 
non-phagocytic cells (Jadoun et al. 1998). 
FBP54 can bind both fibronectin and fibrinogen and is present in all clinical strains tested 
(Courtney et al. 1994; Kawabata et al. 2001). Furthermore, FBP54 was demonstrated to 
be associated with infection as a significantly higher IgG titre against this adhesin was 
observed in patients with S. pyogenes infections compared to healthy volunteers. 
Immunisation with FBP54 elicited protection in mice against lethal S. pyogenes infection, 
indicating a putative role as a vaccine candidate for this streptococcal adhesin. 
SOF (serum opacity factor) is a 112 kDa bi-functional protein which binds fibronectin at 
its C-terminus and contains an N-terminal domain responsible for turning mammalian 
sera opaque by cleaving a serum apolipoprotein (Rivera et at 2007). The sof gene is co- 
transcribed with the gene sJbX, which encodes a second fibronectin-binding protein 
(Oehmcke et at 2004). SOF promotes adherence to and invasion of human HEp-2 
pharyngeal epithelial cells independently of SfbX, and it is the N-terminal domain of 
SOF that is responsible for this function (Timmer et at 2006). Furthermore, SOF has 
been demonstrated to significantly contribute to virulence of S. pyogenes in a murine 
model of necrotising skin infection. 
SpeB (streptococcal exotoxin B), a 40 kDa protein, mediates binding to laminin, a 
glycoprotein expressed on host cells (Hytönen et al. 2001). SpeB does not contain the 
Gram positive peptidoglycan anchoring motif LPXTG, it is suggested that the protein is 
anchored to the bacterial surface via its propeptide moiety. SpeB is controlled by the 
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multiple gene regulator Mga and all strains of S. pyogenes contain the speB gene, 
although expression levels vary. 
1.6.2. Toxins and invasins 
The family of proteins known as the pyrogenic toxin superantigens (PTSAgs) include the 
streptococcal pyrogenic exotoxins (SPEs), streptococcal superantigen (SSA) and 
streptococcal mitogenic exotoxin Z (SMEZ) (Earhart et al. 2000; Proft et al. 2004). These 
proteins have a highly conserved structure and, similar to the staphylococcal enterotoxins 
(Chapter 1.3.2), the PTSAgs have superantigenic properties, eliciting T cell proliferation. 
The PTSAgs induce fever in the host during infection (pyrogenicity) and SPEs enhance 
the susceptibility of the host to lethal endotoxin shock. SpeB (streptococcal pyrogenic 
exotoxin B) is a 28 kDa cysteine protease expressed by all strains of S. pyogenes in 
varying levels. The adhesive function of this protein has been mentioned previously 
(Chapter 1.6.1), however, SpeB also has an enzymatic role, converting the interleukin-lß 
precursor into its active form, an inflammatory cytokine (Cunningham, 2000). Moreover, 
it is thought that SpeB enhances internalisation of S. pyogenes by epithelial and 
endothelial cells, hence may have a pathogenic role in bacterial invasion. As well as 
promoting dissemination of infecting bacteria, it has also been suggested that this 
cysteine protease promotes phagocytic resistance and hence may also play a role in 
evasion of the host response (Voyich et al. 2004). Immunisation of mice with SpeB has 
been shown to confer protection against infection by S pyogenes and inactivation of the 
protein significantly decreases lethality (Hytönen et al. 2001). 
S. pyogenes can express two cytolysins, streptolysin 0 (SLO) and streptolysin S (SLS). 
SLO is a thiol-activated, cholesterol-binding protein and can act as a leukocidin, forming 
pores in the cell membranes of phagocytes, effectively destroying this immune response 
(Billington et al. 2000). Streptolysin 0 is also capable of interfering with other aspects of 
the host immune reaction, for example, immune cell chemotaxis, respiratory burst and 
lymphocytes. This interference, particularly during the early stages of infection, can 
prevent clearance of the invading bacteria, allowing them to invade and proliferate. 
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Furthermore, it has been suggested that streptolysin 0 may play a role in the regulation of 
bacterial invasion (Coye and Collins, 2004). This protein can induce the expression of 
cytokines, which may promote bacterial infection. 
Streptolysin S (SLS) is a ß-haemolysin, able to lyse erythrocytes. A study by Nizet et al. 
(2000) identified a nine-gene operon responsible for the production of SLS and found 
sequence homologies with the bacteriocin class of antimicrobial peptides. Streptolysin S 
can damage cell membranes of lymphocytes, neutrophils and platelets, and has been 
demonstrated to be a virulence determinant of S. pyogenes in an animal model of necrotic 
skin infection. 
C5a peptidase is a proteolytic enzyme, encoded by the gene scpA, which is anchored to 
the surface of S. pyogenes. This 130 kDa endopeptidase contributes to streptococcal 
invasion by inhibiting the recruitment of polymorphonuclear leukocytes at the infection 
site. C5a peptidase cleaves the complement-derived chemotaxin C5a, which enhances the 
chemotaxis of phagocytes (Voyich et at. 2004). Therefore, phagocytosis is significantly 
inhibited. 
S. pyogenes expresses several DNases, including Sdal. This contributes to virulence by 
allowing the organism to escape killing by neutrophil extracellular traps (NETs), which 
are composed of DNA and contain chromatin and neutrophil granule components, and act 
to capture and kill surrounding bacteria independent of phagocytic uptake (Sumby et al. 
2005; Buchanan et al. 2006). Sdal has been shown to promote virulence in a murine 
model of GAS nectrotising fasciitis and to be necessary and sufficient for effective 
degradation of NETs (Buchanan et at. 2006). 
The 31 kDa protein Sic is secreted by most serotype M1 strains of S. pyogenes. This 
protein disrupts phagocytosis by altering normal polymorphonuclear leukocyte (PMN) 
cytoskeleton function (Voyich et al. 2004). Furthermore, Sic inactivates antibacterial 
peptides, including lysozyme and defensins. 
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S. pyogenes contains a capsule composed of a hyaluronic acid polymer, made up of 
repeating units of glucuronic acid and N-acetylglucosamine (Cunningham, 2000). This 
capsule plays a role in evading opsonisation and hence phagocytosis. The mechanism of 
resistance to phagocytosis may be due to the barrier created by the capsule, preventing 
phagocytes from accessing opsonic complement proteins bound to the streptococcal 
surface. 
S. pyogenes can bind plasmin(ogen) to cell surface receptor proteins and this is thought to 
enhance bacterial invasion by activating extracellular matrix metalloproteases or 
collagenases (Cunningham, 2000). These plasminogen-binding proteins include 
glyceraldehyde-3-phosphate dehydrogenase (Plr), enolase and streptokinase. 
1.7 Regulation of bacterial virulence 
Most virulence factors are accessory genes, i. e. they are not essential for growth under all 
conditions. These accessory genes are often coordinately regulated so that they are only 
expressed when needed. Global regulators allow the control of expression of unlinked 
genes by a single regulatory determinant, enabling a pathogen to rapidly adapt to 
changing environments encountered during infection in order to maximise its virulence. 
1.7.1. Regulation of S. aureus virulence determinants 
The expression of virulence factors in S. aureus is regulated by several interacting 
regulators. The Agr (accessory gene regulator) two-component signal transduction 
system is composed of four structural genes, agrB, agrD, agrC and agrA, but is 
composed of two divergent transcripts, RNAII and RNAIII, which are under the control 
of promoters P2 and P3, respectively (Figure 1.4). agrB encodes a membrane-associated 
protease which modifies the prepropeptide of AgrD and generates small signal molecules. 
These signal molecules are recognised by the sensor kinase AgrC which subsequently 
activates the response regulator AgrA. AgrA upregulates production of the effector 
molecule RNAIII, which alters expression of a range of virulence factors in S. aureus, 
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both at the transcriptional and translational levels (Bronner et al. 2004). The Agr two- 
component system upregulates transcription of toxin genes whilst repressing synthesis of 
cell wall proteins, postexponentially. Transcription profiling demonstrated that mutation 
of agr lead to the altered expression of 138 genes in S. aureus, 104 of which were 
upregulated and 34 of which were downregulated (Dunman et al. 2001). Examples of 
these genes are shown in Table 1.3. 
SarA (staphylococcal accessory regulator) is a 14.5 kDa DNA-binding protein encoded 
by three overlapping transcripts, driven by three distinct promoters, P1, P3 and P2 
(Cheung et al. 2008). SarA promotes synthesis of fibronectin and fibrinogen-binding 
proteins for adhesion and toxins for tissue spread, whilst repressing expression of protein 
A and proteases. Upregulation of a, ß and 8-toxin expression also occurs indirectly via 
upregulation of agr by sarA. Transcription profiling demonstrated that mutation of sarA 
lead to the altered expression of around 120 genes in S. aureus, 76 of which were 
upregulated and 44 of which were downregulated (Dunman et al. 2001). Examples of 
these genes are shown in Table 1.4. 
SarA is a member of a family of regulatory proteins involved in the control of virulence 
genes, including the homologues SarR, SarS, SarT, SarU and Rot. It is suggested that all 
members of the SarA family bind target DNA by a similar mechanism, that is with the 
helix-turn-helix binding to the major groove of the DNA and the winged region 
interacting with the minor groove (Liu et al. 2006). SarR is involved in the regulation of 
sarA expression, and is expressed maximally during the post-exponential growth phase, 
leading to downregulation of sarA during late exponential to the stationary phases of 
growth. SarS promotes transcription of protein A and represses expression of a-toxin, 
and expression of sarS is repressed by both sarA and agr (Bronner et al. 2004). SarT 
represses a-haemolysin expression as well as expression of sarU, which is involved in 
regulation of RNAII and RNAIII from the agr locus and agr-target genes. Down- 
regulation of SarU by SarT results in repression of RNAIII, which in turn is also able to 
repress expression of sarT. This therefore constitutes a feedback loop, which may 
represent an alternative pathway for virulence gene regulation in vivo to that of agr 
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(Bronner et al. 2004). Originally named "repressor of toxin", the regulatory protein Rot 
in fact positively regulates 86 genes and negatively regulates 60 genes (Said-Salim et al. 
2003). Rot generally has opposite effects on gene expression to agr, for example, Rot 
upregulates expression of protein A and the serine proteases SspB and SspC (down- 
regulated by agr) and down-regulates a-toxin and y-haemolysin, which are upregulated 
by agr. 
In addition to Agr and SarA, S. aureus contains several other regulatory systems. The 
two-component system SaeRS (S. aureus exoprotein expression) activates the expression 
of several virulence factors, including serine protease SspA, coagulase, a-haemolysin, ß- 
haemolysin, Eap, Emp, protein A and FnbA (Rogasch et al. 2006). The sae locus consists 
of saeR which encodes the response regulator and saeS which encodes the sensor 
histidine kinase and SaeRS regulates gene expression primarily at the transcriptional 
level (Giraudo et al. 1997). SaeRS plays an important role in virulence during infection, 
inactivation of this regulatory system attenuated virulence in a murine infection model, as 
well as eliminating adhesion and internalisation of bacteria into lung epithelial cells 
(Liang et al. 2006). 
Other two-component systems also regulate virulence factor expression, such as ar1RS 
(autolysis-related locus) which is transcribed from exponential to post-exponential 
growth phase and consists of the response regulator Ar1R and sensor protein Ar1S 
(Bronner et al. 2004). In addition to the control of the potentially destructive autolysins, 
Ar1RS also regulates expression of Ser-Asp-rich bone sialoprotein-binding proteins, 
cysteine protease, serine protease, protein A, ß-haemolysin and leukotoxins (Liang et al. 
2005). The srrAB (staphylococcal respiratory response) system is involved in adaptation 
to anaerobic growth of S. aureus, a common feature during infection, and is involved in 
the regulation of toxic shock syndrome toxin I (ISST-1) and protein A (Yarwood et al. 
2001). 
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Figure 1.4: The agr two-component system in S. aureus. Autoinducing peptide (AIP) 
accumulates extracellularly and activates the agr system. The histidine kinase (AgrC) [1] 
recognises the signal, followed by histidine phosphorylation [2] and phosphotransfer to 
the response regulator (AgrA) [3], which then binds to the RNAIII transcript that encodes 
a small RNA that functions to modulate gene expression [4]. Reproduced from Cegelski 
et al. (2008). 
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Protein Name Gene Regulation 
(type 5) Capsular polysaccharide ca p5 + _ Capsular polysaccharide (type 8) ca p8 + 
Protein A spa - 
Fibronectin binding proteins bA, fn - 
a-toxin hla + 
-toxin hlb + 
S-toxin hld + 
-toxin 
hlgA, hlgCB + 
Panton-Valentine Leukocidin luk-PV + 
LukE-LukD lukED + 
ISST-1 Ist + 
Enterotoxins B, C, D seb, sec, sed + 
Exfoliatin A and B eta, etb + 
V8 serine protease sspA + 
Proteases SIpA, B, C, D, E, F sl A, sl B, sl pC, slpD, sl E, sl F + 
Table 1.3: Examples of agr-regulated genes. Reproduced from Bronner et al. (2004). 
Protein Name Gene Regulation 
Capsular polysaccharide (type $ ca P8 + 
Protein A spa - 
Fibronectin-binding proteins nbA, nbB + 
Collagen adhesin cna - 
AgrA, B, C, D a A, a B, a C, a rD + 
RNAIII + 
a-toxin hla + 
8-toxin hld + 
-toxin hlgA, hlgCB + 
Panton-Valentine Leukocidin 1v + 
LukE-LukD lukED + 
TSST-1 tst + 
Enterotoxin B seb + 
V8 serine protease sspA - 
Table 1.4: Examples of sarA-regulated genes. Reproduced from IIronner et at (2004). 
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In addition to the two-component systems and SarA homologues, S. aureus also 
possesses an alternative sigma factor, aB, a regulator of a wide range of virulence genes, 
including coa, sarA, fnbA, cifA, sspA, h1a and seb (Shaw et al. 2006). The regulation of 
aB activity is modulated by the gene products of rsbU, rsbV and rsbW. RsbW acts as an 
anti-sigma factor by binding aB to form a RsbW-ßH complex, however, RsbV competes 
with aB to bind RsbW, releasing active 6B (Bronner et al. 2004). Many laboratory strains 
of S. aureus, including the 8325-4 lineage, contain deletions in the rbsU gene, restoration 
of which results in a dramatic decrease in the production of exotoxins, including a- 
haemolysin and the major proteases (Horsburgh et al. 2002b). 
1.7.2. Regulation of S. pyogenes virulence determinants 
Throughout the exponential phase of growth of S. pyogenes, the multiple gene regulator 
Mga activates expression of virulence factors associated with adherence of bacteria to the 
extracellular matrix and epithelial cells (e. g. M protein, SOF), as well as molecules 
involved in the subversion of the immune response (e. g. M protein, C5a peptidase, Sic), 
thereby enhancing the early colonisation of the pathogen in the host (Kreikemeyer et al. 
2003). When nutrients become exhausted and conditions more unfavourable for growth, 
bacteria enter the stationary phase of growth and the Mga-controlled pathways are 
repressed by the upregulation of the RofA-like protein (RALP) family of response 
regulators. The RALP family consists of four homologous members, RofA, Nra, RALP-3 
and RALP-4, which together control bacterial-host cell interactions and avoidance of host 
cell damage (Kreikemeyer et at. 2003). Genes regulated by this family include Sfbl, 
streptolysin S, SpeB, SpeA and Mga. Upregulation of genes by RALP and 
downregulation of the exponential phase regulator Mga allows the transition from 
colonisation to persistance and spread of invading S. pyogenes throughout the host. 
During late stationary phase, the transcriptional regulator Rgg (also known as RopB), 
whilst maintaining the downregulation of Mga, upregulates expression of the cysteine 
protease SpeB, resulting in complete loss of adhesins/invasins and lysis of host cells to 
allow spread to other tissue sites (Kreikemeyer et al. 2003). 
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In addition to the "stand-alone" virulence regulators, S. pyogenes also expresses several 
two component systems (TCS), including Ihk/Irr, FasBCAX and CsrRS (CovRS). Ihk/Irr 
is homologous to the S. aureus TCS Ar1SR and is involved in the evasion of PMN- 
mediated killing (Federle et al. 1999; Voyich et al. 2003). FasBCAX consists of two 
sensor histidine kinases and one response regulator and its activity leads to the 
downregulation of adhesins and the upregulation of secreted aggressins at the end of 
exponential growth (Kreikemeyer et al. 2001). The most characterised of the 
streptococcal TCSs is CsrRS (CovRS). CsrRS regulates expression of streptolysin S, 
streptokinase and SpeB, in addition to the genes of the hyaluronic capsule, a crucial 
virulence determinant during adhesion (Kreikemeyer et al. 2003). 
1.8 Identification of bacterial virulence factors 
Gram positive pathogens such as staphylococci and streptococci cause significant 
morbidity and mortality world-wide. Infections by these organisms result in high 
numbers of hospitalised patients and the threat of highly antibiotic resistant strains, 
particularly associated with S. aureus, warrants the development of preventative 
measures to combat these infections. In particular, specific protection of high risk 
individuals, such as health care workers, patients facing surgery, implant recipients and 
immunocompromised patients, is necessary to reduce the morbidity associated with these 
infections. Identification of bacterial virulence factors and putative antigenic targets is 
fundamental for the development of effective vaccines. In particular, the identification of 
antigens expressed in vivo is key to finding an appropriate target, as many vital genes 
would be missed using in vitro methods, which do not represent the complex 
environment encountered by a pathogen during infection. 
1.8.1. Proteomics 
Proteomics is the study of the function, regulation and expression of proteins under 
different conditions, and can be used to elucidate virulence determinants of bacteria, 
which may represent potential novel targets for drug design. Strains exhibiting altered 
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modes of pathogenicity can be compared via protein differential display using two- 
dimensional (2-D) gel electrophoresis in association with mass spectrometry to enable the 
identification and characterisation of proteins (Cordwell, 2006). 
Proteomics techniques have successfully been utilised to identify 25 proteins differing in 
expression levels between the virulent Mycobacterium tuberculosis H37Rv and the non- 
virulent M bovis BCG (Jungblut et al. 1999), and to identify several proteins of 
Helicobacter pylori which were reactive with pooled sera from infected patients, 
including urease B subunit, enolase and catalase (McAtee et at 1998). 
Proteome analysis has also been used in the identification of potential S. aureus vaccine 
candidate antigens (Vytvytska et al. 2002). Sera from healthy individuals and patients 
suffering from S. aureus infections were screened for antibodies against staphylococcal 
lysates and recombinant proteins representing surface antigens. 2-DE immunoblotting 
using S. aureus cell wall protein preparations and the human sera revealed a number of 
highly immunogenic staphylococcal proteins, which were isolated and analysed by mass 
spectrometry. This led to the identification of 15 proteins including known and novel 
vaccine candidates, demonstrating that serological proteome analysis is a powerful tool 
for the identification of novel staphylococcal antigens (Vytvytska et al. 2002). 
1.8.2. Identification of in vivo expressed antigens 
Techniques using human immunogenicity as a primary means of selection on a genome- 
wide basis are particularly valuable for the selection of putative antigenic targets. Indeed, 
antibodies that are induced in the host provide molecular proof of the in vivo expression 
of the corresponding antigenic proteins (Meinke et al. 2004). These antigenome 
techniques have been utilised in several studies to identify antigenic components of 
human pathogens. For example, several in vivo-expressed antigens in an S. aureus MRSA 
strain were identified by Etz et al. (2002). S. aureus peptide libraries were displayed on 
the surface of E. coli via fusion to one of two outer membrane proteins and probed with 
sera selected for high antibody titre and opsonic activity. This method identified 60 
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antigenic proteins, a considerable fraction of which were surface and secreted proteins, 
including the fibronectin binding proteins FnbpA and FnbpB (Etz et at 2002). Similar 
immunoscreening using sera from patients with septicaemia due to an epidemic strain of 
MRSA (EMRSA-15) to probe an EMRSA-15 genomic library resulted in the 
identification of an immunodominant ABC transporter protein (Burnie et at 2000). An 
antibody preparation against this protein is currently being evaluated as an 
immunotherapeutic to be used in conjunction with the antibiotic vancomycin (NeuTec 
Pharma). 
Xu et al. (1997) constructed genomic libraries of two Enterococcusfaecalis strains and 
screened these with serum from a rabbit immunised with surface proteins of an E. 
faecalis endocarditis isolate and sera from four patients with enterococcal endocarditis. 
This identified a number of antigens, including bacterial virulence factors, transporters, 
two-component regulators, metabolic enzymes and cell surface proteins (Xu et al. 1997). 
A similar method was utilised by Lang et at. (2000) to identify antigens of 
Staphylococcus epidermidis. A genomic DNA library, constructed using a Lambda Zap 
Express cloning vector, was screened using serum from a patient with S. epidermidis 
infective endocarditis. This led to the identification of a novel antigen, named SsaA, 
thought to have a role in virulence (Lang et al. 2000). 
More recently, antigenome technology was used to identify the range of antigens of both 
Staphylococcus and Streptococcus species (Meinke et al. 2005). Comprehensive peptide 
libraries were constructed and displayed on the surface of E. colt, which were then 
probed with high-titre sera from patients either infected with or asymptomatically 
carrying the appropriate pathogen. Reactive clones were selected, sequenced and 
immunogenicity confirmed by Western blot analysis. This resulted in the identification of 
approximately 800 antigens of the five staphylococcal and streptococcal species 
screened, with a bias towards proteins involved in cell envelope and cellular 
processes/pathogenesis, as expected for these predominantly extracellular pathogens. 
This included previously identified protective antigens, such as PspA, M1 protein, Sip 
and CIfA (Meinke et at. 2005). 
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In two similar studies, in vivo-expressed antigens of S. aureus and S. epidermidis were 
identified by probing bacteriophage expression libraries with serum samples from 
infected and uninfected individuals (Clarke et al. 2006; Pourmand et al. 2006). In S. 
aureus, eleven putative antigens were selected for further analysis and recombinant 
proteins were produced in order to determine the specific antibody titres in a large 
collection of human serum samples. Seven of these antigens demonstrated significantly 
increased concentrations of reactive IgG in serum from diseased patients compared to 
those in healthy individuals. Furthermore, significantly higher concentrations of reactive 
IgG to four antigens, including IsdA and IsdH (Chapter 1.3.1), were found in serum 
samples from non-nasal-carriers of S. aureus, compared with those in healthy carriers. 
Subsequent work revealed that vaccination of cotton rats with IsdA protected against 
nasal carriage and that this antigen is required for nasal colonisation, making IsdA a 
promising vaccine candidate (Clarke et al. 2006). In S. epidermidis, 53 antigenic loci 
were identified, including members of a novel family of proteins which have homologues 
in S. aureus. Analysis of three selected antigens, At1E, ScaB and Gehl), by screening 
human serum samples, revealed that there were significant increases in the amounts of 
reactive IgG in infected individuals compared to healthy individuals. Furthermore, 
vaccination of mice with recombinant antigens stimulated an immune response which, in 
vitro, opsonised S. epidermidis (Pourmand et al. 2006). This demonstrates that these 
antigens may have important functions in disease and may constitute potential targets for 
immunotherapy. 
1.9 Therapeutic antibody and vaccine development 
Several approaches against S. aureus are being developed. StaphVAXTM is a bivalent 
polysaccharide and protein-conjugated vaccine, directed against the two most prevalent 
capsular polysaccharides, types 5 and 8, which are associated with 80 - 90% of S aureus 
clinical infections (Jones, 2002). During Phase III clinical studies in haemodialysis 
patients, a single immunisation of StaphVAXTM was demonstrated to prevent S. aurcus 
bacteraemia for up to ten months. The vaccine induced high levels of capsular 
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polysaccharide-specific antibodies within 10-14 days, suggesting the potential to prevent 
S. aureus infections in patients with short-term risk, such as those facing surgery (Fattom 
et al. 2004). However, the vaccine failed to provide significant protection against S. 
aureus bacteraemia after one year, the primary end point of the phase III study. 
More recently, a prophylaxis has been developed against S. aureus consisting of a 
humanised monoclonal antibody (MAb) that recognises the surface MSCRAMM CIfA 
(Chapter 1.3.1). Passive immunisation with this MAb, named Aurexis® (tefibazumab), 
was demonstrated to significantly protect against intravenous MRSA challenge in murine 
septicaemia and rabbit infective endocarditis (IE) models (Patti, 2004; Domanski et al. 
2005), and was reported to be well-tolerated and effective in human trials (Weems et al. 
2006). 
Approaches to vaccination against streptococcal species primarily focused on the surface 
M protein, a major virulence factor present throughout this genus. Antibodies to the 
amino terminus of the M protein have been demonstrated to be opsonic and provide 
protection against infection by streptococci of the same M protein type. However, these 
antibodies are generally type-specific as antibodies directed against the amino terminus 
of one M-type do not protect against infection from other M-types (McMillan et al. 
2004a). Vaccines based on M proteins are hindered by the highly antigenically variable 
amino terminus of the M protein, with over 100 emm-types reported (McMillan et al. 
2004b). Furthermore, some M protein epitopes are immunologically cross-reactive with 
human heart proteins and have been implicated in pathology of rheumatic heart disease. 
The carboxyl terminal of the M protein has also been the focus of vaccination studies as 
this region is more conserved between strains, however, the carboxyl terminus is less 
immunogenic and less opsonic than the amino terminus (McMillan et al. 2004a). 
In attempt to combat these difficulties, a vaccine against S. pyogenes was developed 
which contained amino-terminal M protein fragments from 26 different serotypes (Hu et 
al. 2002). These included the majority of serotypes which cause streptococcal 
pharyngitis, those frequently isolated from cases of invasive disease, and those associated 
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with acute rheumatic fever (Dale, 2008). This had the aim of developing a vaccine to 
have a significant impact on the total disease burden caused by S. pyogenes in North 
America and Western Europe. The 26-valent vaccine was shown to be immunogenic in 
rabbits and evoke broadly opsonic antibodies against the majority of serotypes. More 
recently, the vaccine was demonstrated to be well-tolerated and immunogenic in adult 
volunteers, and is currently being considered for pediatric trials, the primary target group 
for the vaccine (Dale, 2008). 
Several studies have focused on the identification of S. pyogenes vaccine candidates other 
than the M protein. These include the adhesin StbI, which demonstrated 80% and 90% 
protection against challenge with homologous and heterologous strains of S. pyogenes, 
respectively, after intranasal immunisation of mice with the protein (Guzman et al. 1999). 
Serum opacity factor (SOF) was shown to evoke bactericidal antibodies, which can 
opsonise both homologous and heterologous SOF-positive streptococci (approximately 
45% of strains of S. pyogenes) in human blood and protect mice against streptococcal 
infection (Courtney et al. 2003). The fibronectin-binding protein FBP54, which is present 
in all strains of S. pyogenes, was used to immunise mice both orally and subcutaneously, 
resulting in significantly longer survival after challenge with S. pyogenes (Kawabata et 
al. 2001). 
Vaccines against S. pneumoniae are currently in use. A 23-valent polysaccharide vaccine 
(PPV) has been available since 1983 and is effective in reducing invasive pneumococcal 
disease among adults and the elderly. However, the PPV vaccine is ineffective in children 
under 2 years old and in immunocompromised patients (McGee, 2007). A 7-valent 
conjugative vaccine (PCV-7) was introduced in the USA in 2000 and in Europe in 2001. 
This vaccine includes the most common serotypes in children, accounting for 
approximately 80% of strains of S. pneumoniae. Following the introduction of PCV-7 in 
the routine immunisation of US children, a signficant decrease was seen in the incidence 
of invasive pneumococcal diseases, acute otitis media, community-acquired respiratory 
infections and nasopharyngeal colonisation (Leibovitz, 2008). However, introduction of 
this vaccine also resulted in an increase in carriage of replacement serotypes of S. 
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pneumoniae, some of which are antibiotic-resistant, which may concerningly lead to 
replacement disease (McGee, 2007; Leibovitz, 2008). 
1.10 Aims of the project 
The primary aim of this project was to identify antigens expressed by S. pyogenes which 
were cross-reactive with S. aureus-infected patient sera. Results from this were then 
combined with results of four previous screens using S. aureus, S. epidermidis, S. 
agalactiae and S. pneumoniae. Comparative analyses allowed the identification of 
putative conserved and cross-reactive antigens amongst these Gram-positive pathogens. 
These conserved protein fragments were further characterised to assess their roles as 
vaccine targets, including both opsonisation and protection studies. 
The secondary aim of the project was to further characterise conserved proteins which 
were identified during the immunoscreening process. This included overexpression of 
recombinant proteins to determine their activities and mutant analysis of one specific 
member of a large conserved family in order to elucidate its role. 
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Chapter 2 
Materials and Methods 
2.1 Media 
2.1.1.2YT 
Tryptone 16 g 1"1 
Yeast 10 g I'1 
NaCl 5g 1"1 
Oxoid Agar No. 1 (1% (w/v)) was added for 2YT agar. 
0.7% (w/v) agarose was added for 2YT top agarose. 
2.1.2. B2 
Casein acid hydrolysate 10 g 1'' 
Yeast extract 25 g 1-1 
K2HPO4 1g 1'' 
NaCI 25 g I'1 
The pH was adjusted to 7.5. Once autoclaved and cooled, sterile glucose was added to 
a final concentration of 1 mM. 
2.1.3. Brain heart infusion (BHI) 
Brain heart infusion (BHI) 37 g 1'' 
Oxoid Agar No. 1 (1.5% (w/v)) was added for BHI agar. 
2.1.4. Luria-Bertani (LB) (Sambrook et al. 1989) 
Tryptone 10 g I", 
Yeast extract 5g1.1 
NaCl 10 g 1-1 
The pH was adjusted to 7.2 using NaOH. Oxoid Agar No. 1 (1.5 % (w/v)) was added 
for LB agar. 
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2.1.5. LK (modified LB with potassium) 
Tryptone 10 g 1', 
Yeast extract 5g 1"' 
KCI 7g1'1 
Oxoid Agar No. 1 (1.0 % (w/v)) was added for LK bottom agar. Oxoid Agar No. 1 (0.7 
% (w/v)) was added for LK top agar. 
2.1.6. Phage agar 
Casamino acids 3g 1-' 
Yeast extract 3g1.1 
NaCl 5.9 g 1'' 
Oxoid Agar No. 1 (1.0 % (w/v)) was added for phage bottom agar. Oxoid Agar No. 1 
(0.33 % (w/v)) was added for phage top agar. 
2.1.7. Super optimal broth (SOB) 
Tryptone 2% (w/v) 
Yeast extract 0.5% (w/v) 
NaCI lo mm 
KCl 2.5 mM 
Once autoclaved and cooled, filter-sterilsed supplements of MgCl2 and MgSO4 were 
added, each to 10 mM (final concentration). 
2.1.7.1. Super optimal broth with catabolite repression (SOC) 
SOC was prepared by the addition of sterile glucose (to 20 mM) to SOB. 
2.1.8. Terrific broth (TB) 
Tryptone 12 g 1-' 
Yeast 24 g 1-1 
Glycerol 0.4 % (v/v) 
The media was autoclaved and cooled, then 0.17 M KH2PO4 / 0.72 M K211P04 was 
added. 
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2.1.9. Todd-Hewitt Broth (THY) 
Todd-Hewitt broth 36.4 g I"1 
Yeast extract 2g I" 
The pH was adjusted to 7.4 using 0.1 M Tris-CI (pH 10.0). 
2.1.10. Tryptic Soy Broth (TSB) 
Tryptic soy broth (TSB) 30 g 1't 
Oxoid Agar No. 1 (1.5% (w/v)) was added for TSB agar. 
2.1.10.1. Iron-limited TSB 
For iron-limited TSB, lOg Chelex-100 was added to 11 TSB and stirred overnight at 4°C. 
The Chelex-100 was decanted by filtration and the media sterilised by autoclaving. 20 
µM Dipyridyl and 400 µl 1M MgSO4 were then added to the media. 
2.2 Antibiotics 
All antibiotics used in this study are listed in Table 2.1. Stock solutions were filter- 
sterilised using 0.2 µm pore size and stored at -20°C. Concentrations used are also listed 
in Table 2.1. 
2.3 Buffers and stock solutions 
23.1. Phosphate buffered saline (PBS) 
NaCl 8g 1"1 
Na2HPO4 1.4 g 1"1 
KCl 0.2 g 1-1 
KH2PO4 0.2 g 1-1 
The pH was adjusted to 7.4 using HCI. 
23.2. PBS-T 
PBS + Tween-20 0.1 % (v/v) 
O sýYi`F 
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Antibiotic Stock 
Concentration 
(mg m1'1) 
Working 
Concentration in 
E. coil (µg mr) 
Working 
Concentration in 
S. aureus (µg ml-1) 
Ampicillin (Amp) 50" 100 - 
Erythromycin (Ery) 5 or 75 300 5 
Kanamycin (Kan) 50a 50 50 
Lincomycin (Lin) 25° - 25 
Neomycin (Neo) 50a - 50 
Spectinomycin (Spc) 100a 100 - 
Tetracycline (Tet) 5° 12.5 5 
Table 2.1: Antibiotics used in this study. Stock concentrations of antibiotics were 
dissolved in dH2Oa, 95% (v/v) ethanolb, or 50% (v/v) ethanol°, filter-sterilised and stored 
at -20 T. The inducing concentration of Ery was 0.15 µg m1'. 
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2.3.3. Tris buffered saline (TBS) 
Tris 2.4g1" 
NaCl 29.2 g 1'1 
The pH was adjusted to 7.5 using HCI. 
2.3.4. TBS-T 
TBS + Tween-20 0.1% (v/v) 
2.3.5. Phage buffer 
MgSO4 1 mm 
CaC12 4 mM 
Tris-Cl (pH7.8) 50 mM 
NaCI 5.9 g 1"1 
Gelatin 1g 1"' 
2.3.6. SM buffer 
NaCl 5.8g1"' 
MgSO4.7H20 4g 1"1 
Tris-Cl (pH7.5) 50 mM 
2.3.7. HiTrapTM buffers 
2.3.7.1. START buffer 
NaPO4 (pH 7.4) 0.02 M 
NaCl 0.5 M 
+/- Urea 8M 
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2.3.7.2. Elution buffer 
NaPO4 (pH 7.4) 0.02 M 
NaCl 0.5 M 
Imidazole 0.5 M 
+/- Urea 8M 
2.3.8. QIAGEN buffers 
The composition of QIAGEN buffers is detailed in the manufacturer's instructions 
provided with the kits. 
2.3.9. SDS-PAGE buffers 
2.3.9.1. Sample prep buffer 
Tris / HCI pH 6.8 0.125 M 
Sucrose 10% (Q iV 
) 
SDS 4% 
(WfV) 
Bromophenol blue 1g 1', 
ß-mercaptoethanol (7% (v/v)) was added just before use. 
2.3.9.2. SDS-PAGE gel formulations and construction of gel 
The following components were added together in a sterile 30 ml universal: 
17.5% (w/v) Resolving gel: 
30% (w/v) AcrylamideBis (37.5: 1) (BioRad) 
3M Tris-CI (pH8.3) 
dH2O 
10% (w/v) Ammonium persulphate 
10% (w/v) SDS 
TEMED 
3.275 ml 
0.95 ml 
3.2 ml 
100111 
75 µl 
10 µl 
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The components were gently mixed and pipetted into prepared gel-casting apparatus. A 
layer of isopropanol was pipetted onto the top of the gel to isolate it from the air. Once 
set, the isopropanol was removed and the gel washed with dH2O. The following 
components were then added together in a sterile 30 ml universa 
Stacking gel: 
30% (w/v) Acrylamide/Bis (37.5: 1) (BioRad) 0.83 ml 
3M Tris-Cl (pH8.3) 1.25 ml 
dH2O 2.88 ml 
10% (w/v) Ammonium persulphate 100 µl 
10% (w/v) SDS 50 µl 
TEMED 10 µl 
The components were gently mixed and pipetted on top of the resolving gel. A plastic 
comb was inserted into the stacking gel to create wells and to separate the gel from the 
air. Once the gel had solidified, the comb was removed and the gel was transferred to a 
gel-running tank, submerged in SDS-PAGE electrophoresis buffer. 
23.93. SDS-PAGE electrophoresis buffer 
Tris 3g 1-' 
Glycine 14.4 g 1"' 
SDS 1g 1'' 
2.3.9.4. Coomassie blue staining solution 
Coomassie B blue (R250) 1.15 g 1"t 
Methanol 40% (v/v) 
Acetic acid 10% (v/v) 
2.3.9.5. Destain solution 
Acetic acid 10% (v/v) 
Methanol 5% (v/v) 
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2.3.9.6. Renaturing gel incubation buffer 
Triton X-100 1 ml 
1M MgCl2 lO ml 
1M sodium citrate (pH5) 25 ml 
dH2O to 1l 
2.3.9.7.10X Renaturing gel stain 
Methylene blue 2g 
2M KOH 1.79 m1 
dH2O to 200 ml 
lOX renaturing stain was diluted to 1X using dH2O prior to use. 
23.10. Western blotting solutions 
2.3.10.1. Transfer buffer for N-terminal sequencing 
100 mM CAPS buffer (pH 11) 10% (v/v) 
Methanol 10% (v/v) 
23.10.2. Transfer buffer for antibody detection 
Tris 3 fi 1" 
Glycine 14.4 g 1'' 
Methanol 20% (v/v) 
23.103. Blocking solution 
Western blocking solution consisted of TBS-T containing 6% (w/v) dried skimmed milk 
powder (Marvel). 
2.3.10.4. Primary antibody solution 
The primary antibody was diluted 1: 1000 in blocking solution for anti-sera and stored at - 
20°C. 
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2.3.10.5. Secondary antibody solution 
The appropriate secondary antibody was diluted 1: 30,000 in TBS-T. 
2.3.10.6. Alkaline phosphatase (AP) buffer 
Tris/HCIpH 9.5 0.1 M 
NaCl 5.8 g 1'' 
MgC12.6H20 10.2 g I" 
2.3.10.7. Colour substrate solution 
160 µl NBTBCIP stock solution (Roche) was diluted in 25 ml AP buffer. 
2.3.11. Southern blotting solutions 
2.3.11.1. SOX TAE 
Trisma base 242 g 1*1 
Glacial acetic acid 57.1 ml 1-1 
Na2EDTA (0.5 M pH 8.0) 100 ml 1'' 
Before use the buffer was diluted 1: 50 to produce TAE. 
23.11.2. Depurination solution 
HCI 250 mM 
2.3.11.3. Denaturation solution 
NaOH 0.5 M 
NaCl 1.5 M 
2.3.11.4. Neutralisation solution 
Tris-Cl 0.5 M 
NaC1 3M 
The pH was adjusted to 7.5. 
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2.3.11.5.20X SSC 
NaCI 3M 
Sodium citrate 300 mM 
The pH was adjusted to 7.0 with 1M NaOH. 20X SSC was diluted with dH2O to make 
10X, 5X and 0.5X SSC. 
2.3.11.6. Standard prehybridisation buffer 
SSC 5X 
N-lauroylsarcosine 0.1% (w/v) 
SDS 0.02% (w/v) 
Blocking reagent I% (w/v) 
2.3.11.7. Hybridisation solution 
The DNA probe was diluted in prehybridisation buffer to a concentration of 5-25 ng/ml. 
2.3.11.8.2X wash solution 
SDS 0.1 % (w/v) 
SSC 2X 
2.3.11.9.0.5X wash solution 
SDS 0.1% (w/v) 
SSC 0.5X 
2.3.11.10. Maleic acid buffer 
Maleic acid 0.1 M 
NaCl 0.15 M 
The pH was adjusted to 7.5 and the buffer autoclaved prior to use. 
2.3.11.11. Washing buffer 
0.3% (v/v) Tween was dissolved in maleic acid buffer. 
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2.3.11.12. Blocking solution 
Maleic acid buffer containing I% (w/v) blocking reagent (Roche). 
Blocking reagent was dissolved in maleic acid buffer by microwaving and was stored 
at -20°C. 
2.3.11.13. Antibody solution 
Blocking solution containing 0.2 µl ml-1 Anti-digoxigenin-AP conjugate (Roche). 
2.3.11.14. Detection buffer 
Tris-HC1(pH 9.5) 
NaCl 
loo mm 
loo mm 
MgC12"6H20 50 mm 
The pH was adjusted to 7.5 using 1M NaOH. 
2.3.11.15. TE buffer 
Tris-HC1 1 mM 
EDTA 0.1 mm 
The pH was adjusted to 7.5 using IM HCI. 
2.4 Bacterial Strains and Plasmids 
2.4.1. Bacterial maintenance, culture and storage conditions 
Bacterial strains used in this study are listed in Tables 2.2 and 2.3. 
2.4.1.1. Streptococcus and Staphylococcus strains 
Streptococcus and Staphylococcus strains (Table 2.2) were taken from glycerol stocks 
and grown on B111 agar plates containing antibiotics where appropriate to maintain 
selection of resistance markers. Plate cultures were stored for up to two weeks at 4°G, 
before being re-streaked from glycerol stocks. For long-term storage, a single colony 
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was spread onto a BHI agar plate containing relevant antibiotics and grown overnight at 
37°C. A loopful of cells was resuspended in I ml BHI containing 15 % (v/v) glycerol in 
a sterile 1.5 ml microfuge tube. These glycerol stocks were then snap-frozen in liquid 
nitrogen and stored at -70°C. Liquid cultures were normally prepared by inoculation of 
culture medium with a single isolated colony. Unless otherwise stated, cultures were 
grown overnight in 5 ml medium in a sterile plastic 25 ml universal, and were ftPrated on tM 
a rotary shaker at 250 rpm. These cultures were then used to inoculate' 
`ý250 
ml conical 
flasks (culture : flask volume ratio 1: 2.5), and were aerated on a rotary shaker at 250 
rpm. All S. aureus plates or liquid medium cultures were grown at 37°C unless 
otherwise stated. These conditions are referred to as standard conditions. 
2.4.1.2. Escherichla cola strains 
Escherichia coli strains (Table 2.3) were cultured, at 37°C, using LB broth or LB agar 
containing antibiotics where necessary to ensure selection of plasmids. Plate cultures 
were stored at 4°C for up to two weeks before re-streaking from glycerol stocks. For 
long-term storage, glycerol stocks of E. coil strains were prepared as for S. aurcus 
(Chapter 2.4.1.1), using LB medium rather than Bail. 
2.4.2. Plasmids 
Plasmids used in this study are listed in Table 2.4. Plasmid DNA was purified using 
QIAGEN plasmid kits according to the manufacturer's protocol. Purified plasmid DNA 
was stored in EB buffer at -20°C. 
2.4.3. Bacteriophage 
Bacteriophage 4)11 (Mani et al. 1993) and 485 were used for phage transduction of S. 
aureus (Chapter 2. X). These phage are S. aureus-specitc, temperate, transducing phage 
of serological group B, and require Ca2+ ions for maintenance of infection in bacterial 
cells. The genome size of X11 is approximately 45 kb (Novick, 1990). 
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Strain Relevant Genotype / Markers Source / Reference 
S. pyogenes HSC-5 M5 serotype group A streptococcus Lab stock 
S. agalactiae 6313 Serotype III group B streptococcus Lab stock 
S. pneumoniae Serotype III clinical isolate Lab stock 
S. aureus 8325-4 8325 cured of known prophages Novick (1963) 
S. aureus SH1000 Functional rbs derivative of 8325-4 Horsburgh et al. (2002b) 
S. aureus spa spa:: tet Tc` in SH1000 background Harris et al. (2002) 
S. aureus RN4220 Restriction deficient transformation 
recipient 
Kreiswirth et al. (1983) 
S. aureus MSO14 RN4220 Psppc yycFG Dubrac and Msadek (2004) 
Table 2.2: Streptococcus and Staphylococcus strains used in this study. 
Strain Relevant Genotype / Markers Source / Reference 
BL21 (DE3) F om T hsdSB rß ml)-) gal dem (DE3) Nova en 
EL250 F mcrA A(mrr-hsdRMS-mcrBC) 080 lacZ AM 15 Lab stock 
AlacX74 recAl deoR recAl endA1 araD139 
0 ara-leu 7649 gaIU alK rspL nupG 
Top10 F mcrA A(mrr-hsdRMS-mcrBC) 080 IacZ AM15 Invitrogen 
AlacX74 recAl deoR araD139 1(ara-leu)7697 
a1K rs L St endA 1 nu G 
XLOLR A(mcrA)183 A(mcrCB-hsdSMR-mrr)173 endAl thi- Stratagene 
I recAl gyrA96 relAI lac [F' proAB lacIgZAM15 
Tn10 (Tetr)] Su- (nonsuppressing) ?r (lambda 
resistant) 
XLI-Blue MRF' strain A(mcrA)183 A(mcrCB-hsdSMR- Stratagene 
mrr)173 endAl supE44 thi-1recA1 gyrA96 re/AI 
lac F' roAB lacl ZEM15 Tn10 etr 
GroD BL21 containing pREP4groESL and pETDa This Study 
GroDN BL21 containing pREP4groESL and pETDna This Study 
GroDC BL21 containing pREP4groESL and ETDca This Study 
ELD2 EL250 containing pTOPD2 This Stud 
Table 2.3: E. coli strains used in this study. 
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Plasmid Relevant Genotype Marker Source / 
Name Reference 
pBK-CMV Phagemid vector containing MCS Kan Novagen 
flanked by T3 and T7 promoters 
pET-24d 6x His overexpression vector Kan' Nova en 
ET-21d 6x His overexpression vector Am Nova en 
pETC pET-24d containing scaC without KanK This Study 
the signal peptide 
pETD pET-24d containing scaD without Kan This Study 
the si al e tide 
pETE pET-24d containing scaE without Kan This Study 
the signal Peptide 
pETF pET-24d containing scaF without Kan This Study 
the signal peptide 
pETG pET-24d containing scaG without Kan This Study 
the signal peptide 
pETJ pET-24d containing scat without Kan' This Study 
the signal peptide 
pETDa pET-21d containing scaD without Amp This Study 
the signal peptide 
pETDn pET-24d containing scaD N- Kan This Study 
terminal 130 amino acids without 
the signal peptide 
pETDc pET-24d containing scaD C- Kan This Study 
terminal 110 amino acids 
pREP4groESL Overexpression plasmid for Kan Amrein et at. 
chaperones GroES and GroEL (1995) 
pETDna pET-21d containing scaD N- Amp This Study 
terminal 130 amino acids without 
the signal peptide 393 b 
pETDca pET-21d containing scaD C- Amp This Study 
terminal 110 amino acids 327 b 
pOB pGEM3Zf(+) erm containing Amp / Ilorsburgh et a!. 
cloning vector ER (2002a) 
pCR 2.1- Cloning vector allowing insertions Amp / Ery lnvitrogen 
TOPO® via Taq-mediated TOPO® Cloning 
reaction 
pTOPD2 pCR®2.1-TOPO® containing 2.5 kb Amp'/ Kan This Study 
scaD region 
pGI400 Vector containing Pspac promoter Amp"/ Ery / Garcia-Lam, 
and tet resistance gene TetR un ublished 
pGL456 Cloning vector containing amp and Amp = Garcia-Lars, 
e unpublished 
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pGL439 Vector containing Pspac promoter Kan / Amp Garcia-tara, 
and tet resistance gene, flanked by / TetR unpublished 
AscI and Fsel restriction sites 
pDPsl pGL456 containing 1.3 kb scab Amp/ Ery / This Study 
region with insertion of Psi Tet R 
promoter and tet resistance marker 
pMAD Temperature-sensitive cloning AmpR I Ery' Arnaud et al. 
vector with bgaB for colorimetric (2004) 
selection 
pGL433b Cloning vector containing kan Kan / AmPR Garcia-Lara, 
resistance gene cassette unpublished 
pDPs2 pMAD containingl. 3 kb scaD Amp/ Ery / This Study 
region with insertion of PSS TO R 
promoter and tet resistance marker 
pDMutl pMAD containing inactivated scaD Amp / Ery / This Study 
gene region with kan insertion Kan R 
pMJ8426 Cloning vector containing Spc I Tet Jana et al. (2000) 
constitutive Ppcn 
pDComp pMJ8426 containing scaD under Spc / Tet This Study 
control of Ppcn 
Table 2.4: Plasmids used in this study. 
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2.5 Centrifugation 
A number of different centrifuges were used for the harvesting of cells and precipitated 
material. These were: 
1) Eppendorf microfuge 5415D; max. volume 2 ml, max. speed 3200 rpm (10,000 x g). 
2) Centaur 2 centrifuge (Sanyo); max. volume 50 ml, max. speed 10,000 rpm. 
3) Avanti J251 (Beckman); max. volumes and speeds dependent on the rotor used: 
JA-20: max. volume 50 ml, max. speed 20,000 rpm (48,384 x g). 
JA-14: max. volume 250 ml, max. speed 14,000 rpm (30,074 x g). 
JA-10.5: max. volume 500 ml, max. speed 10,000 rpm (18,480 x g). 
Unless otherwise stated, centrifugation was carried out at room temperature. 
2.6 Determination of bacterial cell density 
2.6.1. Spectrophotometric measurement 
To quantify the bacterial yield of a culture, spectrophotometric measurements at 600 nm 
(OD , m), were performed. 
These measurements were taken using a Jenway 6100 
spectrophotometer. Where necessary, the culture samples were diluted 1: 10 in unused 
sterile culture medium to give a reading below 0.8 on this type of spectrophotometer. 
2.6.2. Viable cell counts (CFU) 
An alternative method for the quantification of cell numbers involved viable cell 
counts. Bacterial samples were serially diluted 1: 10 in PBS in duplicate. 100 Al 
samples of each dilution were spread using sterile glass beads onto duplicate 131 1[ agar 
plates containing antibiotics where necessary. After overnight incubation at 37°C, the 
number of colony forming units (CFU) were determined. 
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2.7 Growth Experiments 
Strains were streaked from glycerol stocks onto Bill plates containing suitable antibiotics 
(Chapter 2.4.1.1). 5 ml Bill in a sterile 30 ml universal tube was inoculated using a single 
colony and grown overnight at 37°C, with aeration on a rotary shaker at 250 rpm. The 
overnight pre-culture was used to inoculate 100 ml pre-warmed Bill in a 250 ml conical 
flask to an OD60onm 0.01. The 100 ml culture was grown at 37°C, 250 rpm and the culture 
OD600nm was determined in duplicated over the desired time period. 
2.8 Cell autolysis 
S. aureus was grown to mid-exponential phase (OD6oom 0.5-1.0) in 13E11. Cells were 
harvested by centrifugation (4000 rpm, 4°C, 10 min), washed in 50 mM Tris-CI (p117.5) 
and resuspended in lysis buffer (50 mM Tris-Cl (p'l 7.5) containing 0.05% (v/v) Triton- 
X 100). Generalised cell lysis of cells was followed spectrophotometrically while 
incubation at 37°C with shaking at 250 rpm. 
2.9 Microscopy 
2.9.1. Phase contrast microscopy 
1 ml samples of cells were harvested at specific points during growth in DHI, placed in a 
microcentrifuge and immediately chilled on ice for 5 min. The cell samples were 
recovered by centrifugation for 3 min (10,000 , RT) and resuspended in 1 ml dl120.100 
µl was spread on a slide and allowed to air dry. Once dry, and after heat fixation, a dilute 
methylene blue solution (0.001 % (w/v) in d1120) was spread over the mounted cells and 
washed with dH20. A coverslip was placed on top immediately and the stained cells were 
viewed under the microscope. 
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2.9.2. Transmission electron microscopy 
Cell pellets were fixed in Kamovsky's fixative in 100 mM sodium cacodylate buffer for 
3h at 4°C. The specimens were then washed in 100 mM sodium cacodylate buffer 
containing 10% (w/v) sucrose 3 times with 30 min intervals at 4°C. Secondary fixation 
was carried out in 2% (w/v) osmium tetroxide for I hat room temperature (Hayat, 1981). 
Dehydration was through a graded series of ethanol (75% (v/v), 15 min; 95% (v/v), 15 
min; 100% (v/v), 15 min; 100% (v/v), 15 min; 100% (v/v) dried over anhydrous copper 
sulphate for 15 min) at room temperature. The specimens were then placed in an 
intermediate solvent, propylene oxide, for 2 changes of 15 min. Infiltration was 
accomplished by placing the specimens on propylene oxide-Spurr resin (50: 50) overnight 
at room temperature. The specimens were then left in Spurr resin for 6-8 h at room 
temperature after which they were embedded in fresh Spurr resin for 8h at 70°C 
(Glauert, 1974). Ultrathin sections (-70-90nm) were cut on a Reichert Ultracut E 
ultramicrotome and stained for 15 min with 3% (w/v) uranyl acetate-50 % (v/v) ethanol 
followed by staining with Reynold's lead citrate for 2 min (Watson, 1958; Reynolds, 
1963). The sections were examined using a Philips CM10 Transmission Electron 
Microscope at an accelerating voltage of 80 kV. Electron micrographs were recorded on 
Kodak 4489 Electron Microscope Film. 
2.10 Protein overexpression 
2.10.1. Growth and induction of expression 
E. coil BL21 containing the pET24-d or pET21-d ovcrcxpression plasmid with 
appropriate insert was grown overnight in 5 ml LB and 50 pg/ml kanamycin or 100 
pg/ml ampicillin, as appropriate. 2.5 ml culture was used to inoculate 250 ml TB 
containing antibiotic, and grown at 37°C, 250 rpm until it reached an OD6Wm of 0.6-1.0. 
Protein overexpression was then induced using 1 mM IPTG and the culture grown for a 
further 4-6 h. Cells were harvested by centrifugation (6000 x g, 15 min, 4°C) and the 
pellet was stored at -20°C. 
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2.10.2. Analysis of recombinant protein solubility 
Cells prepared in Chapter 2.10.1 were resuspended in 0.5 ml START buffer and I mg/ml 
lysozyme was added. The suspension was left at room temperature for Ih before being 
sonicated (Sanyo Soniprep 150) three times for 10s. The suspension was then centrifuged 
(13,000 rpm, 10 min) and the supernatant (soluble fraction) separated from the pellet 
(insoluble fraction). The insoluble pellet was resuspended in 0.5 ml START buffer 
containing 8M urea. Both the soluble and insoluble fractions were analysed by SDS- 
PAGE. 
2.10.3. Protein purification using IliTrapTM column 
Harvested cells were resuspended in 5 ml START buffer and freeze-thawed three times 
(10 min at -80°C). The suspension was sonicated three times for 10s (Sanyo Soniprep 
150) and centrifuged (18,000 rpm, 25 min, 4°C). The supernatant (soluble fraction) was 
removed and the pellet, containing the insoluble protein, was resuspended in 50 ml 
START buffer with 8M urea. The protein suspension was then filtered through 0.45 µm 
filters. 
A5 ml HiTrapTm column (Amersham Biosciences) was washed with 15 ml d1120, then 
charged with 20 ml 50mM NiSO4.61120. Excess NiSO4.61120 was washed out with 15 ml 
d1120. The Bio-Rad Econo Gradient pump and Fraction collector tubing was flushed with 
START buffer containing 8M urea. The charged IliTrap column was attached to the 
pump and equilibrated with the START buffer and 8M urea. The filtered Ilis-tagged 
protein was then applied to the column and eluted using an increasing gradient of elution 
buffer. The eluted fractions were analysed by SDS-PAGE and purified protein was 
dialysed into PBS and 8M urea using 12-14 kDa cut-off dialysis membrane (Medicell 
International Ltd). The IliTrap' column was washed with 10 ml 0.1M EDTA followed 
by 10 ml d1120. The column was then flushed with 10 ml 20% (vlv) ethanol and stored at 
4°C. 
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2.10.4. N-terminal sequencing 
Proteins under investigation were separated by 17.5% (w/v) SDS-PAGE gel (Chapter 
2.12) and blotted onto a PVDF membrane (Chapter 2.13) as previously described but 
using CAPS buffer (Chapter 2.3.10.1). After the transfer procedure the membrane was 
soaked in dH2O for 5 min, followed by 5 min in methanol at room temperature. The 
membrane was then stained with Coomassie blue staining solution for 1 min and then 
destained for 3x5 min in destain solution (50% (v/v) methanol). The blot was then 
dried, protein side up, on blotting paper for Ih at room temperature. The protein under 
investigation was then excised from the membrane and sequenced by Dr Arthur Moir 
(Department of Molecular Biology and Biotechnology, University of Sheffield) using an 
ABI 476A sequencer. 
2.11 Preparation of cell walls 
2.11.1. Preparation of purified cell walls 
A mid-exponential phase culture (OD60o,,, 1.0) of the required strain was harvested 
(11,000 g, 10 min, 4°C) and the cell pellet resuspended in ice-cold 50 mM Tris-I ICI (pH 
7.5). Bacterial cells were then autoclaved (15 p. s. i. for 5 min) before being disrupted. S. 
sub gills cells were disrupted by passing the cell suspension twice through a French 
pressure cell (Aminco, 180 MPa, 4°C). S. lutcus, S. aureus and S epidermidis cells were 
disrupted using the Braun homogeniscr (Foster, 1992). Insoluble material was recovered 
by centrifugation (27,000 g, 10 min, 4°C) and the pellet resuspended in 30 ml 50 mM 
Tris-IICI (p11 7.5) plus 2% (w/v) SDS. After incubation at 50°C for 10 min and 
centrifugation as before, the pellet was resuspended in 30 ml of 50 mM Tris-IICI (p11 
7.5) plus 3% (w/v) SDS, 50 mM dithiothreitol (DTT) and 1mM EDTA. The suspension 
was boiled for 20 min, insoluble material recovered as before and the pellet resuspended 
and boiled once more in the same buffer. These walls were then collected by 
centrifugation as before and washed five times in dU2O by centrifugation and 
resuspension. The concentration of the cell suspension was determined by pipetting 200 
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µl onto a pre-weighed weighing boat, evaporating off the liquid in a 60°C oven and 
weighing the resulting dried boat. The final cell wall suspension was stored at -20°C. 
2.11.2. Preparation of cell wall-associated proteins 
2.11.2.1. FastPrep method of cell wall preparation 
Cell walls were prepared as described by Clarke et at. (2002). Bacteria were grown in I 
I TSB to an OD 6w,,,,, 1.0. Cells were harvested by centrifugation (8000 g, 10 min, 4°C). 
The pellet was then resuspend in 15 ml cold TBS. The cells were recovered by 
centrifugation (8000 g, 5 min, 4°C), and the pellet resuspended in 2 ml ice cold buffer 
solution (50 mM Tris-IICI (pl17.5), 0.1M NaCl, 0.5 mM PMSF). 0.5 ml of the bacterial 
suspension was then transferred to a FastPrep tube (Anachem). The tubes were inserted 
in the FastPrep instrument (Anachem), the speed set to 6 and time to 40 s. Disruption 
was repeated 10 times to ensure bacteria cells were broken, with cooling on ice in 
between. The tubes were cooled on ice and breakage of the cells verified by light 
microscopy. The FastPrep beads were allowed to settle, and the supernatant / suspension 
removed into a clean tube. I ml cold 50 mM Tris-HCl and 0.1 M NaCl was added to the 
suspension, before centrifuging at 4000 g for 10 min at 4°C. The supernatant was 
retained and 5 ml cold 50 mM Tris-IICI and 0.1 M NaCl added to the pellet. After 
mixing, the insoluble material was recovered by centrifugation (15,000 g, 10 min, 4°C). 
The pellets were resuspend in I ml ice cold 50 mM Tris-l ICI (p117.5), and recovered by 
centrifugation (as above) to give native cell walls. 
2.11.2.2. lonicidly bound proteins 
The native cell wall material was resuspended in 20 µi SDS sample buffer with 5.6% 
(v/v) IME (added just before use). The suspension was boiled for 3 min, and cooled at 
RT for S min. Insoluble material was removed by centrifugation (13,000 g, 5 min, RT) 
and the supernatant retained. 
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2.12 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-TAGE) 
2.12.1. Mini Protean SDS-PAGE 
Discontinuous SDS-PAGE was performed according to Laemmli (1970) using BioRad 
Mini-Protean II gel slabs (70 mm (L) x 80 mm (W) x 0.75 mm thickness), following the 
manufacturer's instructions (I3ioRad). Reagents for SDS-PAGE were prepared as 
described in Chapter 2.3.9. Samples were diluted at least 1: 4 with sample buffer and 
heated at 100°C for 10 min. Electrophoresis was performed at room temperature with 
constant voltage of 200 V for I h. 
2.12.2. Coomassie blue staining 
Alter electrophoresis, protein gels were placed in approximately 30 ml Coomassie blue 
stain (Chapter 2.3.9.4) for 30-60 min. They were then destained in two volumes of 
approximately 30 ml destain solution (Chapter 2.3.9.5) overnight until the background 
was clear. Gels were dried using Gel-Dryt" Drying Solution and DryEase Mini 
Cellophane (Invitrogen). Molecular masses were determined by comparison to the 
Prestained SDS-PAGE Standards, Low Range (BioRad) (Table 2.5). The gel was dried 
by placing between two DryEaseTM miniccllophane (Invitrogen) sheets which had been 
pre-soaked in Gel-DryTM gel drying solution for 5 min. The sandwich was then fastened 
into a gel drying frame (Novex) and left to stand on the bench overnight to dry. For a 
permanent electronic record, protein gels were scanned using an EPSON Perfection 3170 
scanner. 
2.12.3. Renaturing SUS-PAGE analysis of peptidoglycan hydrolases 
Peptidoglycan hydrolase activity was detected by renaturing gel electrophoresis as 
described by Foster (1992) using purified S. aureus, B. subtilis or M. luteus vegetative 
cell walls as the substrate incorporated into the acrylamide gel to a concentration of 0.1% 
(w/v). A Protean II ([3ioRad) gel apparatus was used for electrophoresis (Chapter 2.12.1). 
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Electrophoresed gels were rinsed in d1120 to remove SDS and then placed in 200 ml of 
renaturing solution (Chapter 2.3.9.6) at RT for 30 min, followed by incubation overnight 
at 37°C in another 200 ml of renaturing solution. The gels were then rinsed in d1120 and 
incubated in IX renaturing stain (Chapter 2.3.9.7) for 3h at RT. After destaining in 
d1120, peptidoglycan hydrolase activity was visualised as zones of clearing in the blue 
opaque background. The gel was dried by placing between two DryEaseTM 
minicellophane (Invitrogen) sheets which had been pre-soaked in 10% (v/v) glycerol for 
5 min. The sandwich was then fastened into a gel drying frame (Novex) and left to stand 
on the bench overnight to dry. For a permanent electronic record, protein gels were 
scanned using an EPSON Perfection 3170 scanner. 
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Protein (_Approiimat molecular weight (Da) 
Phosphorylase B 104,365 
Bovine serum albumin 97,273 
Ovalbumin 50,419 
Carbonic anhydrase 37,191 
Soybean trypsin inhibitor 29,184 
Lysozyme 20,163 
Table 2.5: Prestained SDS-PAGE Standards, Low Range (BioRad). 
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2.13 Western blotting 
2.13.1. Electrophoresis and blotting 
Protein samples were separated by 17.5% (w/v) SDS-PAGE (Chapter 2.12) and the get 
was equilibrated in transfer buffer (Chapter 2.3.10.2) for 15 min. PVDF membrane was 
placed in methanol for a few seconds, before the BioRad Transfer Apparatus (BioRad) 
was assembled, as follows: 
Top electrode BLACK sandwich plate (cathode) 
White sponge (soaked in transfer buffer) 
Filter paper (soaked in transfer buffer) 
Gel 
PVDF membrane (wetted with transfer buffer) 
Filter paper (soaked in transfer buffer) 
White sponge (soaked in transfer buffer) 
Bottom electrode WHITE sandwich plate (anode) 
The electroblotting apparatus was connected to a power pack and transfer of the 
polypeptides onto the PVDF membrane of pore size 0.2 rim (BioRad) was done in 
appropriate transfer buffer at 60 V for I h. 
2.13.2. Western blotting involving detection with alkaline phosphatuse-conjugated 
secondary antibodies 
The PVDF membrane containing the transferred protein was soaked overnight at 4°C in 
blocking buffer (TBS-T containing 6% (w/v) dried skimmed milk powder). The 
membrane was then washed briefly with TBS-T (Chapter 2.3.4) before adding 30 ml 
primary antibody solution (Chapter 2.3.10.4) for 90 min with agitation. The primary 
antibody was removed and the membrane washed for 3x 10 min with TBS-T. The 
membrane was then placed in 30 ml specific secondary antibody solution (Chapter 
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2.3.10.5) for 60 min with agitation. The secondary antibody was raised against antibodies 
from the animal in which the primary originated and was also conjugated with AP to 
allow colourmetric detection. The secondary antibody was then discarded and the 
membrane washed again for 3x 10 min in TBS-T. The membrane was pre-equilibrated 
with AP buffer, before being replaced with 25 ml colour substrate solution. The blot was 
then placed in the dark to allow the membrane to develop. Proteins bound with primary 
antibodies were visualized by the development of purple bands. After sufficient time the 
membrane was washed with 25 ml TE for 5 min to stop the reaction. The membrane was 
then air-dried and stored in the dark. For a permanent electronic record, Western blots 
were scanned using an EPSON Perfection 3170 scanner. 
2.13.3. Ligand affinity blotting 
Recombinant polypeptides were separated by 17.5% (wlv) SDS"PAG@ (Chapter 2.12) 
and transferred to PVDF membranes by clectroblotting (Chapter 2.13). Membranes were 
blocked overnight at 4°C in PBS-T (Chapter 2.3.2) containing 3% (w/v) BSA (Sigma). 
The membranes were incubated with the appropriate ligand labelled with biotin using a 
Biotin Labelling Kit (Roche), to probe the membrane at a final concentration of -2 
pg/ml. Bound ligands were detected using alkaline phosphatase-conjugated avidin 
(BioRad) and NBT-BCIP solution (Roche). 
2.14 Immunoscrecning the genonnic DNA library with untiseru 
Plaques of E. cola XL1 Blue infected with the ) phage containing S. pyogencs genomic 
DNA library were transferred to nitrocellulose membranes pre-treated with 10 mM 
IPTG (Stratagene). The membranes were washed in TBS-T, blocked (TDS-T + 6% 
(w/v) skimmed milk) and probed with human sera (diluted 1: 1000). Detection was 
carried out using alkaline phosphatase-conjugated anti-human 1gG (FC specific) 
(1: 30,000 in TBS-T) and visualised with NBT-BC1P (160 µl in 25 ml Al' buffer). 
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2.15 ELISA analysis of specific antibody titre 
An enzyme-linked immunosorbent assay (ELISA) was used to determine the titre of 
specific antibody against recombinant antigens. Briefly, 100 pi of appropriate 
recombinant polypeptides (10 pg/ml) or BSA in PBS (5 pg/ml), was added to wells of a 
96-well microtiter plate (Nunc) overnight at 4°C. Plates were washed three times with 
PBS-T, and the remaining protein-binding sites were blocked with 5% (w/v) BSA in 
PBS for 2h at room temperature. The plates were again washed three times in PBS-T, 
and different concentrations of human sera (1: 100 and 1: 1000) diluted in PBS-T were 
added. The plates were incubated for a further 1h before being washed three times, and 
alkaline phosphatase-conjugated monoclonal antibody against human IgG (diluted 
1: 50,000 in PBS-T) was added, followed by Ih of incubation. The plates were again 
washed three times in PBS-T and finally, bound antibodies were detected by using the 
Sigma Fast p-nitrophenyl phosphate system (Sigma). Plates were read at 405 nm in a 
Victor microtiter plate reader(Wallac). 
2.16 DNA purification techniques 
2.16.1. QtAquick Gel Extraction 
DNA was purified from an agarose gel using a Q[Aquick gel extraction kit (QIAGEN). 
The DNA excised from the gel using a sharp scalpel blade. The gel slice was weighed 
and 3X the volume of Buffer QG added. The suspension was vortexed and incubated at 
room temperature until the gel had completely dissolved. IX gel volume of isopropanol 
was added to the mixture before transferring it to a QlAquick spin column and 
centrifuging at 13,000 rpm for I min. The flow-through was discarded and 0.75 ml 
Buffer PE added to the column. This was then centrifuged as before, the flow-through 
discarded and centrifuged again. DNA was eluted with 50 µl Buffer EB, and the 
recovered DNA was stored at -20°C. 
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2.16.2. QlAquick PCR Purification 
PCR reactions were purified using a Q[Aquick PCR purification kit (QIAGEN). Briefly, 
5X volume of Buffer PB was added to the PCR reaction. The mixture was applied to a 
QiAquick column and centrifuged at 13,000 rpm for I min. The flow-through was 
discarded and the column washed with 0.75 ml Buffer PE by centrifuging as before. The 
flow-through was again discarded and the centrifugation repeated. DNA was eluted with 
50 µl Buffer EB, and the recovered DNA was stored at -20°C. 
2.16.3. Purification of dye-terminator sequencing reactions using DyeEX spin 
columns 
Unincorporated nucleotides and primers were removed from dye-terminator sequencing 
reactions using a DyeEX spin kit (QIAGEN), according to the manufacturer's 
instructions. 
2.16.4. Genomic DNA preparation 
Genomic DNA was purified from S. aurcus using a DNeasy kit (QIAGEN), based on the 
manufacturer's instructions. A colony was grown overnight in 5 ml 13111 and cells 
recovered by centrifugation (13,000 rpm, 1 min). Pellets were resuspended in 1 ml d1120 
and centrifugation repeated. Pellets were then resuspended in 180 µl d1120. S p1 
lysostaphin (5 mg ml's) and 5 pl RNase (0.5 mg ml'') were added and samples incubated 
at 37°C for 30 min. Once cells had lyscd, 25 pl protcinase K and 200 pl Buffer AL were 
added, mixed by vortexing and incubated at 70°C for 30 min. 200 pl ethanol was added 
and samples pipetted into DNeasy mini spin columns in 2 ml collection tubes. Columns 
were centrifuged at 8000 rpm for I min and the flow-through discarded. 500 pl Buffer 
AW 1 was then added, centrifugation repeated and the flow-through discarded again along 
with the collection tube. 500 pl Buffer AW2 was added and columns centrifuged at 
13,000 rpm for 3 min. Flow-through was discarded and DNA eluted into clean cppendorf 
tubes using 200 pl Buffer AE (8000 rpm, I min). 
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2.16.5. Small scale plasmid preparation from E. colt 
A single colony of the E. coli strain containing the plasmid was used to inoculate 5 ml LB 
containing appropriate antibiotics. The culture was incubated overnight at 37°C, 250 rpm, 
unless otherwise stated. Cells were harvested at 13,000 rpm for I min. Plasmid DNA was 
isolated and purified using QlAprep Spin Miniprep kit DNA purification system 
(QIAGEN), according to the manufacturer's instructions. Plasmid DNA was eluted using 
50 pl Buffer EB and stored at -20°C. 
2.16.6. Large scale plasmid preparation from F. coil and S. aureus 
Large amounts of plasmid (up to 500 µg) were isolated from E. coil and S aurcus using a 
Plasmid Midi kit DNA purification system (QIAGEN). A single colony of the bacteria 
was used to inoculate 100 ml LB (for E. colt) or Bill (for S. aureus), containing 
appropriate antibiotics. The culture was grown overnight at 37°C, 250 rpm, unless 
otherwise stated. Cells were harvested by centrifugation (6000 rpm for 10 min) and 
resuspended in buffer Pl. For S. aurcus cells, 50 µl lysostaphin (5 mg ml'') was also 
added. The protocol was then continued according to the manufacturer's instructions. 
Washed DNA pellets were air-dried overnight, resuspended in 200 µl d1120 and 
incubated at 37°C for 10 min to allow the DNA to redissolve. Samples were then 
centrifuged at 5500 rpm for 3 min to ensure resuspension of all DNA. Purified plasmid 
DNA was stored at -20°C. 
2.16.7. Precipitation of 1)NA using glycogen 
Samples were prepared as follows: 
DNA 100µl 
3M sodium acctatc 10 µl 
Glycogen (20 mg ml") S pl, 
Ethanol 300 p1 
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Samples were incubated at -20°C for 15-60 min before being centrifuged at 13,000 rpm, 
10 min, RT. Pellets were then washed five times with 70% (v/v) ethanol, air-dried and 
redissolved to the required volume. 
2.17 In vilro DNA manipulation techniques 
2.17.1. Polymerase chain reaction (PCR) 
2.17.1.1. Primer design 
The primers used for PCR amplification were short synthetic oligonucleotides (19 - 74 
bp) that were based on DNA sequences from published studies or obtained from 
cloning vector information and S. aureus databases (http: //www. ncbi. nlm. nih. gov/ and 
http: //www. genome. ou. edu/staph. htmi). Suitable restriction sites were introduced where 
necessary at the 5' ends of primers to enable subsequent cloning. The primers used in 
this study are shown in Table 2.6. Oligonucleotide primers for PCR and sequencing 
reactions were all synthesised by eurofins MWG Gmbl1(http: //www. eurofinsdna. com/). 
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Primer Sequence 5'-* 3') Source 
T3 AATTAACCCTCACTAAAGGG Strata ene 
T7 forward GTAATACGACTCACTATAGGG Strata gene 
T7 reverse GCTAGTTATTGCTCAGCGG Strata gene 
pETC_F TTITI FCCATGGCAGAACAAAATAACAATGG This study 
ETC R TTTTTTCTCGAGATGAATGAAA'ITATATGAAC This study 
pETD-F TTITI"ITCCATGGCATCTGAGCAAGATAACTACG This stud 
ETD R TITTITCT GAGGTGAATGAAGTTATAACCAG This stud 
pETE F TTTTfTTCCATGGCACAACAACATGGCACACAA This study 
ETE R TTTTTTCTCGAGGTGGATGTAATTATATT'iTCCT This study 
pETF F TTTTTTTCCATGGCATATACGAATGATAGCAAAACA This stud 
ETF R TT"ITTTCT G CGATGGATGTAATTATATGATGAA This stud 
pETG F TTTTTTTC TG , CAGTTAATTATTATAGTAAAAA This study 
ETG R T'ITMCTCGAGGTAAATATAGTTAAAGTTACGT This study 
pETI F rrITTTTCCATGGCACCTGATTTAAATAAAGGTAAA This stud 
ETI R TTI"I"I"ICTCGAGCTCCTTATCATGAATAAAAC This study 
pETJ F TTT I'lTI'CCATGGCTGAAAATTATACAAATTACA This study 
pETJ R TCIT7TCTC(iAGAATATGGATGTAGTTGTAGTT This study 
pETD F2 ITrVrTTCCATGGCATATACTTCAGGACGTAACTT This study 
pETD R2 1TI"CITCTCGAGACCACTTGAGATTGAACGG This stud 
DIF T11TITGGATC TGGTTCCAGATGATATATTA This study 
DIR TITITFGGATCCTGATATTCCAATTCAAGTATT This stud 
D2F =, IGGATCCTGTTAATATCTTGCCACGCA This study 
D2R TTTT'ITGGATCCGTAACGATATTTTGCGGATAT This stud 
PS 
- 
RedF TAACATTAATTTGTCACACGGACATTACGAAAATATTAG ATTTAAAATTAGAAATCCCTTTGAGAATGTTT This study 
PS RedR ATAGTAGCTGTAGCGATTTTCTTCATTTTAAAAATATCCTCC TAAAAATTGTGAGCGGCTCACAATTCCAC This study 
InvDI TIT1"ITGTCGACTTAAAATTTAGATTTFATAAAAG This stud 
InvD2 1"r= ETCGACAAATCCTCCTATAAAAATTTT This study 
D3 1TT'ITT000 GGCCAATTTTAAATCTAAAATATTTTCGT This study 
D4 TTTTTTG(iCGCGCCTTTAGGAGGATATT'i"ITAAAATG This stud 
PsFI TCTGTCATCTI ACATCCTCA This stud 
PsF2 AGCCAACTAATGACAATGATT This study 
PsR GAAGTTATAACCAGCAGCTT This study 
Mutt TTITTTGO CAATTAAGCAATGCTCCAG This study 
Mutt TTTT7TG TATATGATGTTGGGTCGTTT This study 
Mut3 TTTT Vr T Ci (; CAATCTCAAGTGGTTATACT This study 
Mut4 TITrI"TG T CACGTTTAACTTAATGTGAG This stud 
KanF T ITTTG .G CCAGCGAACCATTTGAGG This stud KanR TTTTTTC CGAOATTCCTCGTAGGCGCTCGG This stud 
Com F 1TITTTGGA CCACAAGGACGCTAATTTCT This study 
Com R 77TT I FGA CGGCGTAAACATAGCCATC This stud 
Table 2.6: Synthetic oligonuclcotides used as primers for PCR amplification of DNA 
fragments in this study. Relevant restriction sites are underlined. 
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2.17.1.2. DNA amplification 
Where accurate DNA amplification was not required, PCR reactions were carried out 
using l. lx ReddyMixTM PCR Master Mix (Aßgene). The following components were 
added, on ice, to a 0.5 ml thin-walled PCR tube: 
PCR Master Mix 45 pl 
Forward primer 300 nM 
Reverse primer 300 nM 
Template DNA 100 - 500 ng 
d1120 to 50 µ1 
PCR amplification was performed using an Eppendorf 5330 Mastercycler. The lid was 
heated to 105°C for the duration of the PCR amplification, and the block was pre-heated 
to 94°C. The following thermal cycling programme of 30 cycles of steps 2-4 was used: 
1) Denature 95°C 5 min 
2) Denature 95°C 30 s 
3) Anneal 50-60°C 30 s 
4) Extension 72°C t min (t=1 min kb'' + 10 %) 
5) Extension 72°C 10 min 
2.17.1.3. III-fidelity DNA amplification 
DNA amplifications that required 3'-5' proof-reading activity were performed with 
Extensor iii-Fidelity PCR Master Mix (AIIgene). The following components were added, 
on ice, to a 0.5 ml thin-walled PCR tube: 
Extensor Master Mix 12.5 t1 
Forward primer 200 nM 
Reverse primer 200 nM 
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Template DNA 100-250 ng 
dH20 to 25 pI 
PCR amplification was performed using an Eppendorf 5330 Mastercycler. The lid was 
heated to 105°C for the duration of the PCR amplification, and the block was pre-heated 
to 94°C. Once the tubes were added, the DNA was denatured at 94°C for 2 min, 
followed by 10 cycles of programme A, then 20 cycles of programme B: 
Programme A: 
Denaturation 94°C los 
Annealing 50-68°C 30 s 
Extension 68°C t min (t = 45 sec kb-1) 
Programme B: 
Denaturation 94°C 10 s 
Annealing 50-68°C 30 s 
Extension 68°C t min (t = 45 sec kb" +l Os / cycle) 
Once all the cycles were complete a final step of 68°C for 7 min was added to allow 
complete extension of the primers. The PCR products were stored at -20 °C. 
2.17.2. Restriction digestion of DNA 
DNA restriction digests were performed according to the manufacturer's instructions, in 
volumes from 20 - 100 µ1. The reactions were prepared as follows: 
Restriction enzyme buffer 10% (v/v) 
Restriction enzyme(s) 5 units 
DNA solution To final volume 
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Where appropriate the reaction volume was made up with dH2O. The restriction digests 
were incubated at 37°C for 2.5 h, unless otherwise stated. Before digested DNA was used 
for further manipulation, it was purified using QIAGEN PCR purification kit (Chapter 
2.15.2) or separated by 1% (w/v) agarose gel electrophoresis (Chapter 2.16.5) and 
purified using a QlAquick gel extraction kit (Chapter 2.15.1). 
2.17.3. Alkaline phosphatase treatment 
The 5' ends of plasmids digested with only one restriction enzyme were 
dephosphorylated using Calf Intestinal Alkaline Phosphatase (CIAP) (Roche) to reduce 
the re-ligation of the vector during subsequent cloning steps. The reactions were prepared 
as follows: 
Restriction digest reaction 20 - 50 µl 
CIAP buffer (10x) 8 µl 
CIAP 1µl 
dH2O to 80 µl 
Reactions were incubated at 37°C for 15 min. The DNA was then immediately separated 
by 1% (w/v) agarose gel electrophoresis (Chapter 2.17.5) and purified by gel extraction 
(Chapter 2.16.1). 
2.17.4. DNA ligation 
The following were added on ice: 
Digested plasmid DNA 100 ng 
Digested DNA insert x ng* 
IOX DNA ligase buffer (Promega) 2 µl 
T4 DNA ligase (Promega) 1 µl 
*the amount of insert added was calculated using the following equation to allow a 1: 1 
and 1: 3 molar ratio of vector: insert to be used: 
72 
Materials and Methods 
100 ng of plasmid X kb size of insert X molar ratio of insert = ng of insert 
kb size of plasmid plasmid 
The reaction was made up to 20 pl with dH2O and incubated overnight at 15°C using an 
Eppendorf 5330 Mastercycler. The completed ligation mix was then purified using 
glycogen (Chapter 2.16.7) used to transform E. coli (Chapter 2.20.1). 
2.17.5. Agarose gel electrophoresis 
DNA fragments were separated by horizontal gel electrophoresis using various size 
electrophoresis tanks (Life Technologies). An appropriate volume of agarose gel (1% 
(w/v)) was dissolved in TAE by microwaving and poured into the gel tray. Once set, the 
gel was submerged in a suitable volume of TAE electrophoresis buffer (Chapter 
2.3.11.1). For visualisation of the DNA, 10 pl ethidium bromide (10 mg/ml, BioRad) was 
added to the TAE running buffer. DNA loading dye (6X, MBI Fermentas) was added to a 
IX final concentration with the samples and loaded into the gel wells. To estimate the 
sizes of DNA fragments, I kb DNA size markers (Abgene) were also loaded onto the gel. 
If the concentration of DNA was also to be determined, Hyperladder I (Bioline) DNA 
markers were used (Table 2.7). The gel was run at 100 V for Ih and visualised using a 
UV transilluminator at 260 nm. Gels were photographed using BioDoc-It system (UVP) 
and printed by Sony Video Graphic Printer using Thermal Print Media (UPP-110HA). 
Photographs were then scanned using an Epson Perfection 3170 scanner. 
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1 kb DNA Size Marker (Abgene) Hyperladder I (Bioline) 
Band Size (bp) Band Size (bp) ng / Band 
10,000 10,000 100 
8,000 8,000 80 
6,000 6,000 60 
5,000 5,000 50 
4,000 4,000 40 
3,000 3,000 30 
2,500 2,500 25 
2,000 2,000 20 
1,500 1,500 15 
1,000 1,000 100 
750 800 80 
500 600 60 
250 400 40 
200 20 
Table 2.7: Size of DNA an ds used as size markers for 1% (w/v) TAE agarose gel 
electrophoresis. 
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2.18 DNA hybridization techniques 
2.18.1. Labelling of DNA probes with digoxigenin 
Gel purified DNA fragments were labelled by a random priming method using a 
commercially available digoxigenin (DIG) DNA labelling and detection kit (Roche). 
DNA to be labelled (up to 3 pg in a maximum of 15 µl EB in a microfuge tube) was 
denatured at 100°C for 10 min, then immediately chilled on ice for 10 min. The 
following components were added on ice: 
Random hexanucleotide mixture 2 µl 
dNTP labelling mixture (containing DIG-dUTP) 2 µl 
Klenow enzyme (2 units) I µl 
The volume of the reaction was made up to 20 µl with d1120. The reaction was 
incubated overnight at 37°C, then gel purified (Chapter 2.16.1). The purified probe was 
then quantified (Chapter 2.18.2) and, if not used immediately, stored at -20°C. Prior to 
use the probe was denatured by boiling for 10 min, followed by immediate chilling on 
ice for 10 min. 
2.18.2. Quantification of DIG-labelled DNA probes 
The amount of DIG-labelled material in a volume of labelled DNA was determined by 
comparison to labelled control DNA of known concentration supplied in the DIG DNA 
labelling and detection kit (Roche). The sample DNA and the control DNA were diluted 
according to the manufacturer's instructions, using a single pre-dilution step to obtain an 
estimated concentration of 1 ng µl'', followed by five serial 10-fold dilutions. 1 µ1 of 
each 10-fold dilution was spotted onto Hybond-N+ Extra (positively charged) nylon 
membrane (Amersham Life Sciences). The DNA was permanently bound to the 
membrane using a UV crosslinker (Chapter 2.18.4) and DIG-labelled DNA was then 
detected immunologically, using AP-linked anti-dioxygenin antibody (Chapter 
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2.3.11.13). The spot intensities of the control and probe dilutions were compared visually 
to estimate the concentration of the probe. 
2.18.3. Southern blotting 
Digested genomic DNA was separated by 1% (w/v) agarose gel electrophoresis 
(Chapter 2.17.5). DIG-labelled DNA molecular weight marker of size range 0.12-21.2 
kb (Roche) was loaded onto the gel to estimate the size of DNA 
41nd 
following 
development of the blot using AP-conjugated anti-DIG antibody. The gel was soaked in 
depurination solution (Chapter 2.3.11.2) for 10 min and washed in dH2O. This acts to 
nick large DNA molecules, aiding their transfer onto the membrane during the blotting 
procedure. The gel was then soaked in denaturation buffer (Chapter 2.3.11.3) twice for 
15 min and rinsed in dH2O. The gel was neutralised by soaking in neutralisation buffer 
(Chapter 2.3.11.4) twice for 15 mins. The DNA was transferred from the gel to a 
Hybond-N+ Extra membrane by vacuum blotting at 70 mbar for 90 mins, using IOX 
SSC as the transfer buffer. 
2.18.4. Fixing the DNA to the membrane 
DNA was fixed to the Hybond-N+ Extra (positively charged) nylon membrane with the 
use of a UV crosslinker (Amersham Life Sciences RPN 2500) at 70 mJ / cm2 for 15 sec. 
2.18.5. Prehybridization and hybridization 
All prehybridisation and hybridisation procedures were done in Techne Hybridiser HB- 
1D. Membranes to be probed with the DIG-labelled DNA were prehybridised for 2h at 
68°C in pre-hybridisation solution (Chapter 2.3.11.6) (20 ml per 100 cm2 of membrane). 
Just prior to use, the labelled probe (Chapter 2.18.1) was denatured in a microfuge tube 
by placing in a boiling water bath for 10 min. The labelled probe was immediately 
chilled on ice for 10 min and added to pre-heated hybridisation solution to give a final 
probe concentration of 5-25 ng ml''. The membrane was then hybridised with the 
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labelled probe overnight at 68°C. After hybridisation the solution was retained for future 
use and stored at -20°C. Unbound probe was removed by washing the membrane twice 
in 2X wash solution (Chapter 2.3.11.8) for 5 min at room temperature. The membrane 
was then washed twice in 0.5X wash solution (Chapter 2.3.11.9) for 5 min at 68 °C. 
2.18.6. Colorimetric detection of DIG-labelled DNA 
The hybridised and washed membranes were equilibrated with washing buffer (Chapter 
2.3.11.11) for 1 min and then blocked for 30 min with gentle rocking in blocking 
solution (Chapter 2.3.11.12). The membrane was then transferred to antibody solution 
containing a 1: 5000 dilution of stock anti-DIG-AP antibody (Chapter 2.3.11.13) 
(Roche). After 30 min incubation with gentle rocking, the membrane was washed twice 
for 15 min with washing buffer. The membrane was equilibrated for 2 min with 
detection buffer (Chapter 2.3.11.14) before 10 ml colour substrate solution (Chapter 
2.3.10.7) was applied to the membrane. This was then incubated in the dark to allow the 
membrane to develop. The presence of anti-DIG-AP bound to DIG-labelled DNA was 
visualised by the appearance of purple bands. After the colour had developed 
sufficiently, the membrane was washed in 1X TE (Chapter 2.3.11.15) for 5 min to stop 
the reaction. The membrane was then air-dried, scanned using an EPSON Perfection 
3170 scanner and stored in the dark. 
2.19 Phage techniques 
2.19.1. Preparation of phage lysates 
The donor strain was grown in broth with appropriate antibiotics at 37°C until in log 
phase. 1-3 ml of cultures were centrifuged (5000 rpm, 10 min, 4°C). The pellet was 
resuspended in 5 ml BHI in a 30 ml universal and 5 ml phage buffer was added. 30 pl 
stock lysate (phi 11, phi 85) was added and the mixture left at room temperature for 10 
min. The lysate was then incubated on a slow shaker (50 rpm) at 30°C for 2-4 h until 
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clear. If lysis took longer, the tube was left stationary overnight at 25°C. Once clear, the 
lysate was filter-sterilised (0.2 µm filter) and stored at 4°C. 
2.19.2. Determination of phage concentration 
S. aureus SH1000 was grown in BHI until log phase (ODD 0.6-1.0). Phage lysate was 
diluted up to 10"7 and 100 µl diluted phage mixed with 400 µl SH1000 culture. 50 µl 1M 
CaC12 was added and the tube was left for 10 min. 5 ml phage top agar (cooled to 50°C) 
was added to the phage mixture and used to overlay a phage bottom agar plate. Once set, 
plates were incubated at 37°C overnight. Plaques were counted and pfu/ml calculated (no. 
plaques x 108). 
2.19.3. Phage transduction 
The recipient bacteria were grown overnight in 20 ml LK. The cells were recovered by 
centrifugation at 5000 rpm for 10 min and the pellet resuspended in 1.5 ml LK. 500 µl 
and 100 f il phage lysate was added to 500 µl cells (control = no phage lysate) and the 
volume made up to 2 ml with LK + 10 mM CaC12. Tubes were incubated statically at 
37°C for 25 min, followed by 15 min at 37°C with gentle shaking. I ml ice-cold 0.02 M 
sodium citrate was added on ice and left for 5 min before centrifuging at 5000 rpm for 10 
min. The supernatant was removed and the pellet resuspended in I ml ice-cold 0.02 M 
sodium citrate. Mixtures were left on ice for 45-90 min, before 100 µl and 200 µl aliquots 
were spread onto LK-citrate plates (0.05% (w/v) sodium citrate). Plates were incubated at 
37°C for 90 min, then overlayed with 5 ml LK top agar containing 6 times the normal 
concentration of selective antibiotic. When set, plates were left at 37°C for 24-48 h until 
colonies developed. 
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2.20 Transformation techniques 
2.20.1. Transformation of E. cola by electroporation 
2.20.1.1. Preparation of electrocompetent E. coil cells 
E. coli Top 10 was grown overnight in LB and 2.5 ml was used to inoculate 250 ml LB. 
The culture was grown at 37°C, 250 rpm, until log phase (OD600 0.5-0.6). The culture 
was chilled on ice for 30 min before cells were harvested at 5000 rpm, 15 min, 4°C, in 50 
ml tubes. Pellets were washed twice with 25 ml ice-cold dH20 and then twice with 2 ml 
ice-cold 10% (v/v) glycerol. The final pellet was resuspended in 1.5 ml 10% glycerol, 
snap frozen in liquid nitrogen and stored at -80°C. 
2.20.1.2. Electroporation of E. coli competent cells 
50 p1 electrocompetent E. coli Top 10 cells were defrosted on ice and 4 pl plasmid was 
added (I µl control plasmid, e. g. pUC 18). Cells were transferred to a pre-chilled 0.1 cm 
cuvette and electroporated at 2500 V, 25 µF, 200 SZ. 1 ml SOC was added immediately 
and cells recovered at 37°C, 250 rpm for 90 min. Various sized aliquots were plated onto 
LB containing appropriate antibiotics and incubated at 37°C overnight. 
2.20.2. Transformation of S. aureus by electroporation 
2.20.2.1. Preparation of S. aureus electrocompetent cells 
S. aureus RN4220 was grown overnight at 37°C, 250 rpm in 10 ml B2 medium. 2 ml of 
culture was used to inoculate 11 132. The culture was grown at 37°C, 250 rpm, until log 
phase (OD600,,,,, 0.5-1.0). Cells were harvested by centrifugation for 10 min at 5000 rpm, 
4°C. The pellet was washed three times with 300 ml sterile dH20 at room temperature, 
then three times with decreasing volumes of 10% (v/v) glycerol (i. e. 100 ml, 50 ml, 25 
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ml). Finally, cells were resuspended in 1.25 ml 10% (v/v) glycerol before being snap- 
frozen in liquid nitrogen and stored at "80°C. 
2.20.2.2. Electroporation of S. aureus competent cells 
50 µl electrocompetent S. aureus RN4220 cells were defrosted on ice and 5- 20 µg 
plasmid DNA was added. The plasmid/cell mixture was then transferred to a 0.1 cm gap 
cuvette (BioRad) and electroporated at room temperature at 2300 V, 25 pF, 100 0 using 
a BioRad Gene Pulser. Cells were recovered by adding I ml pre-warmed B2 (containing 
an inducing concentration of Ery (i. e. 0.15 µg ml's), or no addition for Tet or Kan/Neo, 
where appropriate). Cells were recovered at 37°C, 250 rpm for 90 min before being 
plated out on Bill agar containing appropriate antibiotics and incubated overnight at 
37°C. 
2.21 Lambda Red cloning 
A single colony of E. coli EL250 containing an appropriate plasmid was grown overnight 
at 30°C, 250 rpm in LB containing appropriate antibiotic. 1 ml overnight culture was 
used to inoculate 50 ml fresh LB with antibiotic and cells were grown at 30°C to 
exponential phase (OD6oo,,,,, 0.4-0.5). Cells were then heat-shocked for 15 min by swirling 
at 42°C, transferred to a slurry ice-water bath for 10 min with swirling to induce the 
lambda red system. Cells were harvested by centrifugation at 5500 rpm, 10 min, 4°C. The 
supernatant was removed and cells resuspended in 25 ml sterile ice-cold water. The 
centrifugation process was repeated and cells were washed with ice-cold water twice 
more. The supernatant was removed after the last wash and the cell pellet was 
resuspended in 500 µl with ice-cold sterilised water. The freshly prepared competent cells 
were kept once for Ih before they were used for electroporation. Electroporation cuvettes 
(BioRad) were cooled in an ice-water bath for at least 10 min prior to use. A 50 µl sample 
of electrocompetent cells was mixed with 1-5 µl of DNA samples containing 0.08-0.4 µg 
of purified DNA fragments, transferred to the electroporation cuvette, and incubated on 
ice for I min. The cells were transformed by electroporation at 1.75 kV, 25 µF, 200 t: 2. 
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Following electroporation, cells were recovered by adding 1 ml LB, transferring the cell 
suspension into a sterile eppendorf tube and incubating at 30°C, 250 rpm, for 90 min. 50- 
100 pl aliquots were then plated on LB plates containing appropriate antibiotic and 
incubated for 2 days at 30°C. 
2.22 Opsonisation 
In order to determine the opsonophagocytic activity of specific antisera, assays were 
carried out using both S. aureus SH1000 and S. agalactiae 6313 in the presence of human 
neutrophils. Neutrophils were isolated from freshly obtained human blood (kindly 
provided by Dr. Lynne Prince and Dr. Kathryn Vaughan, University of Sheffield Medical 
School). Baby rabbit serum (Cederlane Laboratories Ltd. ) was used as a source of 
complement and antibodies against S. aureus or S. agalactiae were removed prior to use. 
Bacteria were grown to OD600m 0.5, washed once in PBS and diltued to 107 cells/ml in 
PBS. 100 [d washed cells (either S. aureus or S. agalactiae) were added to 500 µl baby 
rabbit serum and incubated at 4°C for 30 min on a rotating wheel. The baby rabbit serum 
was filter sterilised before use. Bacteria were grown to log phase (ODD,,,,, 0.5) in either 
BHI (S. aureus) or THY (S. agalactiae), and resuspended in PBS. To allow expression of 
iron-regulated genes, such as isdA in S. aureus, both species were also grown in iron- 
limited TSB. 
For the assay, 1x 105 cfu bacteria were incubated with 2.5 x 105 neutrophils, along with 
the specific antiserum (1: 10 dilution) and complement source (1: 10 dilution). Samples 
were made up to 500 pl using RPMI medium (Sigma). Appropriate controls were carried 
out by replacing the antiserum with either pre-immune serum or no serum (RPMI). In 
addition, controls were carried out with no neutrophils and with no complement source, 
each being replaced by RPMI. 
Immediately after mixing, a sample was removed and vortexed, and the number of 
bacteria counted by diluting in TSB containing 0.25% (v/v) Tween-20 and plating onto 
13111 agar plates. The bacteriafneutrophil samples were incubated at 37°C on a slow 
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shaker and samples were removed after 1.5 h (and 3 h), and the number of bacteria 
counted again as above. The plates were incubated overnight at 37°C and the percentage 
of initial bacteria calculated at each time point. 
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Chapter 3 
Identification of Streptococcus pyogenes components recognised 
by human sera 
3.1 Introduction 
Successful vaccine development requires identification of suitable targets. Developments in 
whole-genome sequencing of bacteria have enabled comprehensive analysis for vaccine 
candidates by bioinformatics-based screens. This approach has been utilised to identify 
putative antigenic targets in a number of bacterial pathogens, including Streptococcus 
pneumoniae (Wizemann et al. 2001) and Neisseria meningitidis (Pizza et al. 2000). Surface 
or secreted proteins are the most promising candidates for immunogenic targets as they are 
involved in processes such as cell adhesion, intracellular entry and immune system evasion. 
These proteins are at the interface between pathogen and host immune defences. 
The success of genomics-based approaches greatly relies on the proper identification and 
annotation of genes and is difficult to apply to those of no known function, which comprise 
approximately 40% of sequenced genomes (Weichhart et al. 2003). Furthermore, 
bioinformatic analysis does not reveal those proteins which are expressed in vivo during 
infection and are able to induce an immune response, an important factor for the 
development of effective targets for vaccines or therapeutic antibodies. 
To overcome the limitations of whole-genome analysis approaches, alternative methods 
have been developed to identify immunogenic proteins produced in vivo. For example, 
Weichhart et al. (2003) identified novel antigens of Staphylococcus aureus using in vitro 
protein selection by ribosome display. Proteins expressed in vivo during infection which are 
able to induce an immune response were identified using human antibodies from S. aureus- 
infected patients, identifying 14 possible candidate vaccine peptides. 
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Comparative proteome analysis has also led to the identification of putative vaccine 
candidates. Using two-dimensional electrophoresis, Jungblut et al. (1999) identified 25 
proteins differing in expression levels between the virulent Mycobacterium tuberculosis 
H37Rv and the non-virulent M. bovis BCG. Similarly, McAtee et al. (1998) identified 
several vaccine candidates of Helicobacterpylori by Western blotting for proteins reactive 
with pooled sera from infected patients and identification by N-terminal sequencing. 
Proteins identified include urease B subunit, enolase and catalase. 
Another promising strategy for antigen identification involves screening bacterial genomic 
DNA expression libraries with human sera to identify proteins expressed in vivo which 
stimulate an immune response within the host. This technique was successfully used to 
identify novel putative virulence determinants of Enterococcus faecalis, an opportunistic 
pathogen (Xu et al. 1997). The same method was employed by Lang et al. (2000) to 
identify antigens of Staphylococcus epidermidis, resulting in the identification of a novel 
protein, SsaA, thought to have a role in virulence. Immunoscreening has been used to 
identify putative antigens of Staphylococcus aureus in several studies, including an 
immunodominant ABC transporter protein in MRSA, homologous to the B. subtilis ABC 
transporter YkpA (Burnie et al. 2000), as well as Empbp, IsaA and Coagulase (Etz et al. 
2002). 
Recently, immunoscreening has identified antigenic components of both S. aureus (Clarke 
et al. 2006) and S. epidermidis (Pourmand et al. 2006), including a conserved family of 
proteins named the Sca family (See Section 3.3.1.1). Further to this, antigenic components 
of both Streptococcus agalactiae and Streptococcus pneumoniae were identified by similar 
methods (Stapleton et al. unpublished). In this study, a genomic expression library of 
Streptococcus pyogenes was screened for putative cross-reactive antigens using sera from 
S. aureus-infected patients. Bioinformatic analysis of the output from all five screens 
enabled the identification of conserved polypeptide domains, which may represent putative 
antigenic targets for prophylaxis against a range of Gram positive pathogens. 
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3.2 Results 
3.2.1. , ZAP expression library preparation 
In order to identify antigens expressed by Streptococcus pyogenes which were cross- 
reactive with human sera, a lambda ZAP expression library was screened in E. coli by 
plaque hybridisation. The lambda ZAP Express (Stratagene) library was previously 
constructed by Dr S. Clarke as follows: S. pyogenes HSC-5 genomic DNA was partially cut 
with Sau3A and the resulting fragments (2-10 kb in length) ligated into the BamHI site of 
Lambda ZAP Express, according to the manufacturer's instructions. The library was shown 
to have > 30% phage-containing inserts. 
3.2.2. Library Titration 
The phage titre of the library was determined by plaque enumeration using E. coli XL1- 
blue as the host strain. The phage titre was determined to be 7.3 x 107 pfu/ml. 
3.2.3. Human sera samples 
Nineteen sera were used to screen the S. pyogenes genomic expression library. These 
included sera from 11 patients infected with S. aureus, sera from 4 nasal carriers of S. 
aureus and sera from 4 non-carriers (Table 3.1) (all kindly provided by Dr R. Read, 
University of Sheffield). 
3.2.4. Immunoscreening of the expression library with human sera 
A primary screen of the S. pyogenes library using human sera was carried out by infection 
of phage into E. coif XLI-blue, resulting in plaque formation. Clones cross-reactive with 
human sera were identified after plaque lift onto nitrocellulose membranes. A summary of 
the screening protocol is shown in Figure 3.1. 
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In order to achieve good overall coverage of the S. pyogenes genome library, approximately 
3.6 x 104 pfu were screened per agar plate, and 10 plates were screened per serum. 
Therefore, at least 10.8 x 104 insert-containing plaques were screened for each serum. The 
genome size of S. pyogenes is approximately 1.89 Mb (www. tigr. org); if the insert size for 
each clone were 2 kb, 216 Mb of inserts would be screened for each serum, giving more 
than 100 times coverage of the genome. 
Serum antibodies bound to antigens present on the nitrocellulose membranes were detected 
using alkaline phosphatase-conjugated anti-human antibody (Chapter 2.14). Membranes 
were developed and positive primary clones were identified, as purple spots against a pink 
background (Figure 3.2). The number of positive clones varied between sera, up to 10 
putative positive clones were picked per plate for each serum. 
Positive clones from the primary screen were then subjected to a second round of screening 
at approximately 200 pfu per plate. Up to 20 well-separated clones were picked for each 
serum in the secondary screen. To ensure these clones were both pure and antigenic, a 
tertiary screen was carried out. The positive clones were spotted directly onto membranes 
(approx. 20 pfu) and probed with the original sera to confirm their reactivity. 
These pure clones were then excised to yield pBK-CMV-based phagemids (Figure 3.3) in 
E. coli XLl-blue. A total of 114 phagemids were excised from 14 sera. To confirm the 
presence of insert DNA within the phagemid, restriction digests were carried out using 
EcoRI and Pst! (Figure 3.4). The pBK-CMV backbone is seen as a 4.5 kb fragment in each 
clone, with S. pyogenes inserts represented by the various other fragments on the gel. In 
order to accurately identify and map the clones within the S. pyogenes genome, sequencing 
reactions were carried out. T3 and T7 primers (Table 2.6) were used for sequencing as they 
flank the insertion site in the vector, allowing the S. pyogenes inserts to be identified. DNA 
sequences corresponding to the ends of the cloned fragments were compared to the S. 
pyogenes MGAS8232 genome by BLAST analysis at TIGR (http: /tigrblast. tigr. org/cmr- 
blast/), allowing the entire insert sequence to be identified. 
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Serum Serum Type Positive Clones Identified Total 
No. of 
Number Clones 
D C 1 
G A 1 
F D 1 
55 - 0 
44 - 0 
36 S. aureus-infected A, B, G, M, P 5 
31 patient sera D, E, F, I, L, M, N, Q 8 
30 B, C 2 
28 A, B, C, D, H, I, L, M, 0, P, R 11 
24 B, D, H, I, K, O, P, Q, S, T 10 
21 - 0 
Total 39 
D62 C, E, F, G, H, I, J, M, N, P, Q, R, S 13 
D74 A, B, C, G, H 5 
D75 Nasal carriers B, C, D, E, G, H, I 7 
D78 A, C, D, E, F 5 
Total 30 
D59 - 0 
D60 A, B, E, F, H, I 6 
D63 Non-carriers - 0 
D65 B, C, E, F, H, I 6 
Total 12 
Total Clones Isolated 81 
Table 3.1: Positive clones identified from immunoscreening of the S. pyogenes library with 
human sera. 
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Bacteriophage lambda ZAP library of S. pyogenes was constructed, 
containing 2-10 kb DNA fragments. 
Primary Screen: Phage library infected into E. coli XL I -blue. 
Plaque lift onto nitrocellulose membranes. 
S. aureus-infected patient, hospital worker and 
community sera used to identify antigens. 
Secondary Screen: A further round of screening was 
carried out to isolate pure clones. 
Tertiary Screen: A final screen was carried out to ensure clones were both 
pure and antigenic. 
Positive clones were excised as kanamycin- 
resistant phagemids 
Phagemid DNA was purified and inserts sequenced. 
Database analysis (http: //tigrblast. tigr. org/cmr-blast/) was used to identify antigen- 
encoding genes of S. pyogenes. 
81 clones identified - 48 loci 
Figure 3.1: Flow diagram illustrating the method for screening the X ZAP expression 
library to identify S. pyogenes antigens. 
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Figure 3.2: Screening of the genomic library of S. pyogenes. Purple spots (identified by 
arrows) correspond to positive clones on the nitrocellulose membrane. 
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bl: ;, n I' :, 'J4: i_l 
4: ) 1A. 
reoiL:: r 
I 
_. .. Z 
Kp 
_!! 
n I 
pBK-CMV s« -Nd I AIL 
ii 
I Ii%" "ýrý _ 
ý/ `I 
. 1. 
pU L on 
pBK-CMV Multiple Cloning Site Region 
(sequence shown 952-1196) 
T7 Promoter 
AACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGAATTGGGTACACTTACCTGGTACCCCACCCGGGTGGAAA... 
T7 primer binding site 
... ATGGGCCCGCGGCCGCTCTAGAAGTACTCTCGAGAAGCTTTTTGAATTCTTTGGATCCACTAGTGTCGACCTGCAG... BamHl 
T3 Promoter O -gal Ia -fragment 
GCGCGCGAGCTCCAGCTTTTGTTCCCTTTAGTGAGGGTTAATTTCGAGCTTGGCGTAATCAAGGTCATAGCTGTTTCCTGT 
T3 primer binding site 
Figure 3.3: The pBK-CMV phagemid vector and polylinker sequence containing the 
multiple cloning site (MCS) flanked by T3 and T7 promoters (Novagen) (highlighted in 
red). The BamHl site into which inserts were cloned is underlined. 
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loh 
5 kl 
3 kl 
1.5 
5 kb 
Figure 3.4: 1% (w/v) agarose gel electrophoresis of restriction digests (EcoRl and Pstl) of 
representative S. pyogenes genomic library phagemid clones. The pBK-CMV backbone can 
be seen by the filled arrow at 4.5 kb. Inserts are shown by the open arrow. The gel shows 
examples of clones obtained from screening the library with S. aureus-infected patient sera 
28. Lane 1, molecular size marker; 2, clone 28A; 3,28B; 4,28C; 5,28D; 6,28H; 7,281; 8, 
28L; 9,28M; 10,280; 11,28P; 12,28R. 
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3.2.5. Bioinformatic analysis of cloned antigens 
The location of the sequenced clones on the Streptococcus pyogenes MGAS8232 genome 
was determined using BLAST analysis, using the following website: 
http: //tigrblast. tigr. org/cmr-blast/. In total, 81 clones were identified during the 
immunoscreen, corresponding to 48 loci in the S. pyogenes genome (Table 3.2). 172 full 
and partial open reading frames were identified within these loci and the cellular location of 
each of the proteins was predicted using SOSUIsignal (http: //bp. nuap. nagoya- 
u. ac jp/sosui/sosuisignal/sosuisignal_submit. html). Proteins were designated as secreted if 
they possessed a signal sequence and membrane proteins were assigned according to the 
presence of membrane spanning regions. 
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3.2.6. Analysis of putative antigenic loci 
Loci identified during the immunoscreen of S. pyogenes (Table 3.2) which were of 
particular interest were selected for further analysis. These included loci containing 
putatively surface located proteins and loci which were identified by multiple clones during 
the screen. The loci are shown below, the grey bars represent clones which were identified 
during the screen. 
Locus 6 (3029 bp; 152987 - 156015; 5 clones) 
500 bp 
SP0149 SF0150 SP0151 SF0152 
Analysis of locus 6 revealed the presence of four ORFs, represented by five individual 
clones. As SPO150 is represented by all five clones, this is most likely the antigenic protein 
in the locus. SPO150 encodes the toxin streptolysin 0 (Slo) and contains a signal peptide, 
suggesting that it is secreted or surface-located (Billington et al. 2000). 
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Locus 18 (3682 bp; 786173 - 789854; 3 clones) 
500 bp 
SF0891 
SF0892 SF0893 SF0894 SF0895 
Analysis of locus 18 identified five ORFs, represented by three individual clones. SP0891 
and SP0892 encode PyrF and PyrE, respectively, enzymes involved in pyrimidine 
ribonucleotide biosynthesis (Turnbough and Switzer, 2008). SP0893, which is represented 
by all three clones, encodes the enzyme AmiC which contains an amidase domain 
(PF01425). SP0894 is a secreted/surface-located amino acid ABC transporter, and the N- 
terminus of this protein is also represented by all three clones, indicating that this may be 
the antigenic protein within the locus. SP0895 is also an amino acid ABC transporter, 
although it is does not contain a signal peptide and is only partially contained within a 
single clone. 
Locus 35 (2407 bp; 1544830 - 1547236; 3 clones) 
500 bp 
SP1745 
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Analysis of locus 35 identified a single ORF represented by three individual clones. 
SP 1745 is a leucine-rich repeat protein of 1240 amino acids. Sequence analysis revealed the 
presence of two NEAT domains from amino acids 330-466 and 937-1094, suggesting a role 
for this protein in the transport of iron (Andrade et al. 2002). 
Locus 36 (4257 bp; 1555527 - 1559783; 5 clones) 
500 bp 
SP1753 SP1754 
SP1755 
SP1756 
Locus 36 consists of four ORFs represented by five individual clones. SP1754 encodes a 
fructokinase of 294 amino acids, SP1755 encodes a hypothetical protein of 31 amino acids 
and SP1756 encodes a putative endoglycosidase of 975 amino acids. SP1756 contains a 
signal peptide, indicating a secreted / surface location and as the C-terminus of this protein 
is represented by all five clones, it can be suggested that this is the most likely antigen 
within this locus. 
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Locus 39 (2470 bp; 1604401 - 1606870; 3 clones) 
500 bp 
SP1802 SP1803 SP1804 SP1805 
(2) 
(1) 
Analysis of locus 39 identified four ORFs, represented by 3 individual clones in two 
groups. SP1802 is a conserved hypothetical protein of 374 amino acids, and SP1803 is a 
deoxyribose-phosphate aldolase, DeoC, involved in nucleotide metabolism (Han et al. 
2004). SP 1804 is a putative nucleoside transporter of 400 amino acids and SP 1805 is a 259- 
residue uridine phosphorylase. 
Locus 42 (3120 bp; 1741557 - 1744676; 15 clones) 
500 bp 
SP1935 SP1936 SP1937 
(6) 
(9) 
Locus 42 consists of 3 ORFs, represented by 15 individual clones in two distinct groups. 
SP1937 is an immunogenic secreted protein (Isp) of 538 amino acids (McIver et al. 1996). 
The C-terminus of this protein is represented by all 15 clones isolated. Isp is a putative 
autolysin and contains a CHAP domain at the C-terminus, denoting an amidase function. A 
signal sequence is also present, indicating that Isp is a secreted / surface located protein. 
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SP 1936, an 83-residue protein of unknown function, contains homologues throughout S. 
pyogenes (83% identity over the full length of the protein). These homologues have been 
named immunogenic proteins (http: //www. tigr. org), suggesting the surface-located SP1936 
may also be immunogenic. 
Locus 47 (4552 bp; 1864737 - 1869288; 2 clones) 
500 bp 
X066 X067 SP2068 SF2069 SF2070 SP2071 SP2072 
Locus 47 contains seven ORFs represented by two clones in the screen. SP2066 is a tRNA 
methyltransferase and SP2067 is a surface-located hypothetical protein. SP2068 and 
SP2069 are both L-serine dehydratases, enzymes likely involved in the gluconeogenesis 
pathway. SP2070 is an immunogenic secreted antigen (IsaA), which is 66% identical over 
295 amino acids to IsaA in S. aureus (SACOL2584), a putative lytic transg I ycosy lase 
(Stapleton et al. 2007). SP2070 contains a signal sequence, indicating a secreted / surface 
location. SP2071 and SP2072 are both ABC transporter proteins. 
3.3 Immunoscreening of other Gram positive expression libraries with human sera 
Previously, bacteriophage expression libraries of S. aureus LH607 and S. epidermidis 138 
were probed with sera from patients with staphylococcal infection in order to identify 
antigenic and cross-reactive proteins (Clarke et al. 2006; Pourmand et al. 2006). In 
addition, libraries of Streptococcus agalactiae 6313 and Streptococcus pneumoniae 
(serotype III clinical isolate) were screened as above by Dr. Melanie Stapleton and Hilde 
Moseby, respectively. Results of these screens are shown in Table 3.3 and Table 3.4. 
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Locus Locus Clone Genes within locus Designation, putative Cellular 
co- coordinates (cloned region function or homology location 
ordinates (Clone amino acids) 
occurrence) 
1 ? -30318 ? -30318 (5) GBS0016 (? -447) PcsB, cell wall hydrolase S 
2 37239 - 37239- GBS0024 (* 195- phosphoribosylformylglycina C 
40554 40554(l) 1241*) mide synthase 
3 58525 - 58525 - GBS0042 (*213-420) Purl), phosphoribosylamine- C 
60012 60012 (1) glycine ligase 
GBS0043 (1-163) PurE, C 
phosphoribosylaminoimidazo 
le carboxylase 
GBS0044 (1-34*) PurK, S 
phosphoribosylaminoimidazo 
le carboxylase 
4 99888- 99888- GBS0088 (*154-183) unknown C 
102659 102659 (3) GBS0089 (1-139) unknown C 
GBS0090 (1-159) ComXI, role unknown C 
GBS0091 (1-230) putative phosphoglycerate C 
mutase 
GBS0092 (1-183*) serine-type D-ala D-ala M 
carbox e tidase 
5 275220 - 275220 - GBS0257 (*110-180) unknown M 
277811 277811(l) GBS0258 (1-304) GlyQ, glycyl-tRNA C 
synthetase (alpha subunit) 
GBS0259 (1-213) acyl carrier protein C 
phosphodiesterase 
GBS0260 (1-168*) GlyS, glycyl-tRNA C 
synthetase (beta subunit) 
6 320442 - 320442 - GBS0297 (*80-246) putative membrane protein M 
322053 322053 (1) GBS0298 (1-361) histidine kinase M 
GBS0299 i-8* response regulator C 
7 666392 - 666392 - GBS0651 (*154-667) CylE, unknown C 
668629 668629(l) GBS0652 1-232* CyIF, unknown C 
8 860546 - 860546 - GBS0836 (1-266*) ribonucleoside diphosphate C 
863346 863346 (1) reductase, ß-subunit 
GBS0837 (*599-719) ribonucleoside diphosphate C 
reductase 2, a-subunit 
9 1345584 - 1348424 - GBS1301 (*36-253) OrM, transposase C 
1350543 1350368 (1) GBS 1302 (1-96) pXOI, transposase C 
1345584 - GBS1306 (1-822) histidine triad protein S 
1350543(l) 
10 1351880- 1351880- GBS 1308 (*309- ScpB, C5a peptidase S 
1354239 1354239(3) 1094*) 
1352247 - 
1353873(l) 
11 1375822 - 1375822 - GBS1329 (1-225*) LacG, 6-phospho-ß- S 
1377466 1377466 (1) galactosidase 
GBS 1330 (*276-568) LacE, lactose-s cific PTS M 
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system enzyme IIBC 
component 
12 1407262 - 1407262- GBS1356 (1-401*) ASPi, agglutinin receptor M 
1409398 1409398(l) GBS1357 (1-196) AbiGI, abortive infection C 
protein 
GBS1358 (1-133*) AbiGII, abortive infection C 
protein 
13 1588571- 1588571- GBS1529 (*555- cell wall surface anchor C 
1590843 1590843(l) 1310) protein 
14 1732604 - 1732604 - GBS1674 (1-242*) HtpX, heat shock protein M 
1734906 1734906 (1) GBS1675 (1-184) membrane protein M 
GBS1676 (1-237) GidB, methyltransferase C 
GBS1677 (1-48*) sodium-transport family M 
protein 
15 1750256 - 1750256 - GBS1691 (*64-113*) unknown C 
1750411 1750411(l) 
16 1754356 - 1754356 - GBS1696 (*48-124) DhaK3, dihydroxyacetone C 
1755833 1755833(l) kinase 
GBS1697 (1-237) glycerol transport protein M 
GBS1698 *49-134 unknown C 
17 1810660 - 1810660 - GBS1752 (1-46*) unknown M 
1812243 1812243 (1) GBS1753 (*20-499) putative multi-drug resistance M 
protein 
Table 3.3: Identification of S. agalactiae 6313 loci encoding antigens recognised by human sera. 
The genomic expression library was screened with 11 patients with confirmed S aureus bacteremia, 
4 nasal carriers and 4 non-carriers. Locus, clone and gene co-ordinates correspond to the S. 
agalactiae NEM316 genome (http: //cmr. tigr. org), and function is assigned according to this genome 
database. "? " refers to sequence which could not be mapped to the S. agalactiae NEM316 genome. 
Results obtained by Dr. Melanie Stapleton. Asterisks indicate partially cloned genes. Predicted 
subcellular location is shown according to SOSUlsignal (http: //bp. nuap. nagoya- 
u. ac jp/sosui/sosuisignal/sosuisignal_submit. html): C, cytoplasmic; M, membrane; S, secreted / 
surface protein. 
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Locus Locus No. of Genes within locus Designation, putative function or Cellular 
co-ordinates Clones (cloned region homology location 
amino acids 
1 58164-61441 13 SP0055 (*62-75) hypothetical protein S 
SP0056 (1-432) PurB, adenylosuccinate lyase C 
SP0057 *708-1312 StrH, -N-acet lhexosaminidase S 
2 177326- 15 SP0186 (*151-943) UvrA, excinuclease ABC subunit C 
180252 A 
SP0187 1-183* e tidase M24 family protein C 
3 249373- 1 SP0273 (*315-693) FusA, translation elongation factor C 
253330 G 
SP0274 1-904* DNA polymerase III, a subunit C 
4 559641- 22 SP0588 (*561-737) Pnp, polyribonucleotide C 
561854 nucleotidyltransferase 
SP0589 (1-205) CysE, serine acetyltransferase C 
SP0590 (1-294) acetyltransferase, GNAT family C 
SP0591 1-22* C sS, c stein l-tRNA synthetase C 
5 615142 - 1 SP0648 (1-2093*) BgaA, ß-galactosidase S 
621723 
6 885552- 6 SP0932 (*88-420) ProA, y -glutamyl phosphate C 
887635 reductase 
SP0933 (1-265) ProC, pyrroline-5-carboxylate C 
reductase 
SP0934 (1-32) hypothetical protein C 
SP0935 1-55* Tmk, th id late kinase C 
7 944840- 1 SP1003 (*193-543*) conserved hypothetical protein S 
945893 
8 963764- 2 SP1020 (*105-359) PrfA, peptide chain release factor I C 
966490 SP 1021 (1-279) HemK protein C 
SP1022 (1-199) SuaS/YciO/YrdC family protein C 
SP1023 (1-143) acetyltransferase, GNAT family C 
SP1024 (1-13*) GlyA, serine C 
h drox eth ltransferase 
9 1106295- 1 SP1171 (1-235*) hydrolase, haloacid dehalogenase- C 
1113004 like family protein 
SP1172 (1-39) hypothetical protein C 
SP1173 (1-124) conserved hypothetical protein S 
SP1174 (1-819) conserved domain protein S 
SP1175 *94-802 conserved domain protein C 
10 1216210- 1 SP1282 (1-519) ABC transporter C 
1218716 SP1283 *39-299 HtpX, heat shock protein M 
11 1776017- 1 SP1870 (*187-318) iron-compound ABC transporter M 
1780064 SP 1871 (1-250) iron-compound ABC transporter C 
SP1872 (1-321) iron-compound ABC transporter S 
SP1873 (1-80) conserved hypothetical protein C 
SP 1874 (1-240) RluB, ribosomal large subunit C 
pseudouridine synthase B 
SP1875 (1-189) ScpB, segregation and C 
condensation rotein B 
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SP 1876 (*220-242) ScpA, segregation and C 
condensation protein A 
12 1863087- 1 SP1960 (*240- RpoC, RNA polymerase, ß subunit C 
1865606 1078* 
13 2051178- 2 SP2141 (1424*) glycosyl hydrolase-related protein C 
2054073 SP2142 (1-289) ROK family protein C 
SP2143 *663-886 conserved hypothetical protein C 
14 2108143- 1 SP2188 (*67-290) HslO, chaperonin C 
2112376 SP2189 (1-318) putative TIM-barrel protein, NifR3 C 
family 
SP2190 (1-693) CbpA, choline binding protein A S 
SP2191 *110-175 conserved hypothetical protein M 
15 2118276- 1 SP2195 (*8-152) CtsR, transcriptional regulator C 
2121133 SP2196 (1-242) ABC transporter C 
SP2197 (1-335) putative ABC transporter M 
SP2198 (1-249) ABC transporter M 
SP2199 *25-96 conserved hypothetical protein S 
16 2131598- 1 SP2211 (? ) IS66 family element, Orf3, ? 
2137361 degenerate 
SP2212 (1-81) transposase family protein, C 
truncation 
SP2213 (? ) IS66 family element, Orf2, ? 
interruption 
SP2214 (1-346) Tsf, translation elongation factor C 
Ts 
SP2215 (1-259) RpsB, ribosomal protein S2 C 
SP2216 (1-392) Usp45, secreted protein S 
SP2217 (1-164) MreD, putative rod shape- M 
determining protein 
SP2218 (* 165-272) MreC, rod shape-determining M 
rotein 
Table 3.4: Identification of S. pneumoniae loci encoding antigens recognised by human sera. The 
genomic expression library was screened with 11 patients with confirmed S. aureus bacteremia, 4 
nasal carriers and 4 non-carriers. Locus, clone and gene co-ordinates correspond to the S. 
pneumoniae TIGR4 genome (http: //cmr. tigr. org), and function is assigned according to this genome 
database. Results obtained by Hilde Moseby. Asterisks indicate partially cloned genes. "7' indicates 
insufficient protein sequence data available for analysis. Predicted subcellular location is shown 
according to SOSUIsignal (http: //bp. nuap. nagoya-u. ac jp/sosui/sosuisignal/sosuisignal_submit. html): 
C, cytoplasmic; M, membrane; S, secreted / surface protein. 
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3.3.1. Identification of potential antigenic protein families 
Data from the screens of expression libraries of S. aureus (Clarke et al. 2006), S. 
epidermidis (Pourmand et al. 2006), S. agalactiae, S. pneumoniae and S. pyogenes (this 
study) were subjected to bioinformatic analysis in order to identify potential families of 
cross-reactive antigens. Open reading frames identified in the S. aureus screen which 
corresponded to known or potential surface located or antigenic proteins were subjected to 
BLAST analysis to identify homologous proteins from the screens of the four other species. 
These were then grouped into putative antigenic families based on the sequence homology. 
Proteins were considered to have homologous regions if they contained regions of z15 
residues which were at least 25% identical and 40% similar. If the similarity was greater 
than 40%, then 21-24% identity was also considered homologous. The homologous regions 
from all strains are detailed in Table A. 1 (see Appendix). 
The bioinformatic analysis identified 13 families from nine S. aureus proteins which 
contained homologous regions of potentially cross-reactive proteins identified from at least 
four of the five expression libraries screened. These 13 families are summarised in Table 
3.6 and Figure 3.5. 
SdrD (SACOL0609) and CIfA (SACOL0856) are surface-located fibrinogen-binding 
proteins, anchored covalently to the cell wall via an LPXTG motif (Josefsson et al. 1998). 
These two proteins are members of a multigene family of proteins in S. aureus which 
contain serine-aspartate (SD) repeats, including SdrD, SdrC, SdrE, C1fA, C1fB and Pls 
(Clarke and Foster, 2006). SdrD has a direct homologue in S. epidermidis, which is 37% 
identical over 1118 amino acids to that of S. aureus. Similar cell wall anchor family 
proteins are present in the streptococci; these proteins also contain regions of repeating 
peptides. FnbpB is an LPXTG surface protein able to bind fibronectin, along with the 
related protein FnbpA. These two proteins are similar in structure, and this structure is also 
conserved within the fibronectin-binding proteins of streptococci (Joh et al. 1994). 
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SACOL2666 (ScaH) is an ionically bound surface protein, which contains both a C- 
terminal CHAP domain (amino acids 493-617) and a glucosaminidase domain (amino acids 
327-468). ScaH is a member of a family of ten proteins in S. aureus, designated the 
staphylococcal conserved antigen (Sca) family, which contain a conserved C-terminal 
CHAP domain (Pourmand et at. 2006). This family has direct homologues in S. 
epidermidis and ScaH is 55% identical in the two species 
(http: //www. ebi. ac. uk/emboss/alignfj. Related proteins are also found in streptococci, 
including Usp45 in S. pneumoniae, PcsB in S. agalactiae and Isp in S. pyogenes, which all 
contain a C-terminal CHAP domain homologous to that of ScaH. 
FmtB, also known as SasB, is an LPXTG protein and contains 18 repeats of 71 amino 
acids. It is present throughout the staphylococci and shares low similarity with the cell wall 
surface anchor family proteins in the streptococci, predominantly over the repeat regions of 
these proteins (e. g. FmtB is 16% identical over 688 amino acids to SA1647 of S. 
agalactiae). SasC is 31% identical over 2076 amino acids to SasB and contains 17 repeats 
of 71 amino acids (Brummell, 2005). 
Three members of a multigene family proposed to be involved in iron transport were 
identified to contain homologous fragments. IsdA (SasE), IsdB (SasJ) and Isdi (SasI) are 
surface proteins and are present throughout strains of S. aureus, as well as having 
homologues in S. epidermidis and Bacillus species. The proteins contain at least one NEAT 
domain, putatively associated with iron transport (Grigg et al. 2007). Although no direct 
homologues of Isd proteins have been identified in the streptococci, a NEAT domain was 
identified during the immunoscreen in a leucine-rich repeat domain protein (SP 1745) of S. 
pyogenes. NEAT domains have also been identified in Listeria species and Clostridium 
perfringens (Andrade et al. 2002). 
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S. aureus protein Common fragment (amino acids) 
SACOL0609 (SdrD) 30 - 200 
SACOL0856 (C1fA) 155 - 320 
SACOL2509 (FnbpB) 36-170 
SACOL2666 (ScaH) 
345 - 465 
510-619 
SACOL2150 (FmtB / SasB) 
1220 -1510 
1511-1780 
SACOL 1806 (SasC) 
1095-1275 
1600-1760 
SACOL1140 (IsdA / SasE) 215-310 
SACOL 1781 (IsdH / Sasl) 
275-405 
650 - 760 
SACOL 1138 (IsdB / SasJ) 490 - 620 
Table 3.6: Domains of S. aureus antigens which represent common homologous fragments 
across a range of cross-reactive antigens from staphylococcal and streptococcal species. 
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100 as 
SdrD (1315 aa) 
A domain CnaB-type domains SD Repeats 
100 as 
CIfA (933 aa) 
A domain R domain 
100 as 
FnbpB (940 aa) 
Fn-binding 
domains 
100 as 
ScaH (619 aa) 
Glucosaminidase CHAP 
100 as 
FmtB/SasB (2478 aa) 
Repeat region 
100 as 
SasC (2186 aa) 
Repeat region 
100 as 
IsdA/SasE (350 aa) 
NEAT 
100 as 
IsdH/Sasl (895 aa) 
NEAT NEAl NLAI 
100 as 
IsdB/SasJ (645 aa) 
NEAT NEAT 
Figure 3.5: Proteins with conserved domains identified during the immunoscreening. Conserved 
regions are highlighted by the red stripes. Pfam domains were identified according to 
http: //pfam. sanger. ac. uk. Gram-positive anchor domains are shown in yellow, all other Pfam 
domains are as labelled. 
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3.3.1.1. Alignment of protein families 
For each of the 13 families, all of the homologous regions of proteins from S. epidermidis, 
S. pneumoniae, S. agalactiae and S. pyogenes were aligned with the S. aureus full-length 
protein to determine which families were particularly well-conserved. This analysis 
identified the N-terminus of SdrD (amino acids 30-200) (Figure 3.6) and the C-terminus of 
IsdA (215-3 10) (Figure 3.7) as the most conserved domains amongst these families, as they 
contained homologous regions from proteins of all species within the most conserved 
fragments. Homologous fragments within other families mapped to more divergent regions 
of the S. aureus proteins (not shown). 
In addition to these two protein domains, one further domain was selected for subsequent 
analysis. Screening of the S. epidermidis expression library identified two novel proteins, 
SE0433 and SE2319 (Pourmand et al. 2006), which share 42% identity over their entire 
length and 60% identity in their C-terminal regions (www. ebi. ac. uk/emboss/align/). These 
were found to be members of the Sea family of proteins, with a conserved -110 amino acid 
C-terminal CHAP domain. SE0433 and SE2319 were hence named ScaB and ScaA, 
respectively. The Sea family consists of 10 proteins in S epidermidis, ScaA-J. Based on 
sequence homology, this family was also identified in S. aureus, which contains direct 
homologues of the ten S. epidermidis proteins. Furthermore, ScaH (SACOL2666) was 
identified in the S. aureus expression library screen (Clarke et al. 2006), and the CHAP 
domain of this protein is 36% identical to the CHAP domains of ScaB in both S. 
epidermidis (SE0433) and S. aureus (SACOL0723). Further members of this family were 
identified from screening of the streptococcal expression libraries: SP 2216 (Usp45) from 
S. pneumoniae, GBS0016 (PcsB) from S. agalactiae, and NT03SP1937 (Isp) from S. 
pyogenes. As the Sea family has members in several Gram positive species, some of which 
are potentially antigenic during infection, the conserved C-terminal CHAP domain of S. 
aureus ScaB (SACOL0723) was also chosen for further analysis. 
Fragments from the alignments were mapped to the S. aureus proteins as shown in Figures 
3.7-3.9. The conserved fragments, SdrD3o-200 (Figure 3.8), IsdA21s. 310 (Figure 3.9) and 
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ScaB14 265 (Figure 3.10), were subjected to BlastP analysis (http: //tigrblast. tigr. org/cmr- 
blast/) and fragments identified during the alignments of the protein families were mapped 
to the S. aureus protein. Putative Pfam domains of each protein were identified using 
http: //pfam. sanger. ac. uk. 
This analysis demonstrated that the N-terminus was predominantly the homologous domain 
for each of the fragments identified by SdrD30-200 (Figure 3.8). A direct homologue of SdrD 
was identified in S. epidermidis, SE033 1, which contained a comparable SD repeat region, 
Gram-positive anchor domain and CnaB-type domains. Several amidases were also 
identified, four of which contained CHAP domains. 
When domains homologous to IsdA215_310 were analysed (Figure 3.9), it was apparent that 
the regions within each protein were distributed more diversely, unlike the relatively well- 
conserved N-terminus seen for SdrD. However, homologous fragments were generally 
present in the N-terminal region of each protein. 
Five of the six proteins identified to be homologous to ScaB contained CHAP domains and 
the sequence homology occurred in this region in each case (Figure 3.10). The analysis also 
identified two direct homologues of ScaB in S epidermidis which were identified in the 
screen, SE0433 (ScaB) and SE2319 (ScaA). ScaA was also identified by the SdrD domain, 
although the N-terminus was shown to be the homologous region in this case. 
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SACOL0609 SdrD (1381 aa) 
51O1`)0432* (195) 
SE0750 35-159 (124) 
SE0750 676-723 (47) 
SE0750 1137-1163 (26) 
SE0750 1118-1163 (45) 
SE0245 1-190 (190) 
SE0245 130-354 (224) 
SE0245 96-259 (163) 
SE0245 618-654 (36) 
SE0245 304-335 (31) 
SE0331 601-825 (224) 
SE0331 54-1025 (971) 
SE0331 1-203 (203) 
SE0185 4-185 (181) 
SE0185 187-226 (39) 
SE2319 9-82 (73) 
SE2319 34-69 (35) 
SP_0648 7-171 (164) 
SP_0648 672-708 (36) 
SP_0648 676-718 (42) 
SP 0648 1879-1917 (38) 
SP 0648 963-978 (15) 
SP_0648 252-264 (12) 
SP_1174 232-312 (80) 
SP 2190 330-474 (144) 
SP 2190 628-672 (44) 
SP 2190 627-642 (15) 
SP 2216 7-184 (177) 
SP_2216 348-388 (40) 
GBS0016 15-182 (167) 
GBS1529 134-597 (463) 
GBS1529 1259-1278 (19) 
SP1937 88-179 (91) 
SP1937 420-437 (17) 
Figure 3.6: Alignment of the SdrD antigen family identified in the immunoscreen. The 
full-length S. aureus protein is shown by the bold black line. Homologous regions of 
proteins from other species are mapped to this, cloned regions (plus size) in amino acids are 
shown. Blue, S. epidermidis protein fragments; Red, S. pneumoniae protein fragments; 
Green, S. agalactiae protein fragments; Purple, S. pyogenes protein fragments. The 
conserved region chosen for further analysis (amino acids 30-200) is shown by the thick 
grey line. 
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SP_0057 29-94 (65) 
GBS0016 247-329 (82) 
GBS1356 131-207 (76) 
SP1745 1111-1184 (73) 
SP1745 341-382 (41) 
Figure 3.7: Alignment of the IsdA antigen family identified in the immunoscreen. The full- 
length S. aureus protein is shown by the bold black line. Homologous regions of proteins 
from other species are mapped to this, cloned regions (plus size) in amino acids are shown. 
Blue, S. epidermidis protein fragments; Red, S. pneumoniae protein fragments; Green, S. 
agalactiae protein fragments; Purple, S. pyogenes protein fragments. The conserved region 
chosen for further analysis (amino acids 215-3 10) is shown by the thick grey line. 
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Figure 3.8: Homologous proteins identified during immunoscreening and subsequent 
alignment of homologous protein regions. Fragments homologous to the conserved region 
of SdrD identified (amino acids 30-200) are shown in red stripes. Pfam domains were 
identified according to http: //pfam. sanger. ac. uk. Gram-positive anchor domains are shown 
in yellow, all other Pfam domains are as labelled. 
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Figure 3.9: Homologous proteins identified during immunoscreening and subsequent 
alignment of homologous protein regions. Fragments homologous to the conserved region 
of IsdA identified (amino acids 215-310) are shown in red stripes. Pfam domains were 
identified according to http: //pfam. sanger. ac. uk. Gram-positive anchor domains are shown 
in yellow, all other Pfam domains are as labelled. 
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Figure 3.10: Homologous proteins identified during immunoscreening. Fragments 
homologous to the conserved CHAP domain of ScaB (amino acids 146-265) are shown in 
red stripes. Pfam domains were identified according to http: //pfam. sanger. ac. uk and as 
labelled. 
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3.4 Use of conserved protein domains as vaccine candidates 
3.4.1. Overexpression of conserved protein domains 
In order to facilitate the analysis of the cross-genera identified domains for vaccination, the 
recombinant proteins were produced in E. coli. IsdA-c (amino acids 215-310), SdrD-n 
(amino acids 30-200) and ScaB-c (amino acids 156-265) were overexpressed by Dr. 
Melanie Stapleton (unpublished), and the purified recombinant polypeptides were used to 
raise polyclonal antisera in rabbits by the Antibody Resource Centre, Sheffield University. 
3.4.2. Role of specific antisera in opsonisation of S. aureus and S. agalactiae 
In order to determine the opsonophagocytic activity of specific antisera against the 3 
conserved domains, sera were tested in assays using both S. aureus SH1000 and S. 
agalactiae 6313 in the presence of human neutrophils (Chapter 2.22). To allow expression 
of iron-regulated genes, including isdA, bacteria were grown in iron-limited media when 
the IsdA-c antiserum was being tested. Log phase bacteria were incubated with neutrophils, 
along with the specific antiserum and complement source. 
3.4.2.1. Preliminary Control Experiments 
Figure 3.11 demonstrates that killing of S. aureus is greatly increased in the presence of 
specific antisera. When no neutrophils are present, bacterial counts increase both with pre- 
immune serum (262% initial CFU after 3h) and no serum (657% initial CFU after 3h). 
With no complement, bacteria either increase (274% initial CFU after 3h with pre-immune 
serum) or decrease only slightly (73% initial CFU after 3h with no serum). When both 
neutrophils and complement are present, killing occurs with both pre-immune serum and no 
serum (48% and 40% initial CFU after 3h, respectively). However, the level of killing is 
highest when SdrD-n or ScaB-c antisera are present (1.6% and 2.3% initial CFU after 3h, 
respectively). 
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In iron-limited media (Figure 3.11 B), killing occurs in the no neutrophil and no 
complement controls in pre-immune serum (18% and 10% initial CFU after 3h, 
respectively), and the no neutrophil control with no serum (52% initial CFU after 3h). 
When both neutrophils and complement are present, killing occurs in both cases (pre- 
immune serum: 4% initial CFU after 3h; no serum: 18% initial CFU after 3h). With only 
neutrophils there is an increase of initial CFU (150% after 3h). Importantly, the level of 
killing is highest when the IsdA-c antiserum is present (0.3% initial CFU after 3h). 
Figure 3.12 demonstrates an increased level of killing of S. agalactiae in the presence of 
specific antisera. Control experiments demonstrate that in the presence of pre-immune 
serum, bacterial numbers increase in all cases. 
In THY medium (Figure 3.12 A), some killing occurs when no antiserum is present. With 
both neutrophils and complement included in the assay only 4% initial CFU is recovered 
after 3h. Similarly, when only complement is included only 9% initial CFU remains after 
3h. When neutrophils alone are assessed, surviving bacteria increase (289% initial CFU 
after 3h), suggesting that neutrophils are not effective at opsonising S. agalactiae in the 
absence of a complement source. Importantly, bacteria are most effectively killed when 
SdrD-n and ScaB-c antisera are present (0.8% and 1.6% initial CFU after 3h, respectively). 
Under iron-limited conditions (Figure 3.12 B), bacteria are not killed in the absence of 
antisera. When both neutrophils and complement were present 100% initial CFU remained 
after 3h and when complement was removed, 122% remained. As above, killing occurred 
in the absence of neutrophils (29% initial CFU after 3h). However, when these controls 
were compared to the sample including IsdA-c antiserum it was clear that the specific 
antibodies played a role in opsonising the bacterial cells as only 3.9% initial CFU remained 
after 3h. 
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3.4.2.2. Opsonisation Assays 
In order to confirm the statistical significance of the opsonophagocytic killing, experiments 
were repeated in triplicate and data interpreted by t-test analysis (Figures 3.13,3.14; Table 
3.9). 
Figure 3.13 and Table 3.9 show that incubation of S. aureus with the SdrD-n and ScaB-c 
antisera resulted in significant reductions in the number of bacteria recovered (3% and 5% 
initial CFU after 90 min, respectively) compared to pre-immune serum (37% initial CFU 
after 90 min; P=0.0168 and 0.0185, respectively) and no serum (71% initial CFU after 90 
min; P=0.0001 and 0.0003, respectively). Incubation with IsdA-c antiserum also resulted 
in a significant reduction in the number of bacteria recovered (2.7% initial CFU after 90 
min, compared to 66% for pre-immune and 53% for no serum; P=0.0192 and 0.0005, 
respectively). 
Analysis of the opsonisation of S. agalactiae (Figure 3.14; Table 3.9) showed that 
incubation of bacteria with SdrD-n and ScaB-c antisera increased the opsonic killing after 
90 min (20% and 30% initial CFU after 90 min, respectively) compared to the no serum 
control (44% initial CFU after 90 min; P=0.0766 and 0.2534, respectively), and was 
significantly different when compared to pre-immune serum (223% intial CFU after 90 
min; P=0.0004 and 0.0005, respectively). Incubation with IsdA-c antiserum resulted in a 
significant reduction in the number of bacteria recovered (28% initial CFU after 90 min, 
compared to 291% for pre-immune and 107% for no serum; P=0.0007 and 0.0145, 
respectively). 
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Figure 3.11: Opsonisation of S. aureus SH 1000. Panel A, S. aureus grown in BHI; Panel 
B, S. aureus grown in iron-limited media (TSB). Components included in each assay are 
identified by the key. 
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Figure 3.12: Opsonisation of S. agalactiae 6313. Panel A, S. agalactiae grown in THY; 
Panel B, S. agalactiae grown in iron-limited media (TSB). Components included in each 
assay are identified by the key. 
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Figure 3.13: Percentage bacteria remaining after 1.5 h opsonisation of S. aureus SH 1000 
grown with (A) and without (B) iron. All samples contained both neutrophils and 
complement, results are from triplicate samples. Standard error bars are shown. 
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Figure 3.14: Percentage bacteria remaining after 1.5h opsonisation of S. agalactiae 6313 
grown with (A) and without (B) iron. All samples contained both neutrophils and 
complement, results are from triplicate samples. Standard error bars are shown. 
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Pre-immune serum No serum 
S. aureus 
a-SdrD 0.0001 0.0168 
a-ScaB 0.0003 0.0185 
a-IsdA 0.0005 0.0192 
S. a alacllae 
a-SdrD 0.0766 0.0004 
a-ScaB 0.2534 0.0005 
a-IsdA 0.0145 0.0007 
Table 3.6: t-test analysis of effect of immune sera on bacterial opsonisation as measured by 
killing. P-values were calculated by comparing results to both the pre-immune serum 
control and the no serum control. 
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3.4.3. Protection studies 
IsdA-c and ScaB-c polypeptides were tested in mouse models of septic arthritis (in 
collaboration with Prof. Andrej Tarkowski and Dr. Margareta Verdrengh, Department of 
Rheumatology and Inflammation Research, University of Göteborg, Sweden). Mice were 
immunised with 50 gg protein and infected with either S. aureus or S agalactiae. Control 
mice were injected with ovalbumin (OVA). After 20 (IsdA-c) or 14 (ScaB-c) days mice 
were assessed for prevalence of arthritis, mortality and weight loss. 
Vaccination with IsdA-c (Table 3.7) displayed some efficacy in the case of staphylococcal 
infection, although differences were less evident with streptococcal infection. After 
infection with S. aureus, immunised mice had a lower prevalence of arthritis and mortality, 
although no differences were observed in the weight changes between groups. The 
protection against S. agalactiae infection was less apparent. No data was obtained for the 
percentage arthritis as induction of arthritis failed (for unknown reasons). There was no 
difference in the level of mortality between the immunised mice and the control mice, 
however, immunised mice demonstrated a reduction in weight loss. 
Vaccination with ScaB-c (Table 3.8) resulted in a trend to higher survival and lesser 
arthritis in the staphylococcal group, although differences are relatively minor. 
Immunisation with ScaB-c did not, however, provide any protection against S. agalactiae 
infection. 
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S. aureus S. agalactiae 
IsdA-c OVA IsdA-c OVA 
Arthritis 70% 100% ND ND 
Mortality 0% 40% 40% 40% 
Weight change 0% 0% -0.9% -10.0% 
Table 3.7: Effect of vaccination with IsdA-c polypeptide in mouse septic arthritis model. 
Prevalence of arthritis, death and changes in weight were assessed. ND = no data. 
S. aureus S. agalactlae 
ScaB-c OVA ScaB-c OVA 
Arthritis 44% 57% 44% 11% 
Mortality 10% 30% 10% 10% 
Weight change -10.0% -4.6% -6.2% -3.4% 
Table 3.8: Effect of vaccination with ScaB-c polypeptide in mouse septic arthritis model. 
Prevalence of arthritis, death and changes in weight were assessed. 
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3.5 Discussion 
The primary aim of this study was to identify antigenic components of S. pyogenes which 
were cross-reactive with antibodies raised against S. aureus antigens expressed during 
infection. The immunoscreen allowed the detection of genes expressed in vivo rather than 
in vitro and the use of a genomic library of S. pyogenes meant that a large number of clones 
could be screened, decreasing the possibility of potential antigens being missed. 
Furthermore, expression using this method does not rely on the correct in-frame cloning of 
insert DNA and the use of phage lambda allows the production of insoluble proteins or 
those toxic to E. coll. 
Despite these advantages, the immunoscreen was not completely comprehensive. For 
antigens to be identified they must be represented in the library and expressed from either 
their own or the lac promoter, hence, the partial Sau3A digest of the genomic library may 
disrupt some genes. In addition, many clones identified in the screen contained several 
ORFs, so the true immunotarget could not be conclusively determined. 
In total, 81 clones were identified by the screen, representing 48 different loci in the S. 
pyogenes genome. Interestingly, the largest proportion of clones was identified from sera of 
S. aureus-infected patients, and that of nasal carriers. The fewest clones were isolated from 
immunoscreening with sera samples of non-carriers. The immunoscreen identified 128 
putatively cytoplasmic proteins, 31 membrane proteins and 13 secreted or surface-located 
proteins. Surface / secreted proteins in particular represent promising vaccine targets as 
they have key roles in the interaction between pathogen and host cells. The high proportion 
of cytoplasmic proteins may be due to epitopes shared with staphylococcal proteins or 
proteins of other bacterial species to which we are exposed. Alternatively, these antigens 
may be released upon cell lysis. 
The most commonly identified locus in the immunoscreen was locus 42, represented by 15 
separate clones. Mapping of the clones to this region showed that Isp, a putative autolysin, 
was the most likely antigen. Isp (immunogenic secreted protein) is conserved amongst 
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strains of S. pyogenes, as well as containing homologous regions to proteins of other 
streptococcal species (McIver et al 1996). Bioinformatic analysis revealed that Isp is in 
fact a member of the Sca family of proteins, along with Usp45 from S. pneumoniae and 
PcsB from S. agalactiae. Analysis of antibody titre in convalescent sera from a patient with 
GAS throat demonstrated that Isp is expressed during infection and generates an antibody 
response (McIver et al. 1996), therefore, this antigen may represent an appropriate 
immunotherapy target. 
Another putative autolysin, IsaA, was identified by two clones during the immunoscreen 
(locus 47). NT03SP2070 is 66% identical over 295 amino acids to SACOL2584 (IsaA) in 
S. aureus. SACOL2584 is a putative lytic transglycosylase, which is related to 
SACOL2088 (SceD), a protein of similar function. When tested in a mouse septic arthritis 
model, a mutant of isaA was slightly attenuated for pathogenicity, and an isaA sceD double 
mutant was significantly attenuated (Stapleton et al. 2007). IsaA of S. aureus has also been 
previously identified to be expressed during S. aureus infection by immunoscreening (Etz 
et al. 2002), and a significantly higher titre of reactive IgG against IsaA was detected in 
serum from S. aureus-infected patients (Clarke et al. 2006). 
A leucine-rich repeat domain protein (NT03SP1745) was identified by three clones in the S. 
pyogenes screen (locus 35). Leucine-rich repeat domains are present throughout Gram 
positives and have been demonstrated to be involved in virulence. LrrG, a leucine-rich 
repeat domain protein of GBS, is present in S. agalactiae and has a homologue in S. 
pyogenes. Vaccination with this protein was shown to protect mice against lethal infection 
by GBS (Seepersaud et al. 2005). Furthermore, disruption of the elM gene, which encodes 
a leucine-rich repeat domain protein of Enterococcus faecalis, significantly attenuated 
bacterial virulence in a mouse peritonitis model (Brinster et al. 2007). 
Analysis of locus 36 identified a secreted endoglycosidase (NT03SP1756) as a putative 
antigen, recognised by five clones. This S. pyogenes enzyme specifically hydrolyses human 
IgG by removing the glycan chains from the y-chains of the IgG molecule (Collin and 
Olsdn, 2001), a mechanism which blocks antibody-mediated phagocytosis and killing by 
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neutrophils (Voyich et al. 2004). A homologue of this endoglycosidase, EndoE, has also 
been identified in E. faecalis (Collin and Fischetti, 2004), suggesting this virulence- 
associated protein may also be conserved amongst several Gram positive pathogens. 
Five clones from the screen identified the toxin streptolysin 0 (locus 6), a key virulence 
factor of S. pyogenes infection. This toxin can permeabilise mammalian cell membranes 
and is expressed during infection. It is associated with several streptococcal diseases, 
including acute rheumatic fever (Martins et at 2008). 
Several ABC transporters were identified during the screen as being cross-reactive 
antigens. These proteins are ubiquitous among bacteria, involved in the import and export 
of a wide variety of molecules. The protein complexes consist of two types of domain: an 
ATP-binding cassette (ABC), which is highly conserved, and a transmembrane domain that 
is less well-conserved (Linton and Higgins, 1998). Some ABC transporters have been 
demonstrated to be involved in virulence, for example, immunization with the iron uptake 
ABC transporter proteins PiaA and PiuA has been demonstrated to prevent respiratory 
infection by S. pneumoniae (Jomaa et at 2006). An immunodominant ABC transporter was 
also identified in MRSA (Burnie et al. 2000). This ABC transporter is homologous to the 
B. subtilis protein YkpA, which is putatively involved in cell wall biosynthesis. It was 
therefore proposed that targeting of this antigen in MRSA by the immune response may 
disrupt synthesis of the cell wall, reducing the virulence of the bacteria. 
Once S. pyogenes antigenic components had been identified in this study, the results were 
combined with results from other studies in order to identify putative cross-reactive 
antigens amongst five Gram positive species. To reduce the number of database searches to 
an appropriate and manageable number, the S. aureus proteins identified in the 
immunoscreen (Brummell, 2005; Clarke et al. 2006) were used as the basis to search the 
other genomes. A threshold limit of 25% identity and 40% similarity over at least 15 amino 
acids was used for the analysis (or 21-24% identity if the similarity was greater than 40%). 
This limit allowed for expected differences between species. Using a relatively low 
threshold level of homology allowed for cross-species variability so that antigenic groups 
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could be determined with the potential to protect across the range of Gram positive 
pathogens. The bioinformatic analysis of genome databases identified many homologous 
fragments which were not found during the original immunoscreen of that species. As 
discussed previously, many antigens may have been missed during the screening due to the 
technique utilised, therefore, additional screening may have given a more comprehensive 
complement of antigens but was not deemed worthwhile due to time constraints. 
Primary bioinformatic analysis identified 13 families of proteins containing homologous 
fragments of proteins from at least four of the five screened species. SACOL2666, also 
named ScaH (Pourmand et al. 2006), has been shown to be a member of a multigene family 
in both S. aureus and S. epidermidis. The Sca family consists of 10 proteins, which have a 
conserved C-terminal -110 amino acids. This C-terminus (amino acids 510-619 in ScaH) 
was identified during the screen as being cross-reactive and conserved between species 
(Table 3.5). The Sca family will be discussed further in Chapter 4. Scall has also been 
shown to be part of a family of four putative N-acetylglucosaminidases, along with Atl 
(SACOL1062), SACOL1825 and SagA (SACOL2298) (Syed Mohamad, 2007). The 
glucosaminidase domain has been identified as being amino acids 338-466 in ScaH, 
corresponding approximately to that found to be conserved during the screening analysis. 
CIfA is an LPXTG protein which binds fibrinogen (Fg) by an A domain of approximately 
500 amino acids. C1fA is structurally related to another Fg-binding protein, CUB, although 
the genes are not highly conserved, with only 27% identity in the A domain. CIfA is an 
important virulence factor in infective endocarditis and staphylococcal arthritis, mediating 
the binding and activation of platelets during infection (O'Brien et al 2002). It has also 
been demonstrated that CifA, along with another related protein, FnbpA, promotes early 
valve colonisation during infective endocarditis (Que et at 2005). The analysis of the 
protective effect of immunisation with CIfA revealed a marked reduction in the severity of 
arthritis in a mouse model of infection, suggesting that CIfA is a crucial virulence 
determinant for this disease (Josefsson et al. 2001). Monoclonal antibodies generated 
against the ligand-finding domain of CIfA were shown to provide significant protection in 
mice against sepsis-associated death by S. aureus infection, as well as demonstrating broad 
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reactivity among clinical strains (Hall et at. 2003). Furthermore, CIfA has been 
demonstrated to inhibit phagocytosis, both in the presence and absence of fibrinogen, and 
the effect was proposed to be comparable to that of protein A (Higgins et al. 2006). Recent 
studies have evaluated the role of Aurexis® (tefibazumab), a humanised monoclonal 
antibody that recognises ClfA. This MAb was demonstrated to significantly protect against 
intravenous MRSA challenge in murine septicaemia and rabbit infective endocarditis (IE) 
models (Patti, 2004; Domanski et al. 2005), and was reported to be well-tolerated and 
effective in human trials (Weems et al. 2006). Aurexis® represents a novel approach using 
passive immunisation against a specific MSCRAMM and this MAb is currently under 
development as adjunctive therapy in combination with the antibiotic vancomycin. 
Fibronectin-binding protein B (FnbpB) is 30.5% identical over 933 amino acids to C1fA 
(Brummell, 2005). In addition to mediating an interaction between bacterial and host cells 
during the initial stages of colonisation, FnbpB, along with its homologue FnbpA, can 
initiate internalisation into non-professional phagocytes (Clarke and Foster, 2006). The 
structures of FnbpB and FnbpA are similar to each other, and to equivalent fibronectin- 
binding proteins in streptococci, e. g. PFBP of S. pyogenes (Keane et al. 2007; Rocha and 
Fischetti, 1999). Despite their similarily, FnbpB and FnbpA have demonstrated different 
roles in infective endocarditis. Whereas FnbpA induced the aggregation of platelets when 
present on S. carnosus cells, FnbpB did not (Heilmann et al. 2004). 
SasB has been named Mrp (Wu and De Lencastre, 1999) and FmtB (Komatsuzawa et al. 
2000). SasB is an LPXTG family protein containing 18 repeats of 71 amino acids. The role 
of this protein remains to be fully determined, although mutation of fmtl3 has been shown to 
affect oxacillin resistance in MRSA (Komatsuzawa et al. 2000). ELISA analysis of SasB 
with serum samples from diseased and healthy individuals, and carriers and non-carriers of 
S. aureus demonstrated that this protein is positively associated with disease, and with nasal 
carriage (Clarke et al. 2006). 
Another Sas protein was identified in the analysis, SasC. This protein contains 17 repeats of 
71 amino acids and is 31% identical over 2076 amino acids to SasB. The N-terminal A 
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region has a similar predicted structure to the A regions of CIfA and SdrD (Roche et al. 
2003). Despite this similarity, SasC is unable to bind many of the human ligands these 
proteins have been shown to adhere to, including fibronectin, fibrinogen and fetuin 
(Brummell, 2005). The role of SasC remains to be determined. 
Two fragments of Sasl were identified as being conserved during the analysis. SasI has also 
been named HarA (Dryla et al. 2003) and IsdH (Mazmanian et al. 2003). This protein is 
part of a family of proteins involved in the uptake of haem-iron across the cellular 
envelope, although it is encoded by a gene at a separate locus to the other Isd proteins 
(Mazmanian et al. 2003). The isd genes are transcriptionally controlled by the iron- 
responsive regulator Fur and are expressed under iron-limited conditions (Clarke and 
Foster, 2006; Mazmanian et al. 2003). SasI contains three NEAT domains, the active sites 
for ligand binding, and binds human haptoglobin, a protein that sequesters free 
haemoglobin in serum, in the transfer of heroin via the Isd proteins (Liu et al. 2008). Sasl 
has been shown to be present in 96% of invasive strains of S. aureus, and a significantly 
elevated IgG titre was observed in convalescent patient sera, confirming its expression 
during infection (Roche et al. 2003; Clarke et al. 2006). 
Another member of the Isd family of proteins, IsdB (SasJ), was identified to contain a 
conserved domain. IsdB contains two NEAT domains and can bind several iron-containing 
proteins (Mazmanian et al. 2003). It is proposed to be involved in the binding of 
haemoglobin and subsequent transfer of heure to IsdA during heure acquistion via the Isd 
proteins (Liu et al. 2008). IsdB is positively associated with infection, as a significantly 
elevated IgG titre was observed in convalescent patient sera (Roche et al. 2003). 
Vaccination with IsdB has provided significant protection in animal models, including 
rhesus macaques, in which a more than five-fold increase in antibody titres was observed 
after a single immunisation (Kuklin et al. 2006). 
IsdA, also known as StbA (Taylor and Heinrichs, 2002), FrpA (Morrissey et al. 2002) and 
SasE (Roche et al. 2003) was first identified for its ability to bind transferrin, IsdA is an 
LPXTG cell wall protein regulated by exogenous iron levels via the Fur protein, only being 
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expressed under iron-limited conditions (Clarke et al. 2004). It is part of a family of iron- 
regulated surface determinant (Isd) proteins, some of which were also identified as 
containing conserved regions in this screen, e. g. SasC/IsdC and SasJ/IsdH. In addition to 
binding transferrin, IsdA is a broad spectrum adhesin able to bind both fibrinogen and 
fibronectin via a NEAT domain. Recently, it has been shown that IsdA also binds 
lactoferrin, an anti-staphylococcal polypeptide found in human nasal secretions, hence 
conferring resistance to its killing (Clarke and Foster, 2008). IsdA is required for nasal 
colonisation and mutation of isdA resulted in a reduction in the ability of bacteria to bind 
human nasal epithelial cells and to colonise the anterior nares of cotton rats (Clarke et al. 
2006). Furthermore, significantly higher titres of reactive IgG against IsdA are detected in 
serum samples from individuals infected with S. aureus, indicating that IsdA is a marker of 
infection (Clarke et al. 2006). Alignment of all homologous fragments found during the 
screen with the IsdA protein resulted in a highly conserved C-terminal region (amino acids 
215-3 10; Table 3.5; Figure 3.6). This conserved C-terminus has been shown to decrease the 
cellular hydrophobicity of S. aureus, conferring resistance to hydrophobic fatty acids, 
antimicrobial peptides of the host cell. This function therefore promotes the survival of the 
pathogen on human skin (Clarke et al. 2007). As IsdA has been proven to be a putative 
antigenic target expressed during infection, with virulence properties, this conserved C- 
terminus was chosen for further analysis to assess its ability to protect against infection by 
Gram positive pathogens. 
Recombinant lsdA-c polypeptide was tested in mouse models of septic arthritis using both 
S. aureus and S. agalactiae. The protein offered some protection against S. aureus 
infection, reducing the incidence of both arthritis and mortality. Whilst there was no 
confirmed protection against S, agalactiae, a reduction in weight loss was observed. 
Specific antisera raised against IsdA-c was also shown to opsonise S. aureus and S. 
agalactiae. Significantly fewer bacteria survived in the presence of the IsdA-c antiserum 
when compared to either pre-immune or no serum controls, inferring an ability of the 
antiserum to opsonise these pathogens for phagocytic uptake and subsequent killing. 
Similar results were found by Stranger-Jones et al. (2006), who found that complement- 
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mediated opsonophagocytic killing of S. aureus Newman was increased in the presence of 
antibodies against full-length IsdA protein. 
SdrD was identified as part of the serine-aspartate (SD) repeat protein family, which also 
includes C1fA and CIfB (Josefsson et al. 1998). Similar to OR and C1fB, it contains an N- 
terminal ligand binding domain (A domain) and an R domain composed of SD dipeptide 
repeats. However, unlike the Cif proteins, SdrD also contains five B repeat domains of 
unknown function. The N-terminus of SdrD (part of the A domain) was identified during 
the analysis as being conserved. The presence of the gene sdrD has been shown to be 
associated with bone infections, osteomyelitis and methicillin resistance, as well as having 
higher expression in strains expressing Panton-Valentine leukocidin (PVL), which cause 
staphylococcal necrotizing pneumonia (Labandeira-Rey et al. 2007). Whilst two sdr genes 
have been shown to be present in all strains, only sdrC is present in every case. sdrD is 
generally absent in MSSA strains (Sabat et al. 2006) and in total is only present in 
approximately 48% of invasive S. aureus strains (Peacock et al. 2002). 
Although SdrD-n was not tested in protection studies with mice, it did produce promising 
results by opsonisation. Significantly fewer S. aureus were recovered after opsonisation 
with specific SdrD-n antibodies, compared to pre-immune serum and no serum controls. In 
a similar study, Stranger-Jones et al. (2006) found that antibodies against full-length SdrD 
mediated complement-dependent phagocytosis of S. aureus. However, results here also 
show that significantly fewer S. agalactiae survived opsonisation in the presence of the 
antiserum compared to pre-immune serum. These results suggest that the antiserum may be 
effective in providing cross-reactive protection against Gram positive pathogens, and that 
the N-terminus may be the antigenic domain of the protein. To fully determine the cross- 
protective ability of this antiserum, it could be tested in the mouse septic arthritis model, 
similarly to IsdA-c and ScaB-c. 
In addition to the homologous regions of IsdA and SdrD, one additional fragment, the C- 
terminus of ScaB, was chosen for further analysis (Chapter 3.3.1.1. ). ScaB was identified 
from screening the S. epidermidis expression library (Pourmand et al. 2006) and was found 
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to be a member of a multigene family with a conserved C-terminal CHAP domain. ScaH 
was also identified during the S. aureus screen (Clarke et al. 2006) and this C-terminus was 
found to represent one of the 13 families of conserved fragments among the Gram positives 
screened. The CHAP domain of ScaB is 41.8% identical to that of ScaH in S. aureus, and 
as this domain is part of a family of proteins present throughout the Gram positive 
pathogens, this fragment was further analysed. 
ScaB-c protein was used to immunise mice which were subsequently infected with both S. 
aureus and S. agalactiae. The protein failed to provide any protection against streptococcal 
infection, although results showed a trend towards higher survival and lesser arthritis in the 
staphylococcal-infected group. Despite the low level of protection in mice, the specific 
antibodies against ScaB-c were effective at opsonising bacteria for phagocytic uptake by 
human neutrophils. Significantly fewer S. aureus cells survived incubation with neutrophils 
in the presence of ScaB-c antiserum compared to controls with both pre-immune and no 
serum. Fewer S. agalactiae were shown to survive phagocytosis, with bacterial counts 
being significantly lower in the presence of antiserum compared to pre-immune serum. 
Taken together, these results suggest that specific ScaB-c antisera may be cross-reactive 
and protective against Gram positive infections. 
My work has highlighted protein domains potentially efficacious as novel vaccine 
components. Their development will require further study. Analysis of SdrD-n and ScaB-c 
antibodies have shown that both these antigens contribute to the killing of S. aureus and S 
agalactiae. The absence of SdrD from all strains of S. aureus means that its effect may be 
limited as an individual vaccine target and must be assessed across a wider range of strains 
and species. IsdA-c has been shown to be an effective protector of infection by both S. 
aureus and S. agalactiae. Although several studies have identified proteins which increase 
opsonophagocytic uptake and killing of pathogens by human neutrophils, few have 
identified antigens capable opsonising numerous species. Identification of the protective 
fragment of the IsdA protein and confirmation of its ability to confer cross-protection 
across different Gram positive species makes this an attractive target for immunotherapy. 
Further work to elucidate its ability to protect a range of Gram positive species, using 
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mammalian models of infection, would help to evaluate the potential for this antigen as a 
vaccine candidate against Gram positive pathogens. 
Chapter 3- Summary 
" Immunoscreening of a S. pyogenes genomic DNA expression library with human 
sera identified 48 putative cross-reactive antigenic loci in the S. pyogenes genome. 
" Bioinformatic analysis of results of immunoscreens of five Gram positive pathogens 
identified 13 groups of homologous fragments which are potentially cross-reactive. 
" Three conserved protein fragments were identified as being particularly highly 
conserved across species. 
" Antibodies against the IsdA C-terminus, SdrD N-terminus and ScaB C-terminus 
were shown to be opsonic during infection by S. aureus and S. agalactiae. 
" IsdA C-terminus polypeptide can protect against infection of S. aureus and S. 
agalactiae in mouse models of arthritis. 
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Chapter 4 
Characterisation of the Sca family of proteins in 
Staphylococcus aureus 
4.1 Introduction 
The Gram-positive cell wall is a 15-30 nm thick layer, made up primarily of 
peptidoglycan (Figure 4.1). Peptidoglycan consists of glycan strands of repeating 
disaccharides of N-acetylmuramic acid-(ß1-4)-N-acetylglucosamine (MurNAc-GIcNAc), 
which are cross-linked to form a murein sacculus surrounding the cell (Navarre and 
Schneewind, 1999). Attached to this are accessory molecules such as teichoic acids, 
teichuronic acids, polyphosphates and carbohydrates (Figure 4.1). Surface proteins are 
also anchored to the cell wall via a C-terminal LPXTG motif or by hydrophobic 
interactions (Fischetti, 2000a). The cell wall is vital for maintaining bacterial integrity 
and functions to provide a protective exoskeleton to resist mechanical and physical 
stresses, such as osmotic pressure in the cytoplasm and elevated hydrostatic turgor 
pressures (Koch, 2006). The peptidoglycan layer is a highly dynamic and tightly 
regulated macromolecule and is constantly remodelled to allow growth and division 
(Boneca, 2005). Furthermore, the cell wall represents the primary site of interaction with 
the environment. Peptidoglycan and attached surface proteins are at the interface between 
the bacteria and the host, therefore, these proteins represent key virulence factors during 
infection. 
In order to allow cell growth and division, the bacterial cell wall peptidoglycan must be 
constantly remodelled, allowing the insertion of new material permitting the expansion of 
the cell. Remodelling requires the activity of peptidoglycan hydrolases. Those enzymes 
capable of hydrolysing their own peptidoglycan are known as autolysins. 
139 
Characterisation of the Sca family 
Lipuprugvi 
Carbohydrate 
Peptidoglycan 
Membrane 
cyloplum 
Figure 4.1: Major surface structures of the cell wall of Gram-positive bacteria. Linked to 
the surface of the peptidoglycan are surface proteins and polysaccharide structures, 
including teichoic acid (TA) and lipoteichoic acid (LTA). Reproduced from Fischetti 
(2000a). 
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As described in Chapter 3, immunoscreening of genomic libraries of five Gram positive 
pathogens resulted in the identification of a novel family of proteins, the staphylococcal 
conserved antigen (Sca) family. Studies have identified ScaA and ScaH in S. aurcus as 
peptidoglycan hydrolases with the ability to bind various human ligands (Pourmand et al. 
2006; Heilmann et al. 2005; Kajimura et al. 2005; Syed Mohamad 2007). 
Several classes of peptidoglycan hydrolase exist, each able to hydrolyse different bonds 
within the peptidoglycan structure (Figure 4.2). N-acetylglucosaminidases cleave the 0- 
1,4 glycosidic bond between the GIcNAc and MurNAc, N-acetylmuramoyl-L-alanine 
amidases hydrolyse the amide bond between the N-acetylmuramic acid and the peptide 
side chain, endopeptidases cleave the amide bonds between two amino acids, and 
muramidases and lytic transglycosylases cleave the ß-1,4 glycosidic bond between 
MurNAc and GIcNAc (Vollmer et al. 2008). 
Peptidoglycan hydrolases are multifunctional enzymes and have been implicated in 
numerous cellular processes, including cell growth, cell wall turnover, peptidoglycan 
maturation, cell division, separation, motility, chemotaxis, genetic competence, protein 
secretion and pathogenicity (Smith et at 2000; Blackman et at 1998). As bacteria 
produce several peptidoglycan hydrolases of each class, with overlapping functions, it is 
difficult to ascertain the specific role of an individual enzyme. 
4.1.1. Cell separation 
During cell division, peptidoglycan hydrolases are required to cleave the septum and 
allow separation of the daughter cells. In Gram-positive bacteria, the septum is formed 
and cleaved by these enzymes along a mid-line (Vollmer et at 2008). Several examples 
of strains lacking various peptidoglycan hydrolases have resulted in defective cell 
separation. For example, two enzymes have been identified in S. aureus to be responsible 
for separation of daughter cells, Atl and Slel (Sugai et at 1994; Kajimura et al. 2005). 
All is the most predominant peptidoglycan hydrolase in S. aureus and this bi-functional 
enzyme contains a C-terminal glucosaminidase domain and an N-terminal amidase 
141 
Characterisation of the Sca family 
domain, a proform undergoing proteolytic processing to generate two extracellular cell 
wall hydrolases (Foster, 1995; Oshida et al. 1995). It has been predicted that the 62 kDa 
amidase and the 51 kDa glucosaminidase form a ring structure on the cell surface at the 
septal site and, once the septum has been formed, these autolysins digest the 
peptidoglycan to allow the daughter cells to separate (Figure 4.3) (Yamada et al. 1996). 
Inactivation of Atl in S. aureus results in growth in large cell clusters, indicating an 
inability of cells to separate correctly (Foster, 1995; Biswas et al. 2006). Furthermore, 
studies in B. subtilis involving the inactivation of peptidoglycan hydrolases have resulted 
in cells which grow in long chains with abnormal septa (Priyadarshini et al. 2007; 
Carbillido-Lopez et al. 2006), indicating that these enzymes are vital for the correct 
separation of cells during cell division. 
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Figure 4.2: Bond specificities of peptidoglycan hydrolases on bacterial peptidoglycan. 
Adapted from Boneca et al. 2005. 
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Figure 4.3: Model for the function of all gene products in cell separation in S. aureus. 
The processed Atl hydrolase enzymes (black dots) form a ring at potential septal sites (I ) 
and once the septum has been formed (2,3), the peripheral peptidoglycan is hydrolysed 
(4,5) to allow separation of the daughter cells (6). Reproduced from Yamada et al. 
(1996). 
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4.1.2. Cell wall turnover 
Peptidoglycan hydrolases release fragments from the cell wall during growth, a process 
termed cell wall turnover. The inside-to-outside mechanism of cell wall growth involves 
the attachment of new peptidoglycan outside the cytoplasmic membrane, underneath the 
existing cell wall (Vollmer et al. 2008). The inner layer of the cell wall consists of newly 
synthesised, unstressed peptidoglycan, which passes outward as the cell elongates (in 
rod-shaped bacteria), becoming the middle, stress-bearing zone (Smith et al. 2000). The 
outer layer consisting of old peptidoglycan must be solubilised, a function carried out by 
peptidoglycan hydrolases. These autolysins cleave the outer layer of peptidoglycan, 
removing the oldest wall material from the outer surface and releasing it into the growth 
medium. This role in cell wall turnover has been demonstrated in B. subtilis, where 
inactivation of the major autolysin-encoding gene lytC led to cell wall and septal 
thickening and a large decrease in the rate of turnover (Blackman et al. 1998). In S. 
aureus, mutant cells lacking the major autolysin Atl displayed a rough outer surface, 
indicative of a lack of peptidoglycan release at the cell surface (Foster, 1995). 
4.13. Peptidoglycan maturation 
New peptidoglycan is synthesised at the outer surface of the cytoplasmic membrane from 
disaccharide pentapeptides which are transglycosylated to give glycan strands and cross- 
linked by transpeptidation, both carried out by penicillin-binding proteins (Sauvage et at. 
2008). Endopeptidases and lytic transglycosylases are also involved in this process, 
degrading the original glycan strand to allow new peptidoglycan to be synthesised 
without disturbing the cell wall integrity in a "three-for-one" model (Hältje, 1998). In 
addition, autolysins have been shown to be involved in certain modifications to this 
peptidoglycan structure. For example, glucosaminidase activity in S. aureus is 
responsible for observed minor satellite peaks in glycan strand analysis (Boneca et at, 
2000). 
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4.1.4. Antibiotic-induced lysis 
It is long-established that inhibition of peptidoglycan synthesis by ß-lactam antibiotics 
induces autolysis leading to bacterial death. Penicllin G-induced autolysis of S. aureus 
begins with localised perforation of the cell wall at initiated nascent cross walls, followed 
by general lysis (Sugai et al. 1997). It is suggested that peptidoglycan hydrolases are 
responsible for this effect. The major autolysin of S. aureus, Atl, has been implicated in 
the onset of penicillin-induced lysis, involved in the initial perforation of the cell wall 
during the autolytic process. When exposed to antibiotic, the cell wall localised at the 
presumptive site of cross wall formation is digested by atl gene products without forming 
a new cross wall, which causes a wall defect to form at the site. This leads to autolysis of 
the cell (Sugai et al. 1997). 
4.1.5. Pathogenesis 
Involvement of autolysins in pathogenesis has been demonstrated, for example, a S. 
aureus mutant lacking the two putative lytic transglycosylases IsaA and SceD was 
attentuated for virulence in a mouse septic arthritis model of infection (Stapleton et al. 
2007). SceD is also required for nasal colonisation of S aureus, suggesting that alteration 
of peptidoglycan by autolysins may allow bacteria to adapt to different host 
environments. In addition, Aaa of S. aureus and its homologue in S. epidermidis Aae, 
have been demonstrated to be adhesins, able to bind several human ligands, therefore 
promoting colonisation of host tissues (Heilmann et al. 2003; 2005). 
In this chapter, the Sea family of proteins in S. aureus was further characterised. 
Recombinant proteins were overexpressed to determine their hydrolytic activities, ligand 
binding abilities and potential as antigens. In particular, analysis of ScaD was undertaken 
to characterise this novel autolysin. 
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4.2 Results 
4.2.1. Bioinformatic analysis of the Sca family 
The staphylococcal conserved antigen (Sca) family consists of ten proteins in S. aureus, 
named ScaA to ScaJ (Figure 4.4). Bioinformatic analysis of the protein sequences of the 
Sca family (httpd/pfam. sanger. ac. uk) demonstrated the presence of a conserved C- 
terminal CHAP domain (PF05257). The CHAP (cysteine, histidine-dependent 
amidohydrolases/peptidases) domain is a region between 110 and 140 amino acids in 
length, associated with amidase function (Bateman and Rawlings, 2003). Proteins which 
contain this domain are often involved in bacterial cell wall metabolism, functioning in 
peptidoglycan hydrolysis. The CHAP domain contains two invariant residues, a cysteine 
and a histidine, which form part of the putative active site of the protein. The CHAP 
domains of the Sea proteins vary in length from 114 to 125 amino acids and occur at the 
C-terminus of each protein. These regions contain a high level of homology between 
proteins, the percentage identity of each CHAP domain to that of ScaD is shown in 
Figure 4.4. 
Three of the Sea proteins (ScaA, ScaB and ScaE) contain LysM (lysin motif) domains of 
43 amino acids (PF01476). These domains were originally identified in bacterial lysins 
and are involved in bacterial cell wall degradation (Bateman and Bycroft, 2000). The 
LysM repeats are one of the most commonly occurring domains in bacterial surface 
proteins and putatively function in peptidoglycan binding. The LysM domains of the E. 
faecalis protein AtIA and the L. lactic protein AcmA are both required to maintain 
activity of these autolysins (Eckert et at. 2006; Steen et at. 2005). This suggests that 
peptidoglycan binding via these motifs is crucial, potentially allowing the correct 
positioning or conformation of the catalytic domain towards its substrate. 
Analysis of the Sca proteins using Signale 3.0 Server (www. cbs. dtu. dk/services/SignaIP/) 
demonstrated the presence of a signal peptide in each case (Table 4.1), indicating that 
these proteins are secreted / surface-located. Analysis of the hydrophobicity 
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(http: //bioweb. pasteur. fr/seganaUinterfaces/toppred. html) of Sea proteins revealed that 
the proteins are mainly hydrophilic, with the exception of a hydrophobic fragment at the 
N-terminus characteristic of the signal peptide. The isoelectric point (pi) of each Sca 
protein was predicted using ExPASy (www. expasy. ch/tools/pi tool. html) and results are 
shown in Table 4.1. 
ScaA was first identified as Aae in S. epidermidis, a surface-located autolysin with 
adhesive properties (Heilmann et al 2003). The same protein was found during 
immunoscreening of S. epidermidis with human sera and bioinformatic analysis revealed 
it to be a member of a ten-protein family (Pourmand et al. 2006). These ten proteins 
contained a conserved C-terminal domain and were named the Staphylococcal conserved 
antigen family. The Sea proteins A-J have direct homologues in S. aureus. ScaA of S. 
aureus (SACOL0507) has been identified previously as Aaa (Heilmann et al. 2005) and 
Slel (Kajimura et al. 2005). Aaa was shown to act as an adhesin, binding the human 
ligands fibrinogen, fibronectin and vitronectin. Furthermore, the autolytic activity of the 
protein was confirmed using both S. carnosus and S. aureus cells. It was further 
demonstrated that the C-terminal portion of the protein was responsible for this observed 
activity and it was proposed that the protein acts as an N-acetylmuramyl-L-alanine 
amidase (Kajimura et al. 2005). 
ScaB (SACOL0723) shares 39.1% identity and 53.4% similarity with ScaA 
(SACOL0507). The identity within the C-terminal CHAP domain is 56.7%. ScaB of S. 
epidermidis (SE0433) was identified by Pourmand et al. (2006) by immunoscreening 
with patient sera (Chapter 3). Further analysis revealed this protein to have adhesive 
properties, binding both fibronectin and lactoferrin (Pourmand, 2005). 
ScaC (SACOL2581) is 255 amino acids in length and is highly homologous to the 267- 
residue ScaD (SACOL2291), sharing 76.7% identity and 81.9% similarity. The 117 
amino acid C-terminal CHAP domains of these proteins are 88.9% identical. Analysis of 
the S. epidermidis ATCC 12228 genome demonstrated that the homologues of ScaC 
(SE1872) and ScaD (SE2124) are both 267 amino acids in length. These proteins are 
100% identical at the amino acid level in this organism and the gene sequences are 99.6% 
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identical, differing by only 3 out of 774 base pairs. The DNA sequence of ScaD 
(SACOL2291) is the most homologous to these S. epidermidis proteins (74.4% identity to 
SE1872,74.2% identity to SE2124), compared to SACOL2581 (74.1% identity to 
SE1872,73.8% identity to SE2124). This high level of homology between ScaC and 
ScaD suggests that these paralogues may have arisen via gene duplication. 
ScaC / ScaD has been identified previously in S. epidermidis by screening of a genomic 
library with patient serum and was named staphylococcal secretory antigen A, SsaA 
(Lang et al. 2000). The 267-residue protein identified was shown to be 75.2% identical to 
a 255-residue protein in S. aureus (ScaC), and was also 69.2% identical to the exoprotein 
SceB of S. carnosus. SsaA was demonstrated to be expressed during S epidermidis 
sepsis, particularly in association with infective endocarditis, suggesting it may have a 
rote in pathogenesis. 
ScaD has also been named Ssa in S. aureus and was demonstrated to be required for the 
expression of high level resistance to macrolide-lincosamide-streptogramin B (MLSn) 
antibiotics (Martin et al. 2002). This study also identified the C-terminus of Ssa to be 
highly similar to that of six additional proteins in S. aureus, now identified as ScaC, ScaJ, 
ScaF, ScaE, ScaA and ScaB. ScaD has been demonstrated to be under the control of the 
two-component regulator YycG/YycF (Dubrac and Msadek, 2004), and further work 
identified other Sea proteins under the control of this promoter, ScaB, Scar, ScaC and 
ScaE (Dubrac et al. 2007). 
The N-terminus of both ScaD and ScaC share a degree of identity with the N-terminus of 
the autolysin LytM (SACOL0263). LytM is a glycyl-glycine endopeptidase belonging to 
the lysostaphin-type metallopeptidases (Odintsov et al. 2003). Alignment of the first 213 
amino acids of LytM with the first 150 residues of ScaD and the first 138 residues of 
ScaC demonstrated that these domains were 28.9% and 27.5% identical to that of LytM, 
respectively. 
ScaH is the largest member of the Sea family, with 619 amino acids. In addition to the 
conserved CHAP domain at the C-terminus, an additional Pfam domain was identified, 
149 
Characterisation of the Sca family 
an endo-ß-N-acetylglucosaminidase catalytic domain (PF01832). This domain is 142 
residues in length in ScaH and further analysis demonstrated homology of this domain 
with three other glucosaminidases in S. aureus, SACOL1062 (Atl), SACOL1825 and 
SACOL2298 (SagA) (Syed Mohamad, 2007). 
Scal is 348 amino acids in length in S. aureus, although it is not present in all strains of 
the organism. Analysis of ten sequenced S. aureus genomes (www. tigr. org) revealed that 
ScaI is only found in three: S. aureus COL, S. aureus subsp. aureus MRSA476 and S. 
aureus subsp. aureus USA300-FPR3757. These strains are all methicillin-resistant 
(MRSA), and the absence of the protein from all other sequenced methiciliin-sensitive 
strains may suggest a possible link between the presence of Seal and resistance to this 
antibiotic. 
ScaJ is highly related to ScaC and ScaD, sharing 39.5% and 39.2% identity, respectively. 
Homology is particularly high within the CHAP domain, which is 62.7% identical to that 
of ScaD and 59.3% identical to that of ScaC. scaJ (SACOL2295) is located four genes 
downstream of scaD (SACOL2291) in S. aureus. 
4.2.1.1. Homologues of ScaD in other species 
BlastP analysis of SACOL2291 (Scab) at http: //tigrblast. tigr. org/cmr-blast/ identified 
several homologous proteins in other species (Table 4.2). Homology primarily occurred 
to the C-terminal region of ScaD, indicating that this CHAP domain is conserved 
throughout several Gram positive species (Figure 4.5). Several of the proteins identified 
by this analysis are also putative Sea family members, e. g. Isp, Usp45 and PcsB. PcsB of 
S. pneumoniae (SP 2216) is 34% identical to ScaD over 84 amino acids. This 
peptidoglycan hydrolase has been identified as being critical in cell separation (Ng et al. 
2004). Interestingly, PcsB was also identified as the most immunogenic protein in a 
screen for conserved vaccine candidates (Giefing et al. 2008). 
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ScaA SACOL0507 50.8 
(334 aa) 
(29-71 aa) (93-135 aa) (160-202 aa) (215-334 aa) 
ScaB SACOL0723 
(265 aa) 
53.7 
(29-71 aa) (91-133 aa) (146-265 aa) 
ScaC SACOL2581 88.9 
(255 aa) (139-255 aa) 
ScaD SACOL2291 100 
(267 aa) 
(151-267 aa) 
ScaE SACOL0820 50.0 
(279 aa) (53-95aa) (163-279 aa) 
ScaF SACOL0270 
(297 aa) 
50.4 
(179-297 aa) 
ScaG SACOL2557 
(143 aa) 
39.3 
(25-143 aa) 
ScaH SACOL2666 
(619 aa) --- 
38.2 
(327-468 aa) (493-617 aa) 
Scal SACOL1576 - 34.6 
(348 aa) 
(222-345 aa) 
ScaJ SACOL2295 62 
.7 (166 aa) 
(52-166 aa) 
Figure 4.4: The Sca family of proteins in S. aureus. The conserved CHAP domain is shown 
in red, LysM domains are shown in blue, the glucosaminidase domain of ScaH is shown in 
green, predicted signal peptides (www. cbs. dtu. dk/services/SignaIP/) are shown in yellow. 
The percentage identity of each CHAP domain to that of ScaD is also detailed. 
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Name Locus 
Gene 
length (bp) 
Protein 
length (aa) 
Molecular 
weight (kDa) 
PI 
Signal 
Sequence (aa) 
ScaA SACOL0507 1005 334 35.8 9.67 1-25 
ScaB SACOL0723 798 265 28.2 6.12 1-25 
ScaC SACOL2581 768 255 27.6 7.77 1-26 
ScaD SACOL2291 804 267 29.3 8.96 1-27 
ScaE SACOL0820 840 279 30.3 10.02 1-24 
ScaF SACOL0270 894 297 33.0 5.85 1-24 
ScaG SACOL2557 432 143 16.9 10.15 1-35 
ScaH SACOL2666 1860 619 69.3 5.96 1-27 
Scal SACOLI576 1047 348 37.8 9.32 1-47 
ScaJ SACOL2295 501 166 17.4 5.59 1-27 
Table 4.1: Summary of the Sca family of proteins in S. aureus. Gene and protein lengths were 
obtained from the TIGR CMR database (http: //cmr. jcvi. org/tigr- 
scripts/CMR/CmrHomePage. cgi), pI scores and molecular weights were predicted using 
ExPASy (www. expasy. ch/tools/pi tool. htmi) and signal sequences were predicted using SignalP 
3.0 Server (www. cbs. dtu. dk/services/Signa]P/). 
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100 as 
0 
ScaD (267 aa) 
CHAP 
SP 1747 (Isp2) - 505 as 
CHAP 
SP0021 (Usp45) - 398 as F-- I 
CHAP 
SP1937 (Isp) - 538 as 
711 
CHAP 
SP0032 (CbpD) - 374 as 
CHAP SH3 
SP1956-169as 
Phosphatldylglycerophosphatase A 
SA1845 (Isp) - 512 as 
CHAP 
SA0050 (PcsB) - 447 as 
CHAP 
SA1923 (GbpB) - 169 as 
CHAP 
SA1174(Isp)-86as 
CHAP 
SP_2201 (CbpD) - 448 as 
CHAP SH3 SH3 Cell wall binding 
domains 
SP_2216 (PcsB) - 392 as 
CHAP 
EF_0252 - 503 as 
Glucosaminidase CHAP 
L159324 (AcmB) - 475 as 
Glucosaminidase CHAP 
L96658 (Usp45) - 456 as 
CHAP 
BS5140 (yybN) - 145 as 
Figure 4.5: Homologues of ScaD. Only SP1956 and BS5140 did not contain CHAP 
domains. Homology occurred within CHAP domains in all cases except BS5140; the 
homologous region here is shown by blue stripes. Homology of SP 1956 to the ScaD 
CHAP is shown by red stripes. 
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4.2.2. Characterisation of recombinant Sca proteins 
4.2.2.1. pET overexpression system 
The pET expression system was initially developed by Studier and Moffat (1986) using 
bacteriophage T7 RNA polymerase. The gene of interest is cloned into the pET vector 
downstream of a T7 promoter with expression of the gene controlled by this inducible 
promoter. 
The pET-24d(+) vector was chosen to overexpress and purify the Sca proteins. The pET- 
24d(+) plasmid carries an N-terminal T7-Tag® sequence and a C-terminal His-Tag® 
sequence for convenient and economical purification of the protein of interest under 
different conditions. The pET-24a(+) plasmid can be seen in Figure 4.6. The maps of 
pET-24c(+) and pET-24d(+) are the same as pET-24a(+) except that pET-24d(+) is a 
5308 bp plasmid; subtract 2 bp from each site beyond BamHI at 198. pET-24d(+) is a 
5307 bp plasmid; the BamHI site is in the same reading frame as pET-24c(+). An Ncol 
site is substituted for the Ndel site with a net I bp deletion at position 238 of pET-24c(+). 
As a result, Ncol cuts pET-24d(+) at 234, and Mel cuts at 229. For the rest of the sites, 
subtract 3 bp from each site beyond position 239 in pET-24a(+). Ndel does not cut pET- 
24d(+) (Novagen pET system manual 10` edition, 2002-2003). pET-24d(+) has a 
multiple cloning site with a choice of eight restriction enzyme sites for cloning. The 
plasmid also carries the lac repressor gene, lacl, which limits basal expression of the gene 
of interest. A kanamycin resistance gene (kanR) provides a selectable marker for E. coli 
clones. Another plasmid that is used in this study, pET-21d(+), has the same 
characteristics as the pET-24d(+) vector except that it contains an ampicillin resistance 
gene (amp') for selection. 
The gene of interest is initially cloned into a host that does not contain the T7 promoter, 
such as E. cola ToplO, eliminating the possibility of plasmid instability due to the 
production of proteins toxic to the host. Once established in a non-expressing host, the 
plasmid is transformed into an expression host strain, such as E. coli ßL21, which 
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contains a chromosomal copy of the RNA polymerase gene under lacUV5 control. E. coli 
BL21 is lysogenic for bacteriophage DE3, a lambda derivative that has the immunity 
region of phage 21 and carries a DNA fragment containing the lacl promoter and the 
gene for T7 RNA polymerase (Studier and Moffatt, 1986). Once a DE3 lysogen has been 
formed, the lacUVS promoter can be induced by IPTG causing the transcription of the T7 
gene and the gene of interest in the plasmid. BL21 is commonly used as the host strain 
because it is deficient in the Ion ompT protease, an enzyme which can degrade proteins 
during purification (Grodberg et al. 1988). 
4.2.2.2. Construction of overexpression plasmids 
Overexpression strains for ScaA, ScaB and ScaH have been created previously 
(Pourmand et al. 2006; Brummell, 2005). Constructs were created to overexpress the 
remaining 7 Sea proteins. 
Sequence analysis revealed that NcoI and Xhol were suitable enzymes to clone each of 
the 7 sca genes. Primers were designed to amplify each of the genes without their signal 
sequences. Predicted signal sequences were identified using SignaiP 3.0 Server 
(www. cbs. dtu. dklservices/SignalP/). Lengths of signal sequences and sizes of amplified 
gene products are shown in Table 4.3. Primers were designed to be in frame with the 
pET-24d vector once cloned. 
PCR reactions (Chapter 2.17.1) were carried out using SH1000 genomic DNA and primer 
pairs pETC_F/pETC R (scaC), pETD F/pETD R (scaD), pETE F/pETE R (scaE), 
pETF F/pETF_R (scaF), pETG_F/pETG_R (scaG), pETI_F/pETI R (scat), 
pETJ_F/pETJ_R (scat) (Table 2.6). Amplified products were separated by 1% (w/v) 
TAE agarose gel (Chapter 2.17.5). The correct sized products were seen for scaC, scab, 
scaE, scaF, scaG and scat, however, no product could be amplified for seal (Figure 4.7). 
Further bioinformatic analysis revealed that Seal is not present in all strains of S. aureus, 
therefore, could not be amplified using SHIM genomic DNA as a template. 
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DNA from the 6 correct inserts was excised from the gel and purified (Chapter 2.16.1), 
before being digested with Ncol and Xhol. Digested inserts were ligated into the pET-24d 
vector (Chapter 2.17.4), which had been digested with the same enzymes. Ligations were 
then electroporated into competent E. coli ToplO cells (Chapter 2.20.1) and colonies 
containing the recombinant plasmids were isolated by selecting for kanamycin resistance. 
Plasmid DNA was purified from transformants using Qiagen mini-prep kits (Chapter 
2.16.5) and recombinant plasmids were digested with Ncol and Xhol and separated by 
1% (w/v) TAE agarose gel electrophoresis to confirm the presence of the insert (Figure 
4.7). Inserts were also verified by PCR using recombinant plasmid DNA as a template 
with T7 forward and reverse primers, which flank the insert in the pET-24d vector 
(Figure 4.5). Positive clones were identified in all 6 cases. Recombinant plasmids were 
named pETC (scaC), pETD (scaD), pETE (scaE), pETF (scaF), pETG (scaG) and pETJ 
(sea]). Inserts were sequenced to verify their fidelity and all 6 sequences matched that 
expected. 
Recombinant plasmids were then transformed into the overexpression host strain E. coli 
BL21 (DE3) by electroporation (Chapter 2.20.1). Clones were verified by plasmid 
preparation, restriction digest and PCR, as above (results not shown). 
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Figure 4.6: The pET-24 expression system (reproduced from the Novagen pET system 
manual 10`h Edition, 2002-2003). A, map of pET-24a(+); E3, pET-24a-d 
cloning/expression region. 
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Sca 
Protein 
Predicted Signal Sequence 
(amino acids) 
Expected Size of Amplified 
Insert (bp) 
C 1-26 690 
D 1-27 720 
E 1-24 765 
F 1-24 819 
G 1-35 324 
1 1-47 903 
J 1-27 501 
Table 4.3: Predicted signal sequences for 7 Sca proteins by SignalP 3.0 Server (www. 
cbs. dtu. dk/services/SignalP/). Expected sizes of genes amplified for overexpression 
without signal sequences are also shown. 
A 
10k 
5 
3b 
1.51 
0.75 
B 
10 kb- 
5 kb- 
3 kb- 
1.5 kb- 
0.75 kb- 
0.5 kb- 
Figure 4.7: 1% (w/v) TAE agarose gels showing amplified overexpression inserts. Panel 
A: Lane 1, molecular size marker; 2, scaC. Panel B: Lane I, molecular size marker; 2, 
scaD; 3, scaE; 4, scaF; 5, scaG; 6, seal (no product); 7, scat. Expected sizes were seen 
for products of 6 sca genes. No product could be amplified for seal. 
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Figure 4.8: 1% (w/v) TAE agarose gels showing the restriction digests of overexpression 
constructs using Ncol and Xhol. Panel A, pETC; Panel B, pETD; Panel C, PETE; Panel 
D, pETF; Panel E, pETG; Panel F, pETJ. Lane I, molecular size marker; 2, digested 
DNA. Filled arrows indicate the digested pET-24d vector (5.3 kb), unfilled arrows 
indicate the sca gene overexpression insert. 
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4.2.2.3. Overexpression of recombinant proteins 
Expression of the Sea proteins was induced using 1 mM IPTG, as described in Chapter 
2.10. To verify overexpression of the proteins, uninduced and induced total protein 
samples of E. coli BL21 were analysed by 17.5% (w/v) SDS-PAGE. Results of total cell 
protein analysis showed successful overexpression of the six Sea proteins (Figure 4.9). 
4.2.2.4. Solubility of recombinant proteins 
In order to allow purification, it was necessary to determine the solubility of the 
recombinant proteins. Induced culture samples were disrupted by sonication and 
separated by centrifugation (Chapter 2.10.2). Total proteins from supernatant and pellet 
were then analysed by 17.5% (w/v) SDS-PAGE. All six recombinant Sea proteins were 
present in the lysate pellet rather than the supernatant (Figure 4.10), indicating that the 
recombinant Sca proteins were insoluble. 
4.2.2.5. Purification of recombinant proteins using a HiTrap affinity column 
Cells harvested from the overexpression culture were prepared for purification as 
described in Chapter 2.10.3. Due to the insolubility of the recombinant Sca proteins, the 
protein lysate was treated with 8M urea in START buffer to solubilise the protein before 
purification by HiTrapTM affinity chromatography (Pharmacia Biotech). The HiTrapTM 
column used is pre-packed with Chelating SepharoseTm High Performance, which 
consists of highly cross-linked agarose beads to which iminodiacetic acid has been 
coupled by stable ether groups. Several amino acids, such as histidine, form complexes 
with many metal ions. The column matrix, charged with suitable metal ions, will 
selectively retain proteins if complex-forming amino acid residues are exposed on the 
surface of the protein. 
The column was prepared and charged with nickel ions, which bind the six histidine 
residues of the His-tagged protein. The sample was applied to the column and washed 
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with START buffer to remove unbound proteins. START buffer containing a gradient of 
0-0.5 M imidazole was used to elute the recombinant protein from the column. Eluate 
was collected into 50 fractions (1 ml/fraction) and eluted proteins were analysed by 
17.5% (w/v) SDS-PAGE to determine when the purified protein had eluted from the 
column (Figure 4.11). Fractions containing purified recombinant protein were combined 
and dialysed overnight at 4°C into PBS + 8M urea. In order to solubilise the recombinant 
proteins, they were subsequently dialysed further into decreasing concentrations of urea 
(4M, 2M, 1M, no urea), however, when dialysed into 2-4 M urea, all six Sca proteins 
precipitated out of solution. The recombinant proteins were therefore stored in PBS + 8M 
urea. 
Eight recombinant Sca proteins were successfully purified as described above. However, 
ScaJ could not be purified by this method, for unknown reasons. Unpurified protein was 
used in further analyses. The nine recombinant Sca proteins, including unpurified ScaJ, 
were analysed by 17.5% (w/v) SDS-PAGE (Figure 4.12). The correct sized fragments 
were seen for all recombinant proteins. As seen previously (Pourmand, 2005), ScaB was 
overexpressed in two forms, seen as two fragments on the gel. The lower fragment is a 
114-residue N-terminally truncated protein, the higher fragment is full-length ScaB. Two 
fragments were also seen for rScaD although the identity of the two forms remains to be 
determined. ScaH was overexpressed by Syed Mohamad (2007) and produced several 
fragments on the gel due to hydrolysis of the full-length protein upon storage. 
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Figure 4.9: 17.5% (w/v) SDS-PAGE analysis of overexpression of six Sca proteins. 
Panel A, ScaC; Panel B, ScaD; Panel C, ScaE; Panel D, ScaF; Panel E, ScaG; Panel F, 
ScaJ. Lane 1, molecular mass marker; 2, uninduced E. coli BL21 protein fraction; 3, 
induced protein fraction containing the overexpressed Sca protein (identified by the filled 
arrows). 
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Figure 4.10: 17.5% (w/v) SDS-PAGE analysis of solubility of six Sca proteins. Panel A, 
ScaC; Panel B, ScaD; Panel C, ScaE; Panel D, ScaF; Panel E, ScaG; Panel F, Scal. Lane 
1, molecular mass marker; 2, soluble E. coli BL2I protein fraction; 3, insoluble protein 
fraction. All six Sca proteins were insoluble (identified by filled arrows). 
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A B 
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Figure 4.11: 17.5% (w/v) SDS-PAGE analysis of purification fractions of ScaD. Panel 
A: Lane 1, molecular mass marker; 2, unpurified extract; 3, purification waste; 4, 
fractions 1-3; 5, fractions 4-6; 6, fractions 7-9; 7, fractions 10-12; 8, fractions 13-15; 9, 
fractions 16-18; 10, fractions 19-21. Panel B: Lane 1, molecular mass marker; 2, fractions 
22-24; 3, fractions 25-27; 4, fractions 28-30; 5, fractions 31-33; 6, fractions 34-36; 7, 
fractions 37-39; 8, fractions 40-42; 9, fractions 43-45; 10, fractions 46-48. ScaD (shown 
by the filled arrow) was eluted from the HiTrapTM column in fractions 22-39. 
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Figure 4.12: 17.5% (w/v) SDS-PAGE analysis of recombinant Sca proteins. Lane 1, 
molecular mass marker; 2, rScaA; 3, rScaB; 4, rScaC; 5, rScaD; 6, rScaE; 7, rScaF; 8, 
rScaG; 9, rScaH; 10, rScaJ. Sizes of full-length proteins are shown by asterisks. rScaB 
produced two fragments, the lower fragment is a 114-residue N-terminally truncated 
protein. rScaD also produced two fragments. ScaH produced many bands due to 
hydrolysis of the full-length protein upon storage. 
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4.2.2.6. N-terminal analysis of the recombinant proteins 
Recombinant proteins were prepared for N-terminal sequencing (Chapter 2.10.4). Results 
are shown in Table 4.4. Sequences were successfully obtained for ScaE, ScaF and ScaG, 
confirming that these proteins had been purified as full-length polypeptides. However, no 
sequence data could be obtained for ScaC, ScaD and ScaJ after 3 independent attempts. 
The inability to sequence these proteins may be due to the presence of urea in the protein 
storage buffer, which is included to solubilise the proteins. The urea may block or modify 
the N-terminus of the protein, making sequencing difficult. Due to these difficulties, 
sequencing was attempted in the absence of urea, however, no sequencing data could be 
obtained by this method. 
4.2.2.7. Analysis of recombinant proteins using mass spectrometry 
As recombinant ScaC, ScaD and ScaJ could not be verified by N-terminal sequence 
analysis, these proteins were digested with trypsin and analysed by mass spectrometry 
using MASCOT (kindly carried out by Dr. Arthur Moir). All three recombinant proteins 
failed to be identified by this method, both after 4h digests and overnight digests with 
trypsin. Undigested proteins were also assessed. Analysis of ScaC produced a peak at 
approximately 25.9 kDa, corresponding to the expected size of the full length 
overexpressed protein without the signal sequence (Figure 4.13). No data was obtained 
for ScaD and ScaJ. 
4.2.3. Reaction of recombinant proteins with human serum 
The ability of the recombinant Sca proteins to react with human sera was tested in 
Western blots. Three sera from the immunoscreen described in Chapter 3 were tested for 
antibodies that react with the nine recombinant Sca proteins. BSA was included as a 
negative control. Results are shown in Figure 4.14 and summarised in Table 4.5. rScaA, 
rScaB and rScaE bound antibodies in all three sera. rScaD and rScaF failed to bind any of 
the sera tested. 
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Sca Protein N-Terminal Sequence Identification 
C Unable to sequence - 
D Unable to sequence - 
E AQQHGTQ SACOL0820 (ScaE) 
F AYTNDS SACOL0270 (ScaF) 
G AVNYYSK SACOL2557 (ScaG) 
J Unable to sequence - 
Table 4.4: N-terminal sequence analysis of recombinant Sea proteins. 
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Figure 4.13: Mass spectrometry analysis of undigested ScaC. A peak at 25.9 kDa 
(shown by the filled arrow) corresponded to the expected size of the full-length 
recombinant protein without its signal peptide. 
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Sca Protein 
Human Serum 
24 28 D62 
ScaA    
ScaB    
ScaC x  x 
ScaD x x x 
ScaE    
ScaF x x x 
ScaG x  x 
ScaH   x 
ScaJ x  x 
Table 4.5: Summary of the reactivity of recombinant Sca proteins with human serum 
antibodies. 
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4.2.4. Peptidoglycan hydrolase activity of the recombinant Sca proteins 
The peptidoglycan hydrolase activity of the recombinant Sea proteins was tested by 
zymogram analysis (Chapter 2.12.3). rScaA and rScaH have previously been 
demonstrated to lyse peptidoglycan from S. aureus, S. epidermidis, Bacillus subtilis and 
Micrococcus luteus (Pourmand, 2004; Syed Mohamad, 2007). The ability of nine Sea 
proteins to hydrolyse peptidoglycan from purified cell walls of three of these species, S. 
aureus, B. subtilis and M luteus, was assessed. All recombinant Sea proteins were able to 
digest S. aureus peptidoglycan (Figure 4.15). Notably, both the full-length rScaB and the 
N-terminally truncated fragment demonstrated activity, hence the C-terminus is most 
likely the active domain. rScaA, rScaB, rScaE, rScaF, rScaG and rScaH were also able to 
hydrolase peptidoglycan from B. subtilis and M. luteus (results not shown). rScaC, rScaD 
and rScaJ did not produce lytic bands of clearing during zymograph analysis with B. 
subtilis and M. luteus cell walls as substrate. Whether this is due to lack of hydrolytic 
activity or insufficient protein on the gel remains to be clarified. The peptidoglycan 
hydrolase activity of the recombinant Sea proteins is summarised in Table 4.6. 
4.2.5. Ligand binding ability of the Sea proteins 
To determine the possible involvement of the recombinant Sca proteins in adhesion to 
human ligands, they were tested in binding assays with a range of plasma proteins 
(Chapter 2.13.3). Fibrinogen (Fg), fibronectin (Fn), fetuin (Ft), mucin (Mc), laminin 
(Lm), lactoferrin (L) and transferrin (Ti) were labelled with biotin and used to probe 
western blots of the nine recombinant Sca proteins. Western blots are shown in Figure 
4.16 and results are summarised in Table 4.7. 
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104 
81 kDa 
48 kDa -º 
36 kDa 
27 kDa 
19 kDa 
ABCDEFGHJ 
Figure 4.15: Zymogram analysis showing activity of the Sca proteins. Recombinant 
proteins were analysed by 17.5% (w/v) SDS-PAGE renaturing gel electrophoresis 
containing 0.1% (w/v) purified S. aureus cell walls as substrate. Lytic fragments 
demonstrating autolytic activity are seen as bands of clearing in the stained gel. Sizes of 
full-length proteins are marked with an asterisk. 
Substrate rScaA rScaB rScaC rScaD rScaE rScaF rScaG rScaH rScaJ 
S. aureus          
B. suhtilis ,/ U U     U 
M. luteus ,ý  U U     U 
Table 4.6: Summary of peptidoglycan hydrolase activity of recombinant Sca proteins 
with three purified cell wall substrates. Confirmed peptidoglycan hydrolase activity is 
shown by a tick, unconfirmed activity is shown by "U". 
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A) Fibrinogen 
123456789 10 
81 kDa. 
36 kDa. 
27 kDa_ W 
19 kDa-* 
B) Fibronectin 
123456789 10 
81 kDa--º 
36 kDa-º 
27 kD-f 
19 kD8-º 
C) Fetuin 
123456789 10 
81 kD&--º 
36 kDa-O 
27 kD8--º 
19 kDa-* 
ý., ý ýýý 
E) Laminin 
123456789 10 
81 kD&-º 
36 kDýº 
27 kDaf 
19 kD-* 
skr ;: 
- 
wý w 
r 
w 
D) Mucin 
123456789 10 
81 kDa--1 
36 kDa-º 
27 kD&-º 
19 kDa-* 
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G) Transferrin 
123456789 10 
81 kDa-* 
36 kDa-º 
27 kDa-º 
19 kDa-+ 
H) No ligand 
123456789 10 
81 09-1 
36 kDa-º 
27 kDa-º 
19 kDa-lo- 
Figure 4.16: Western blots showing binding of recombinant Sca proteins to human 
ligands [A) fibrinogen, B) fibronectin, C) fetuin, D) mucin, E) laminin, F) lactoferrin, G) 
transferrin, H) no ligand control]. Lane 1, molecular mass marker; 2, rScaA; 3, rScaB; 4, 
rScaC; 5, rScaD; 6, rScaE; 7, rScaF; 8, rScaG; 9, rScaH; 10, rScaJ (unpurif ied). 
Ligand rScaA rScaB rScaC rScaD rScaE rScaF rScaG rScaH rScaJ 
Fibrinogen      X    
Fibronectin      x    
Fetuin        x  
Mucin        x  
Laminin      x    
Lactoferrin  x    X    
Transferrin        x  
Table 4.7: Summary of the ability of recombinant Sca proteins to bind human ligands. 
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4.2.6. Characterisation of ScaD 
Previous studies within the laboratory have further characterised several members of the 
Sca family, including ScaA and ScaB (Pourmand, 2004) and ScaH (Syed Mohamad, 
2007). ScaD was chosen for subsequent analysis to attempt to further elucidate the 
activity and role of this protein. 
4.2.6.1. Generation of soluble ScaD protein 
As recombinant ScaD could not be solubilised by step-wise dialysis into PBS, an 
alternative method was sought. In a study by Amrein et at. (1995), production of soluble, 
active p50"* kinase was successfully achieved by co-overexpression of the protein in E. 
coli with the bacterial chaperones GroES and GroEL. It is proposed that these chaperones 
associate with nascent polypeptide chains, aiding their correct folding and hence 
increasing the solubility of the recombinant polypeptides. The two chaperones are 
overexpressed via the plasmid pREP4groESL, which carries a kanamycin resistance 
marker. Therefore, the ScaD overexpression plamsid pETD (Chapter 4.3.2), which is also 
kanamycin resistant could not be used to co-overexpress ScaD with these chaperones. 
pET-21d (Novagen) has the same characteristics as the pET-24d vector except that it 
contains an ampicillin resistance gene rather than a kanamycin gene (Chapter 4.3.1). This 
allowed the easy transfer of the scaD insert DNA from pETD into pET-21 d. 
4.2.6.1.1. Transfer of scab overexpression insert into pET-21d 
Plasmid pETD was digested with Ncol and Xhol and separated by 1% (w/v) TAE agarose 
gel electrophoresis. The 720 bp scaD insert was gel purified and ligated into pET-21d 
digested with the same enzymes. The ligation was transformed into competent E. coli 
lop 10 and colonies containing the recombinant plasmid were isolated by selecting for 
ampicillin resistance. Plasmid DNA was purified from transformants using Qiagen mini- 
prep kits and presence of the insert-containing plasmid was verified by PCR using T7 
forward and reverse primers (Table 2.6). Both PCR using plasmid template DNA and 
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colony PCR of E. coli ToplO cells were employed to verify the scaD insert in the pET- 
21d plasmid. The products of the PCR were analysed by 1% (w/v) TAE agarose gel 
electrophoresis and the correct sized an were seen, confirming the presence of the 
scaD insert within the pET-21d vector (Figure 4.17). The recombinant plasmid was 
named pETDa. Recombinant pETDa was then transformed into the overexpression host 
strain E. coli BL21 (DE3) pREP4groESL by electroporation. Transformants were 
selected on both kanamycin and ampicillin and clones were verified by colony PCR, as 
above (results not shown). The resulting strain, containing two overexpression plasmids, 
was named GroD. 
4.2.6.1.2. Co-overexpression of recombinant ScaD with GroES and GroEL 
In order to produce soluble protein, different overexpression conditions were assessed. 
Strain GroD was grown in 100 ml TB and overexpression induced using increasing levels 
of IPTG (10 µM, 100 µM, 1 mM and 2 mM). Also, cultures were grown at 25°C, 30°C 
and 37°C, both before and after induction. Overexpression of the proteins was verified by 
analysis of uninduced and induced total protein samples of strain GroD by 17.5% (w/v) 
SDS-PAGE. The solubility of the proteins from cultures of each condition was also 
determined by analysis of the insoluble and soluble fractions of induced cultures by 
17.5% (w/v) SDS-PAGE, as previous (Chapter 4.3.4). Results showed that the 29 kDa 
recombinant ScaD was successfully overexpressed along with both GroES (10 kDa) and 
GroEL (58 kDa), however, ScaD remained insoluble in every case (Figure 4.18). 
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3 kb 
1 kb 
0.5 kb 
Figure 4.17: 1% (w/v) TAE agarose gel electrophoresis analysis of PCR using T7 
forward and T7 reverse primers to confirm scaD insert in pETDa overexpression 
plasmid. Lane 1, molecular size marker; 2, PCR product using pETDa template DNA; 3, 
PCR product using colony of Top 10 pETDa as template; 4, no template negative control. 
The correct sized insert was seen at approx. 720 bp, shown by the unfilled arrow. 
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A) 10 pM IPTG 
20 kDa-f 
B) 100 NM IPTG 
1234567 
97 kDa-f "; 
50 kDa-f 
37 kDa_ý... º 
4-w 
29 kDa Me* 'low 
20 kDa-f 
C) 1 mM IPTG 
89 10 11 12 13 14 
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D) 2 mM IPTG 
1234567 
97 kDa 
50 kDa -ý 
37 kDa-ý 
29 kDa 
20 kDa-f 46 
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50 kDa 
_f 
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Figure 4.18: 17.5% (w/v) SDS-PAGE analysis of ScaD overexpression in GroD at 
different temperatures with varying levels of IPTG. Panel A) induction of expression 
with 10 µM IPTG, Panel B) induction of expression with 100 µM IPTG, Panel C) 
induction of expression with 1 mM IPTG, Panel D) induction of expression with 2 mM 
IPTG. Lane 1, molecular mass marker; 2, uninduced protein fraction at 25°C; 3, induced 
protein fraction at 25°C; 4, uninduced protein fraction at 30°C; 5, induced protein 
fraction at 30°C; 6, uninduced protein fraction at 37°C; 7, induced protein fraction at 
37°C; 8, molecular mass marker; 9, soluble protein fraction at 25°C; 10, insoluble protein 
fraction at 25°C; 11, soluble protein fraction at 30°C; 12, insoluble protein fraction at 
30°C; 13, soluble protein fraction at 37°C; 14, insoluble protein fraction at 37°C. 
Overexpressed ScaD protein was seen at approx. 29 kDa (black arrow) and was present 
in the insoluble protein fraction in all cases. Co-overexpressed chaperones GroEL and 
GroES were seen at 58 kDa and 10 kDa, respectively (white arrows). 
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4.2.7. Characterisation of the N-terminus and C-terminus of ScaD 
The C-terminus of ScaD consists of a predicted CHAP domain, associated with 
peptidoglycan hydrolase activity. In order to verify that this C-terminal region is 
responsible for the observed hydrolytic activity of ScaD (Chapter 4.2.4), and to further 
characterise the N-tetminus of this protein, each domain was overexpressed using the 
pET-24d overexpression vector previously described (Chapter 4.2.2.1). 
4.2.7.1. Construction of overexpression plasmids 
Overexpression plasmids were constructed as described in Chapter 4.2.2.2. Sequence 
analysis revealed that Ncol and XhoI were suitable enzymes to clone both the N- and C- 
terminus of scaD and primers were designed to amplify each fragment. The N-terminus 
was amplified without the signal peptide (Table 4.3). PCR reactions were carried out 
using SH11000 genomic DNA and primer pairs pETD_F/pETD_R2 (N-terminal 130 
amino acids) and pETD F2/pETD_R (C-terminal 110 amino acids) (Table 2.6). 
Amplified products were separated by 1% (w/v) TAE agarose gel and the correct sized 
products were seen for both the N- and C-terminus inserts (Figure 4.19). 
DNA was excised from the gel and purified, before being digested with Ncol and XhoI. 
Digested inserts were ligated into the pET-24d vector, which had been digested with the 
same enzymes. Ligations were then electroporated into competent E. coil Top10 cells and 
colonies containing the recombinant plasmids were isolated by selecting for kanamycin 
resistance. Plasmid DNA was purified from transformants using Qiagen mini-prep kits 
and recombinant plasmids were digested with NcoI and XhoI and separated by 1% (w/v) 
TAE agarose gel electrophoresis to confirm the presence of the insert (Figure 4.20). 
Positive clones were identified in both cases. Recombinant plasmids were named pETDn 
(scaD N-terminus) and pETDc (scaD C-terminus). Recombinant plasmids were then 
transformed into E. coli BL21 (DE3) cells by electroporation and clones were verified by 
plasmid preparation and PCR using T7 forward and T7 reverse primers (Table 2.6) 
(results not shown). 
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1.0 
0.5 
0.25 
Figure 4.19: 1% (w/v) TAE agarose gel of PCR products of scaD N-terminus and scab 
C-terminus overexpression inserts. Lane 1, molecular size marker; 2, amplified scaD N- 
terminal 393 bp; 3, amplified scaD C-terminal 327 bp; 4, molecular size marker. The 
correct sized products were seen for both overexpression inserts (unfilled arrows). 
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5.0 kb 
1.0 kb 
0.5 kb 
0.25 kb 
Figure 4.20: Verification of pETDn and pE'F[)c by 1% (w/v) agarose gel analysis of 
restriction digests using Ncol and Xhol. Lane 1, molecular size marker; 2, digested 
pETDn; 3, digested pETDc. Filled arrows indicate the digested pET-24d vector (5.3 kb), 
unfilled arrows indicate the overexpression inserts at 393 bp (N-terminus) and 327 bp (C- 
terminus). 
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4.2.7.2. Overexpression of recombinant proteins 
The N- and C-terminal fragments of ScaD were overexpressed as described in Chapter 
2.10. Overexpression was induced with 1 mM IPTG and successful overexpression was 
verified by analysis of E. coli total protein before and after induction by 17.5% (w/v) 
SDS-PAGE. Analysis demonstrated overexpression of both polypeptides of the expected 
sizes (Figure 4.21). Similarly to the full-length ScaD, two recombinant polypeptides were 
overexpressed for the C-terminus. The identity of these fragments remains to be 
determined. 
4.2.7.3. Solubility of recombinant proteins 
Induced culture samples were disrupted by sonication and separated by centrifugation 
(Chapter 2.10.2). Total proteins from supernatant and pellet were then analysed by 17.5% 
(w/v) SDS-PAGE. Both fragments of ScaD were present in the lysate pellet rather than 
the supernatant, indicating that the recombinant polypeptides are insoluble (Figure 4.22). 
4.2.7.4. Purification of recombinant proteins using a HiTrap affinity column 
ScaD N- and C-terminus polypeptides were purified as described previously (Chapter 
4.2.2.5; Chapter 2.10.3). The C-terminus fragment was successfully purified and eluted 
from the HiTrapTM column. Fractions of eluate were collected and analysed by 17.5% 
(w/v) SDS-PAGE, and fractions containing recombinant polypeptide were combined and 
dialysed overnight at 4°C into PBS containing 8M urea. The N-terminus fragment failed 
to be purified by this method. Insoluble recombinant protein was lost during filtration 
prior to purification, therefore, unfiltered extract was diluted ten-fold in START buffer 
and loaded onto the HiTrap column for purification. However, the column became 
blocked and no protein could be recovered from the purification despite repeated 
attempts. Analysis of ScaD N-terminus polypeptide was therefore carried out using 
unpurified extract. 
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Figure 4.21: 17.5% (w/v) SDS-PAGE analysis of overexpression of ScaD N-terminus 
and C-terminus polypeptides. Panel A, N-terminus; Panel B, C-terminus. Lane 1, 
molecular mass marker; 2, uninduced E. coli BL21 protein fraction; 3, induced protein 
fraction containing the overexpressed fragment of ScaD (identified by the filled arrows). 
ScaD C-terminus produced two bands during overexpression. 
185 
Characterisation of the Sea family 
A B 
123123 
97 kDa I. 
97 kDa º ""' 
50kDa0 
50 kDa No 
37kDa0 
37 kDa f -: ý 
29kDa0 
29 kDa º 
4m 
20 kDa 0 *^ 
20 kDa 10 
Figure 4.22: 17.5% (w/v) SDS-PAGE analysis of solubility of ScaD N-terminus and C- 
terminus polypeptides. Panel A, N-terminus; Panel B, C-terminus. Lane 1, molecular 
mass marker; 2, soluble E. coli BL21 protein fraction; 3, insoluble protein fraction. Both 
ScaD N-terminus and C-terminus were insoluble (identified by filled arrows). 
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4.2.7.5. N-terminal analysis of the recombinant proteins 
In order to verify the identity of the recombinant polypeptides, the N-terminus was 
sequenced (Chapter 2.10.4). No sequence data could be obtained by this method, both 
from samples of protein in buffers with and without urea. Therefore, an alternative 
method of identification was sought. 
4.2.7.6. Analysis by mass spectrometry 
Proteins were digested with trypsin for 4h at 37°C, analysed by mass spectrometry and 
identified using MASCOT (kindly carried out by Dr. Arthur Moir). No positive 
identifications were obtained. Samples were also digested for 24 h at 37°C with trypsin 
and the analysis repeated. Analysis of the lower molecular weight ScaD C-terminus 
fragment identified four digested fragments (Table 4.8). SsaA (Scab) of S. aureus N315 
was identified as being the most likely match for the polypeptide, although results were 
not significant. The region of the protein identified by this analysis is shown in Figure 
4.19. As this corresponds to the expected identity of the protein, it was confirmed that the 
C-terminus had been successfully overexpressed. Verification of the identity of the N- 
terminus could not be made using this method. 
4.2.7.7. Generation of soluble protein 
As both the N- and C-terminus polypeptides were insoluble and due to the problems 
encountered during purification of the N-terminus, both protein fragments were co- 
overexpressed with the bacterial chaperones GroES and GroEL, as described in Chapter 
4.2.6.2. pETDn and pETDc were digested with Ncol and XhoI, gel purified and ligated 
into pET-21d digested with the same enzymes. Ligations were transformed into 
competent E. coli ToplO cells and positive transformants identified by selecting for 
ampicillin resistance. Plasmid DNA was purified from cells using a Qiagen plasmid prep 
kit and presence of the insert was verified by PCR using primers T7 forward and T7 
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reverse (Table 2.6). The recombinant plasmids were named pETDna (scaD N-terminus) 
and pETDca (scaD C-terminus). 
Recombinant pETDna and pETDca were transformed into electrocompetent E. coli BL21 
containing pREP4groESL and positive transformants were identified by selecting for 
both ampicillin and kanamycin resistance. Presence of the pETDna and pETDca plasmids 
was verified by colony PCR using T7 forward and T7 reverse primers. The resulting 
strains were named GroDN (scaD N-terminus) and GroDC (scaD C-terminus). 
4.2.7.7.1. Co-overexpression of recombinant ScaD with GroES and GroEL 
In order to produce soluble protein, different overexpression conditions were assessed. 
Strains GroDN and GroDC were grown in 100 ml TB at 25°C, 30°C and 37°C, and 
overexpression was induced with 1 mM IPTG. Protein overexpression was verified by 
analysis of uninduced and induced total protein samples of strains GroDN and GroDC by 
17.5% (w/v) SDS-PAGE. The solubility of the proteins from cultures of each condition 
was also determined by analysis of the insoluble and soluble fractions of induced cultures 
by 17.5% (w/v) SDS-PAGE, as previous. Results showed that the recombinant ScaD 
polypeptides were successfully overexpressed along with both GroES (10 kDa) and 
GroEL (58 kDa), however, ScaD N-terminus and C-terminus remained insoluble in each 
case (Figure 4.24). 
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Fragment of ScaD (aa) Peptide Identified 
183 - 199 K. IGSTWGNASNWANAAAR. A 
200 - 209 R. AGYTVNNTPK. A 
210 -237 K. AGAIMQTTQGAYGHVAYVESVNSNGSVR. V 
238 - 253 R. VSEMNYGYGPGVVTSR. T 
Table 4.8: Fragments identified during mass spectrometry analysis of trypsin-digested 
ScaD C-terminus (lower molecular weight band). Four fragment corresponding to the C- 
terminus of the protein were identified. 
1 MKKIATATIA TAGFATIAIA SGNQAHASEQ DNYGYNPNDP TSYSYTYTID 
51 AQGNYHYTWK GNWHPSQLNQ DNGYYSYYYY NGYNNYNNYN NGYSYNNYSR 
101 YNNYSNNNQS YNYNNYNSYN TNSYRTGGLG ASYSTSSNNV QVTTTMAPSS 
151 NGRSISSGYT SGRNLYTSGQ CTYYVFDRVG GKI,::, TW ; Nn 
201 ý'(TVN TTKA MN (; Y(; I'(; VV 
251 ; :; }zTISASQA AGYNFIH 
Figure 4.23: Sequence analysis of ScaD. The overexpressed C-terminal residues are 
underlined. The residues corresponding to fragments identified by mass spectrometry 
analysis of the lower molecular mass band of the recombinant C-terminus are shown in 
red, the first amino acid of each fragment is highlighted in blue. 
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Figure 4.24: 17.5% (w/v) SDS-PAGE analysis of ScaD N-terminus (Panel A) and C- 
terminus (Panel B) overexpression in GroDN and GroDC at different temperatures. Lane 
1, molecular mass marker; 2, uninduced protein fraction at 25°C; 3, induced protein 
fraction at 25°C; 4, uninduced protein fraction at 30°C; 5, induced protein fraction at 
30°C; 6, uninduced protein fraction at 37°C; 7, induced protein fraction at 37°C; 8, 
molecular mass marker; 9, soluble protein fraction at 25°C; 10, insoluble protein fraction 
at 25°C; 11, soluble protein fraction at 30°C; 12, insoluble protein fraction at 30°C; 13, 
soluble protein fraction at 37°C; 14, insoluble protein fraction at 37°C. Overexpressed 
polypeptides were overexpressed at the expected sizes (filled arrows) and were both 
present in the insoluble protein fraction in all cases. Co-overexpressed chaperones GroEL 
and GroES were seen at 58 kDa and 10 kDa, respectively (unfilled arrows). 
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4.2.8. Peptidoglycan hydrolase activity of ScaD N-terminus and C-terminus 
rScaD was shown previously to possess peptidoglycan hydrolase activity (Chapter 4.2.4). 
In order to determine which domain of the protein is responsible for this observed 
activity, recombinant ScaD N- and C-terminal regions were assessed by zymography 
(Chapter 2.12.3). The ability of these polypeptides to hydrolyse peptidoglycan from S. 
aureus was determined in 17.5% (w/v) SDS-PAGE renaturing gel electrophoresis 
containing 0.1% (w/v) purified cell walls. Unpurified ScaD N-terminus and purified C- 
terminus were assessed, along with full-length ScaD as a postive control. Analysis of 
zymograms demonstrated that the C-terminus is able to hydrolyse S. aureus 
peptidoglycan, however, the N-terminus cannot (Figure 4.25). Bands of clearing were 
seen in the N-terminus sample, however, these do not correspond to the molecular weight 
of the polypeptide and are due to the presence of other contaminating proteins in the 
unpurified sample. 
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Figure 4.25: Zymogram analysis showing activity of ScaD. Full-length ScaD. the 
unpurified N-terminus and the purified C-terminus were analysed by 17.5% (w/v) SDS- 
PAGE renaturing gel electrophoresis containing 0.1% (w/v) purified S. aureus cell walls 
as substrate. Lane 1, molecular mass marker; 2, rScaD; 3, ScaD N-terminus; 4, ScaD C- 
terminus. Lytic bands demonstrating autolytic activity are seen as bands of clearing in the 
stained gel for rScaD and rScaD C-terminus. Sizes of proteins are marked with an 
asterisk. 
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4.2.9. Immunisation with ScaD 
Approximately 1 mg of recombinant ScaD was used to produce antibodies in a rabbit by 
the Antibody Resource Centre, University of Sheffield. Five injections were given to the 
rabbit at two week intervals. The first bleed was taken after the third injection to assess 
the immune status of the rabbit. Analysis at this stage revealed poor immunogenic 
response to the protein (lack of reactivity seen during ELISA for antiserum diluted 
1: 200), hence further doses of recombinant ScaD were administered. Following the final 
injection of the rabbit, blood was collected and the sera harvested by centrifugation. A 
second analysis revealed that the antibody response remained low, therefore, the sera was 
affinity purified using rScaD. Approximately 80 µg specific antibody was recovered from 
the serum by this method, an amount considerably lower than expected levels as several 
milligrams of antibody are usually obtained. 
4.2.9.1. Analysis of anti-rScaD 
To confirm the reactivity of the anti-Scab antibodies, they were assessed in Western 
blots using recombinant ScaD protein and whole cell lysate of S. aureus SH1000. 
SH1000 was grown to log phase (OD6wn,,, 0.5-1.0) in BHI and 1 OD unit of culture pellet 
was resuspended in sample prep buffer. The S. aureus lysate was separated by 17.5% 
(w/v) SDS-PAGE, along with rScaD and BSA (negative control). One protein gel was 
stained with Coomassie blue, another was blotted onto a PVDF membrane and used in a 
Western blot with the rScaD antibodies (Chapter 2.13). Results indicated that the 
antibodies reacted with rScaD, as well as with likely ScaD in the whole cell lysate. The 
antibodies also cross-reacted with other staphylococcal proteins, although they did not 
bind to BSA (Figure 4.26). 
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Figure 4.26: Western blot analysis of reactivity of anti-ScaD antiserum. Panel A, 17.5% 
SDS-PAGE analysis; Panel B, Western blot probed with anti-ScaD antiserum. Lane 1, 
molecular mass marker; 2, BSA; 3, rScaD; 4, SH 1000 whole cell lysate. Antibodies 
bound to the rScaD, as well as ScaD in SH 1000 (shown by the filled arrow). 
194 
Characterisation of the Sca family 
43 Discussion 
The staphylococcal conserved antigen (Sca) family was originally identified by 
immunoscreening of a S. epidermidis genomic library with patient sera. Subsequent 
analysis revealed direct homologues of these proteins in S. aureus. Bioinformatic analysis 
of the ten Sca proteins in S. aureus identified a highly homologous conserved CHAP 
domain with putative amidase function. This CHAP domain was also found to be 
conserved throughout several other Gram positive species. One protein, ScaH, also 
contains a glucosaminidase domain, indicating a role as a bi-functional autolysin. ScaH 
was also identified to be part of another, four-protein, family of glucosaminidases, 
including Atl, a novel protein (SACOL1825) and SagA (Syed Mohamad, 2007). 
As the Sca proteins contain a C-terminal CHAP domain, their roles as putative autolysins 
were assessed. Zymography analysis of recombinant proteins confirmed their ability to 
hydrolyse peptidoglycan. Notably, overexpression of ScaB produced two polypeptides: a 
full-length protein and an N-terminally truncated fragment. The truncated polypeptide 
also demonstrated hydrolytic activity, indicating that the C-terminus containing the 
CHAP domain is the predicted active domain of this protein. Analysis of the 
overexpressed C-terminus and N-terminus fragments of Scab further supported this, as 
only the C-terminus was shown to hydrolyse peptidoglycan. The CHAP domain is 
predicted to confer amidase function (Bateman and Rawlings, 2003; Rigden et al. 2003), 
therefore, it can be proposed that the Sca proteins are a family of amidases. Further 
analysis of these proteins to confirm the nature of the hydrolytic activity and the specific 
bonds cleaved by these enzymes is required, however, for such biochemical analysis it 
would be necessary to solubilise the recombinant proteins, which could not be achieved 
in this study. 
Autolysins are fundamental enzymes possessed by all bacteria and in addition to their key 
roles in cellular physiology, are considered to be virulence factors, e. g. LytA, the major 
autolysin of S. pneumoniae (Berry and Paton, 2000), IsaA and SceD, two lytic 
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transglycosylases of S. aureus (Stapleton et al. 2007) and IspC of L. monocytogenes 
(Wang and Lin, 2006). 
Bacteria possess several peptidoglycan hydrolases of each class, as demonstrated by the 
ten-protein Sca family of putative amidases. The presence of several enzymes which are 
able to carry out the same activity implies functional redundancy, the reason for which is 
not fully understood. Several studies in which single genes encoding autolysins have 
been mutated have resulted in only minor changes to the phenotype of the bacteria 
(Biswas et al. 2006; Huard et al. 2003) and this can be explained by the presence of 
multiple enzymes which can compensate for those lost. For example, two autolysin 
genes, cw1C and lytC, were demonstrated to have mutually compensatory roles in mother 
cell lysis during sporulation of B. subtilis (Smith and Foster, 1995). Two orders of 
functional redundancy exist: a process may be performed by several enzymes, and 
individual enzymes may be involved in numerous processes (Smith et al. 2000). For this 
reason, no single peptidoglycan hydrolase has been identified as being essential for 
viability. The CHAP domain protein PcsB was originally identified as essential (Ng et al. 
2004), however, recently a gene deletion mutant has been created in S. pneumoniae, 
indicating that whilst this enzyme is crucial for correct cell separation and septum 
formation, and deletion drastically reduces growth, it is not in fact essential for viability 
(Giefing et al. 2008). In B. subtilis, endopeptidase-type autolysin activity, carried out by 
one or other of LytE and YvcE (Cw1O), was found to be essential. Whilst neither gene is 
independently essential, no strains could be obtained in which both autolysins were 
inactivated, indicating the mutually compensatory, yet essential, nature of this class of 
autolysins (Bisicchia et at 2007). 
The occurrence of peptidoglycan hydrolases such as PcsB, which have an important role 
in bacterial physiology, highlights the importance of the bacterial cell wall in maintaining 
viability and cell division. This may also give a reason for the redundancy of autolysins 
found in most species. The role of these enzymes in maintaining proper structure and 
functioning of the cell wall means that cells may have back-up autolysins in the case of a 
non-functional enzyme of choice. Furthermore, alteration of cell wall structure by 
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peptidoglycan hydrolases may be vital for adaptation to different environmental niches 
(Stapleton et al. 2007). Similarly, modification of peptidoglycan may be necessary under 
conditions of stress and different enzymes may be employed by the bacteria under 
different conditions. It could therefore be proposed that the Sca family of putative 
autolysins may be expressed under different environmental conditions, explaining the 
existence of several highly related enzymes with similar activities. Autolysins such as 
these must be well-regulated in order to ensure that enzymes with the correct bond 
specificities target the appropriate peptidoglycan at specific times, which is particularly 
important due to their potential to compromise cell wall integrity (Koch, 2006; Antignac 
et al. 2007). 
The role of ScaA (Slel) as a peptidoglycan hydrolase was assessed by Kajimura et al. 
(2005). Mutants lacking this enzyme were shown to form clusters and exhibited irregular 
morphology with unseparated daughter cells, consistent with a role in splitting of the 
septum during cell division. However, this was not in agreement with a similar study, in 
which a ScaA (Aaa) mutant displayed growth characteristics comparable to that of wild- 
type S. aureus, although this may have been attributable to increased expression of the 
major autolysin Atl in the mutant (Heilmann et al. 2005). 
Whilst the role of ScaA remains unclear, as an amidase it is likely involved in 
peptidoglycan structural dynamics. The peptidoglycan cell wall is essential to the survival 
and functioning of bacteria, enabling cells to resist osmotic and turgor pressures, and to 
grow and divide. Peptidoglycan must be continuously synthesised to maintain the 
integrity and viability of the cell whilst facilitating growth (Biswas et al. 2006; Koch, 
2006). Autolysins are fundamentally involved in this process of cell wall turnover, 
cleaving the cross-linked covalent network to allow incorporation of newly synthesised 
material (Smith et al. 2000). For example, a B. sublilis mutant lacking the amidase LytC 
showed a marked reduction in the rate of cell wall turnover, and this was exacerbated in a 
mutant lacking both LytC and the glucosaminidase LytD, indicating that these autolysins 
were involved in the turnover of the peptidoglycan (Blackman et al. 1998). In S aureus, 
partial inhibition of cell wall synthesis also resulted in repression of autolysin activity, 
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suggesting that cell wall synthetic and hydrolytic enzymes are closely regulated 
(Antignac et al. 2007). Cell wall turnover by peptidoglycan hydrolases is also important 
to allow the secretion of large proteins through the bacterial cell wall (Smith et al. 2000). 
The S. aureus cell wall is subject to specific modifications in order to maintain its unique 
structure and such peptidoglycan maturation can involve peptidoglycan hydrolase 
activity. For example, analysis of S. aureus cell wall glycan strands by reverse-phase 
HPLC resulted in the presence of minor satellite peaks, identified to be the products of N- 
acetylglucosaminidase activity involved with modification of the glycan strand structure 
(Boneca et al. 2000). Furthermore, structural analysis of the peptidoglycan of the closely- 
related B. subtilis identified modifications resulting from the activities of 
glucosaminidases, endopeptidases and amidases (Atrih et al. 1999), and similar analysis 
of Lactococcus lactis cell wall muropeptides identified a novel carboxypeptidase enzyme 
involved in peptidoglycan maturation (Courtin et al. 2006). Cell walls from Gram- 
positive bacteria contain various secondary polymers, such as teichoic acids and anchored 
proteins, which are frequently involved in adhesion and invasion. Therefore, remodelling 
of these surface molecules may be necessary under different environmental conditions 
and enzymes including peptidoglycan hydrolases may be involved in this process 
(Boneca, 2005). Other cell wall modifications including O-acetylation of peptidoglycan 
have been proposed to serve as a level of control of autolysin activity. Indeed, E. faecalis 
produces autolysins with different specificities for O-acetylated peptidoglycan (Pfeffer et 
al. 2006). N-deacetylation of peptidoglycan in Listeria monocytogenes confers resistance 
to host lysozyme, preventing bacterial degradation and subsequent release of 
immunostimulants, hence providing a means of evading immune detection (Boneca et al. 
2007). 
Autolysins are also involved in cell separation and their effects are fairly well 
characterised. Mutants lacking various peptidoglycan hydrolases result in cells of 
irregular shapes and sizes growing in long chains with abnormal septa (Priyadarshini et 
al. 2007; Carbillido"L6pez et al. 2006), indicating that these enzymes are vital for the 
correct separation of cells during cell division. 
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The Sca proteins contain signal peptides, denoting a secreted / surface location. They do 
not contain LPXTG motifs, indicating that they are ionically rather than covalently bound 
to the cell surface. Along with the covalently bound MSCRAMMs, these SERAMs 
(secretable expanded repertoire adhesive molecules) play key roles in pathogenesis, 
involved in the interaction between pathogen and host cells during colonisation and 
invasion (Chavakis et al. 2005). In particular, the ability to adhere to human extracellular 
matrix components and serum proteins promotes initial attachment and subsequent 
dissemination during infection (Clarke and Foster, 2006). 
Several ligand-binding SERAMs have been identified which contribute to the 
pathogenicity of S. aureus. For example, Eap (extracellular adherence protein), a 70 kDa 
fibrinogen-binding protein, inhibits the recruitment of neutophils during bacterial 
peritonitis in mice, acting as an anti-inflammatory agent (Chavakis et at 2002). Eap also 
enhances interactions between major histocompatibility complex molecules and human 
leukocytes, indicating a role in septic shock and fever (Scriba et al. 2008). Eib 
(extracellular fibrinogen-binding) protein shares significant homology with coagulase, 
another protein that binds fibrinogen (Rivera et al. 2007). Efb has been shown to inhibit 
the host immune response by blocking convertases during the complement cascade 
(Jongerius et at 2007) and has demonstrated potential as a vaccine (Shannon et at 2006). 
Coagulase is expressed at varying levels in almost all strains of S. aureus and is 
positively associated with infective endocarditis as approximately 40% of neonatal and 
adult endocarditis is caused by coagulase-positive strains (Rivera et at 2007). 
ScaA (Aaa) has been shown previously to be an adhesin, able to bind fibrinogen, 
fibronectin and vitronectin (Heilmann et al. 2005). Studies in this laboratory have also 
demonstrated the adhesive properties of ScaB (able to bind fibronectin and lactoferrin) 
and ScaH (able to bind seven human plasma proteins) (Pourmand, 2005; Syed Mohamad, 
2007). The ligand binding ability of all the Sca proteins was determined during this study 
and results showed that all nine proteins tested in ligand affinity blots were able to bind a 
wide range of human ligands. In total, S. aureus contains many adhesins, several of 
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which can bind multiple ligands. The overlapping nature of the host components to which 
these proteins bind may imply an ability of bacteria to attach to host organisms in a range 
of environmental conditions (Clarke and Foster, 2006). 
The Sca proteins are likely dual-function proteins, acting as both autolysins and adhesins. 
Homologues of Atl, the major autolysin of S. aureus, have also been demonstrated to 
possess both peptidoglycan hydrolase activity and adhesive properties. For example, At1E 
of S. epidermidis is involved in the primary attachment to polystyrene and binds 
vitronectin (Heilmann et al. 1997), and Aas of S. saprophyticus and AtIC of S. caprae are 
both able to bind fibronectin (Hell et al. 1998; Allignet et al. 2001). All four of these 
proteins display the same overall organisation, containing both N-acetylmuramoyl-L- 
alanine amidase and endo-ß-N-acetylglucosaminidase enzymatic domains. 
Although these enzymes have been proven to have dual activities, the real contribution of 
this ligand-binding ability to bacterial virulence has not been established. Whilst proteins 
such as Aaa (ScaA) demonstrated high affinity for ligands such as fibrinogen (Kd = 12.3 
nM) and fibronectin (Kd = 29.9 nM) (Heilmann et al. 2005), they may only be expressed 
in relatively small amounts'in S. aureus. Therefore, it could be proposed that the ability to 
bind these ligands has little impact on virulence, or even that it is simply fortuitous. 
Indeed, the ligands tested in this study were chosen according to commercial availability 
but may not represent those which are of most importance in vivo. The fibrinogen- 
binding ability of CIfA, an important virulence factor in infective endocarditis and 
staphylococcal arthritis (Que et al. 2005; Josefsson et al. 2001), demonstrated to 
represent a successful vaccine candidate (Weems et al. 2006), has been proposed to be of 
minor importance for the development of septic arthritis (Palmqvist et al. 2004). 
Depletion of plasma fibrinogen in mice did not reduce the arthritogenicity of C1fA- 
expressing S. aureus, indicating that the adhesin activity of this protein may not be the 
major contributing factor to bacterial virulence. 
The key roles of peptidoglycan hydrolases in the maintenance of cell wall structure and 
viability makes them interesting targets for prophylaxis. In particular, those enzymes 
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expressed during infection and recognised by the human immune system could represent 
putative vaccine candidates. Several Gram-positive autolysins have been identified which 
increase pathogenicity by interacting with the host immune response. For example, the 
autolysin p60 in Listeria monocytogenes indirectly suppresses the innate host immune 
response by enhancing the activation of natural killer (NK) cells which produce 
deleterious cytokines, allowing increased virulence during initial infection (Humann et al. 
2007). Furthermore, the surface-associated autolysin Auto is required for entry of this 
organism into eukaryotic cells and for virulence in infection models of both mice and 
guinea pigs (Cabanes et al. 2004). 
Several autolysins have been identified during screens for in vivo-expressed antigens in S. 
aureus. For example, Weichhart et al. (2003) identified the bi-functional autolysin Atl 
using in vitro protein selection by ribosome display, Clarke et al. (2006) identified Atl, 
the lytic transglycosylase IsaA and the bi-functional autolysin ScaH by immunoscreening 
using human sera, and Etz et al. (2002) identified IsaA, ScaC, ScaD, ScaB and ScaA, 
also by immunoscreening with sera. The nine recombinant Sca proteins were tested for 
their ability to react with patient sera in Western blots and results indicated that they may 
be expressed during infection, in agreement with these previous studies. However, both 
ScaD and ScaF failed to bind antibodies from any of the three serum samples tested. 
In addition to the inability to bind human antibodies during Western blot analysis, ScaD 
displayed a relative lack of reactivity during rabbit immunisation. The recombinant 
protein failed to generate the expected immune response and only a low level of 
polyclonal antibodies was obtained from the immunised animal. Despite the lack of 
immmunogenicity seen here, ScaD homolgues have been identified as putative antigens 
previously. In S. epidermidis, screening of a genomic DNA library with S epidermidis- 
infected patient serum identified a novel 257-residue antigen, named SsaA (Lang et al. 
2000). SsaA is in fact ScaC/ScaD, which are identical at the amino acid level in S. 
epidermidis. SsaA is 74.2% identical to ScaC (255 amino acids) and 74.5% identical 
ScaD (267 amino acids) in S. aureus. Analysis of antibody titres in human sera 
demonstrated elevated levels of anti-SsaA IgG antibodies in S. epidermidis-infected sera, 
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with a particular association with infective endocarditis. This suggests that both ScaC and 
ScaD may have a role in pathogenesis in S. epidermidis, and due to the high homology of 
these proteins with their counterparts in S. aureus, it would be expected that ScaC and 
ScaD would be antigenic in this organism as well. 
Furthermore, screening of S. pneumoniae for vaccine antigens using human antibodies 
identified two homologues of ScaD, CbpD (SP 2201) and PcsB (SP-2216) (Giefing et 
at. 2008), which share homology to ScaD in their CHAP domains (Table 4.2; Figure 4.5). 
In particular, PcsB was found to be the most immunogenic protein during this screen, 
hence the lack of reactivity seen for its homologue ScaD is surprising. Isp, a homologue 
of ScaD in S. pyogenes, has also been identified to be immunogenic (McIver et al. 1996). 
Further analysis using more human sera samples is required to fully assess the antigenic 
properties of ScaD in S. aureus. 
Since several Sca proteins were shown to react with human serum antibodies and are 
conserved amongst Gram-positive pathogens, this family of autolysin/adhesins may 
provide interesting targets for immunotherapy. Further work to elucidate their association 
with virulence and roles in infection is required to determine their use as vaccine targets. 
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Chapter 4- Summary 
9 Ten Sca proteins in S. aureus have been demonstrated to be peptidoglycan 
hydrolases. 
9 The C-terminus of the Sca proteins, containing the CHAP motif, is proposed to be 
the active domain of these proteins. 
9 The Sca proteins are able to bind a range of human ligands, hence may be 
involved in invasion and colonisation. 
9 Several Sca proteins react with human serum antibodies, therefore, are associated 
with staphylococcal infection. 
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Chapter 5 
Analysis of the role of scaD in Staphylococcus aureus 
5.1 Introduction 
In Chapter 4, the Sca family of autolysins was characterised. One member, ScaD, was 
identified during a transposon mutagenesis screen as being putatively essential, as no 
mutants were isolated with transposon insertions in the gene encoding this enzyme (Foster, 
unpublished). Thus, ScaD may constitute an essential enzyme. Such a role would have 
important implications for vaccine development and cellular physiology, therefore, further 
work to analyse the role of scaD was undertaken. 
Expression of scaD is controlled by a two-component system in S. aureus, YycG/YycF 
(Dubrac and Msadek, 2004). This regulatory system is specific to low-G+C Gram-positive 
bacteria and is highly conserved. It is reported to be essential for cell growth in B. subtilis, 
S. aureus, S. pneumoniae, S. mutans, E. faecalis and L. monocytogenes (Fabret and Hoch, 
1998; Martin et al. 1999; Throup et al. 2000; Senadheera et al. 2005; Hancock and Perego, 
2004; Kallipolitis and Ingmer, 2001). YycF is a response regulator which is highly 
conserved and essential in all species studied so far, with the exception of L. lactis. YycG is 
a histidine kinase and is less well conserved between species, suggesting variability in the 
signals detected in different bacteria (Bisicchia et al. 2007). 
Two genomic organisations of the yyc operon have been observed: the yycFGHIJ-type 
(Class I) operon in Bacillus, Staphylococcus and Listeria species, and the yycFGJ-type 
(Class 11) operon found amongst Streptococcus species (Szurmant et al. 2007; Bisicchia et 
al. 2007). In B. subtilis, YycH has been demonstrated to down-regulate YycF-dependent 
gene expression, most likely affecting phosphorylation levels of YycF by inhibiting YycG 
(Szurmant et al, 2005). It has been suggested that Yyci and YycH interact to control the 
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activity of YycG, forming a ternary complex with the essential histidine kinase (Szurmant 
et al. 2007). 
YycF recognises the promoter regions of several genes in S. aureus, including several 
putative autolysins. Indeed, Dubrac et al. (2007) reported that this two-component system 
activated the transcription of nine genes involved in cell wall degradation, including lytM, 
at1A, 1saA, sceD, ssaA and four ssaA-related genes. Depletion of YycFG led to a significant 
decrease in peptidoglycan biosynthesis and turnover, and an increase in cell wall 
modifications such as peptidoglycan cross-linking and glycan chain length. YycG and 
YycF were therefore renamed as WalK (histidine kinase) and WaIR (response regulator) to 
reflect their functions as regulators for cell wall metabolism. 
In S. pneumoniae, the essentiality of YycG/YycF was originally attributed to its positive 
regulatory effect on pcsB expression, which encodes a peptidoglycan hydrolase (Ng et al. 
2004). Severe depletion of PcsB lead to abnormal and uncontrolled cell wall synthesis, 
resulting in a rapid cessation of growth, a phenotype similar to that observed during 
depletion of YycFG. Constitutive expression of pcsB in strains depleted for YycFG 
reversed these cell morphology defects, as well as allowing inactivation of the essential 
yycF (Ng et al. 2003). However, more recently the gene encoding this autolysin, pcsB, was 
inactivated, which caused an extreme disruption of growth (Giefing et al. 2008). This 
demonstrated that whilst PcsB is crucial for correct cell wall synthesis and cell division, it 
is not in fact essential for viability. 
In this chapter, the essentiality of scaD in S. aureus is investigated and the role of the 
peptidoglycan hydrolase further elucidated, including the effects of this protein on strains 
depleted for YycG/YycF. 
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5.2 Results 
5.2.1. Analysis of the essentiality of scaD 
To establish the essentiality of scaD in S. aureus, it was attempted to place the gene under 
the control of the IPTG-inducible promoter Pspac. 
5.2.1.1. Use of the Lambda Red system 
The first attempt to place scaD under the control of the Pspac promoter was done using the 
Lambda Red system (Yu et al. 2000). The cloning vector used was pOB (Figure 5.1) 
(Horsburgh et al. 2002a), which has an ampicillin (amp) and erythromycin (ery) resistance 
gene for selection in E. coli and S. aureus, respectively. 
A fragment of approximately 4.4 kb containing the scaD gene and its spanning region was 
amplified by PCR using primers D1F and DiR (Table 2.6) and SH1000 genomic DNA as a 
template. Primers were designed to incorporate BamHI restriction sites at the 5' and 3' ends 
of the DNA fragment to facilitate cloning. The amplified gene region was named Dl. D1 
and the vector pOB were each digested with BamHl, the vector was treated with alkaline 
phosphatase to prevent religation, and products were resolved in a 1% (w/v) agarose gel 
before being gel purified. The insert was then ligated into the digested plasmid, ligation 
reactions purified with glycogen and used to transform electrocompetent E. cols lop 10 
cells. Transformants were selected on LB agar containing ampicillin (100 µg/ml). Despite 
15 independent attempts, the fragment D1 could not be cloned into pOB in this way. 
Due to the inability to clone insert D1 into pOß, primers were redesigned to amplify a 
smaller gene region in the hope that this would facilitate the cloning of the insert. Primers 
were designed to amplify scaD and the upstream and downstream regions to generate a 
product of 2.5 kb, and BamHI restriction sites were incorporated into the primers to enable 
cloning. Primers D2F and D2R (Table 2.6) were used to amplify the fragment from 
SHI000 genomic DNA and the resulting fragment was named D2. As previously, D2 and 
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pOB were each digested with BamHI, the vector was treated with alkaline phosphatase to 
prevent religation and products were resolved in a 1% (w/v) agarose gel before being gel 
purified. The insert was ligated into the digested plasmid, ligation reactions purified with 
glycogen and used to transform electrocompetent E. coli lop 10 cells. Transformants were 
selected on LB agar containing ampicillin (100 pg/mi). However, after 10 independent 
attempts, the fragment D2 could not be cloned into pOB. 
Due to the problems encountered with the ligation of fragments D1 and D2 into pOB, an 
alternative method was sought. Insert D2 was cloned into the vector pCR®2.1-TOPO® 
(Figure 5.2) using a TOPO TA Cloning® kit (Invitrogen). TOPO TA Cloning® allows the 
direct insertion of Taq polymerase-amplified PCR products into a plasmid vector via an 
overhanging 3' deoxythymidine (T) in the linearised vector, which allows the insertion of 
PCR products with a single deoxyadenosine (A) at the 3' end, added by the Taq polymerase 
(Invitrogen User Manual, Version U, 10`h April 2006). PCR products are inserted into a 
lacZa gene, allowing selection of insert-containing clones by blue/white selection on X-gal. 
The cloning reaction was carried out according to the manufacturer's instructions and six 
white colonies were selected for analysis. Plasmid DNA was prepared and restriction 
digests using BamHI carried out. Products were analysed by 1% (w/v) TAE agarose gel 
electrophoresis and results demonstrated the correct insertion of the 2.5 kb product in each 
case (Figure 5.3). The plasmid was named pTOPD2. 
For Lambda Red cloning, plasmid pTOPD2 was transformed into electrocompetent E. coli 
EL250 cells. Transformants were selected on LB agar containing ampicillin (100 pg/ml) 
and clones were verified by digesting with BamHl, as previously described. The resulting 
clone was named ELD2. 
In order to insert the Pspac promoter and let resistance gene into pTOPD2 by Lambda Red 
recombination, primers PS_RedF and PS_RedR (Table 2.6) were designed to amplify the 
2.2 kb Pspac cassette from plasmid pGL400 (Figure 5.4) (Garcfa-Lara, unpublished). 
Primers were designed in such a way that they contained homologous sequences from both 
the Pspac cassette and also from the cloned scaD gene fragment in pTOPD2. This allows 
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the insertion of the Pspac cassette by recombination of the homologous sequences at each 
end with the gene region in the plasmid. The primers were designed such that the promoter 
cassette would be inserted upstream of the ribosome binding site of scaD (Figure 5.4). 
The Lambda Red recombination system involves a two-step process: firstly the preparation 
of E. coli ELD2 cells and secondly, the recombination of the amplified Pspac cassette into 
the plasmid. Strain ELD2 was grown to OD60o 0.4-0.5, before cells were shifted to 42°C 
for 15 min to induce the expression of the Lambda Red genes. Electrocompetent cells were 
then prepared and were transformed with the amplified Pspac cassette. After 10 
independent attempts, it was concluded that the Pspac cassette could not be inserted into 
pTOPD2 using Lambda Red recombination technology. 
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Figure 5.1: Physical map of pOB. The plasmid contains an ampicillin resistance gene 
(amp) for selection in E. coli and an erythromycin resistance marker (ery) for selection in S. 
aureus (Horsburgh et al. 2002a). 
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Figure 5.2: Map of pCR®2.1-TOPO® and sequence surrounding the TOPO® Cloning site 
(Invitrogen TOPO TA Cloning® User Manual, Version U, 10th April 2006). 
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5 kb 
3 kb 
2 kb 
Figure 5.3: 1% (w/v) agarose gel analysis of restriction digests of pTOPD2 using BamHl. 
Lane 1, molecular size marker; 2, clone A; 3, clone B; 4, clone C; 5, clone D; 6, clone E; 7, 
clone F. The vector was seen at the expected size of 3.9 kb (unfilled arrow) and the insert at 
2.5 kb (filled arrow). 
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Figure 5.4: Insertion of P. spac promoter and tet resistance gene into scaD gene region in 
pTOPD2 by Lambda Red recombination. Panel A) Primers PS_RedF and PS_RedR were 
designed to amplify the 2.2 kb Pspac cassette from plasmid pGL400 (Green) (Garcia-Lara, 
unpublished). Panel B) Primers also contained homologous sequences from the cloned 
scaD fragment in pTOPD2 (Purple). Panel C) This allowed insertion of the Pspac/tel 
cassette by recombination of homologous sequences at each end with the scab region. 
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5.2.1.2. Conventional cloning 
As the Pspac cassette could not be inserted into pTOPD2 by Lambda Red recombination 
technology, conventional cloning methods were attempted. 
5.2.1.2.1. Inverse PCR 
A restriction site was engineered upstream of scaD in pTOPD2 in order to insert the Pspac 
cassette via conventional cloning. Primers were designed to amplify the plasmid in an 
inverse PCR reaction (Figure 5.5). They were designed to amplify from the chosen 
insertion site of the promoter cassette, upstream of the scaD ribosome binding site. 
Sequence analysis of pTOPD2 and the promoter cassette revealed that Sall was a suitable 
enzyme to use for the cloning, and restriction sites were incorporated into the primers to 
generate the new enzyme site within the plasmid. The plasmid could then be religated, the 
Pspac cassette amplified with the same restriction sites at the 3' and 5' ends, and the 
cassette ligated into the plasmid. Primers InvDI and InvD2 were used to amplify the 6.4 kb 
product using pTOPD2 as template DNA. However, no products of the correct size could 
be obtained by this method, despite modifications to the PCR protocol. 
5.2.1.2.2. Transfer of scaD to pGL456 
Due to problems encountered previously, cloning was attempted with a new vector, 
pGL456 (Figure 5.6). This plasmid contains an ampicillin resistance marker (bla) for 
selection in E. coli and an erythromycin resistance gene (erm) for selection in S. aureus. 
Insert D2 and pGL456 were both digested with BamHI and the vector was subsequently 
treated with alkaline phosphatase to prevent religation. The insert was ligated into the 
plasmid, ligation reactions purified using glycogen and used to transform electrocompetent 
E. coli Top 10. Transformants were selected on LB agar containing ampicillin (100 pg/mI) 
and verified by plasmid preparation, restriction digestion using BamHl and analysis by 1% 
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(w/v) agarose gel electrophoresis. However, as was seen previously with pOB, the insert 
was unable to be cloned into pGL456. 
5.2.1.2.3. Generation of scaD:: Pspac insert 
As previous attempts to clone the scaD:: Pspac into the vector pGL456 failed, primers were 
designed to amplify the region containing scaD in two separate arms. Primer pairs D2F/D3 
(Arm A) and D2R/D4 (Arm B) were used to amplify the region from SH1000 genomic 
DNA, generating products of 0.9 kb and 1.7 kb, respectively. The primers were designed to 
incorporate the restriction enzyme sites Fsel and AscI into the 3' and 5' ends of arms A and 
B, respectively. In order to generate an insert containing the Pspac promoter and 
tetracycline cassette, a three-way ligation was attempted. A 2.2 kb fragment containing the 
inducible promoter and antibiotic resistance cassette was digested from plasmid pGL439 
(Garcia-Lara, unpublished) using Fsel and Ascl (Figure 5.7). The fragment was gel purified 
and used in a ligation reaction with Arms A and B, digested with Fsel and AscI, 
respectively. Ligations were then used as a template for a second PCR using primer pair 
D2F/D2R to generate a product of 4.8 kb. Amplification products were analysed by 1% 
(w/v) TAE agarose gel electrophoresis and the correct sized product was seen (Figure 5.8, 
Panel A). The insert was verified by restriction digests using BamHI, Fsel and Ascl, and 
results demonstrated that the amplified insert was correct (Figure 5.8, Panel B). The insert 
was named DPI (Figure 5.9). 
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Figure 5.5: Physical map of pTOPD2 demonstrating positions of primers lnvDI and InvD2 
for inverse PCR to create Sall restriction site upstream of scab. 
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Figure 5.6: Physical map of pGL456 (Garcia-Lara, unpublished). This plasmid contains an 
ampicillin resistance gene (bla) for selection in E. coli and an erythromycin resistance gene 
(erm) for selection in S. aureus. 
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Figure 5.7: Physical map of pGL439 (Garcia-Lara, unpublished). This plasmid contains a 
tetracycline resistance gene (tet) and Pspac promoter flanked by the restriction sites Esel 
and Ascl. 
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Figure 5.8: Generation of insert DPI. Panel A, 1% (w/v) TAE agarose gel analysis of 
products of amplification of scaD gene region from SLI1000 DNA. Lane I, molecular size 
marker; 2, Arm A (primers D2F/D3); 3, Arm B (primers D2R/D4). The correct sized 
products were seen at 0.9 kb (unfilled arrow) and 1.7 kb (filled arrow). Panel B, 1% (w/v) 
TAE agarose gel analysis of digested insert DPI. Lane 1, molecular size marker; 2, Bumi ll - 
digested; 3, Ascl-digested; 4, Fsel-digested (incomplete digest, undigested DNA 
highlighted by the filled arrow). Bands were seen at the correct sizes to verify the DPI 
insert. 
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Figure 5.9: Map of insert DPI containing scaD:: Pspac and a tetracycline antibiotic marker. 
Arms A and B were amplified from SH 1000 DNA using primer pairs D21-'/D3 and 
D2R/D4, respectively. The insert was constructed by ligation of the 2.2 kb Pspac cassette 
with the two gene region arms followed by amplification using primers D2F/D2R. 
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5.2.1.2.4. Cloning of scaD:: Pspac into pGL456 
The DPI insert was digested with BamHI and gel purified, before being ligated into 
pGL456 digested with the same enzyme. Ligations were then precipitated with glycogen 
and used to transform electrocompetent E. coli Top10 cells (Chapter 2.20.1). Transformants 
were selected on LB agar containing ampicillin (100 pg/ml) and agar containing 
tetracycline (12.5 pg/ml). Despite ten independent transformations, the insert could not be 
cloned into pGL456. 
As cloning attempts failed, an alternative strategy was sought. Sequence analysis of insert 
DPI revealed the presence of a unique EcoRI site at the 3' end of the fragment, 
approximately 500 bp upstream from the 3' BamHI site (Figure 5.9). As pGL456 contained 
both BamHI and EcoRI within the multiple cloning site, these restriction enzymes were 
used for cloning. Fragment DPI was digested with BamHh/EcoRI, resulting in the 
formation of two products of 4.3 kb and 0.5 kb. The 4.3 kb fragment was gel purified and 
used in a ligation reaction with pGL456 digested with the same enzymes. Ligations were 
purified using glycogen and used to transform electrocompetent E. cola Top10 cells 
(Chapter 2.20.1). Transformants were selected on LB agar containing tetracycline (12.5 
µg/ml), resulting in one putative clone. Plasmid preparation and restriction digestion using 
enzymes BamHI1EcoRI and AscI resulted in bands of the expected sizes (Figure 5.10). The 
resulting plasmid was named pDPsl (Figure 5.11). 
5.2.1.2.5. Transformation of pDPsl into RN4220 
pGL456 is unable to replicate in S. aureus, therefore, transfer requires recombination of the 
homologous regions of the insert into the bacterial genome. pDPsl was used to transform 
electrocompetent S. aureus RN4220 (Chapter 2.20.2) and colonies were selected on ß11I 
agar containing tetracycline (5 µg/ml). However, even after ten independent attempts no 
colonies were obtained. 
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Figure 5.10: 1% (w/v) TAE agarose gel analysis of restriction digests of pDPsl. Lane 1, 
molecular size marker; 2, Bamtll/EcoRl digest of pDPsl; 3, Ascl digest of pDPsl. The 
correct sized products at 5.4 kb and 4.3 kb are shown by the unfilled arrows, and the 
linearised plasmid is shown at 9.7 kb by the filled arrow. 
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Figure 5.11: Physical map of pDPsl. The insert containing Pspac:: scaD and a tetracycline 
resistance marker was cloned into pGL456 using BamHl and EcoRl. S. aureus sequence is 
highlighted by the inner purple lines. 
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5.2.1.2.6. Transfer of Pspac:: scaD into pMAD 
To facilitate the recombination of the Pspac:: scaD into the S aureus chromosome, the 
insert was transferred into the temperature sensitive plasmid pMAD (Arnaud et al. 2004). 
pMAD (Figure 5.12) is a temperature-sensitive plasmid, replicating at 30°C in S. aureus. 
Temperatures above 37°C lead to greatly impaired replication of the plasmid, permitting 
homologous recombination of target genes during mutagenesis. The plasmid contains an 
ampicillin resistance gene (bla) for selection in E. coli and an erythromycin resistance gene 
(ermC) for selection in S. aureus. In addition, a bgaB gene is present, which encodes a 
thermostable ß-galactosidase. When plated onto X-gal, this allows colorimetric blue/white 
selection of bacteria that have lost the plasmid, facilitating the identification of clones 
during recombination. 
The scaD:: Pspac insert was digested from pDPsI (Chapter 5.2.1.2.4) using restriction 
enzymes BamHI and EcoRl. The digested fragment was gel purified and ligated into 
pMAD, which had been digested with the same enzymes. Ligations were purified using 
glycogen and used to transform competent E. coif Top lO cells (Chapter 2.20.1). 
Transformants were selected on LB agar containing tetracycline (12.5 µg/ml) at 30°C. 
Three positive transformants were selected and purified plasmid was digested with 
BamHUEcoRI and Ascl, to produce the expected fragments of 9.7 kb and 4.3 kb, and 14 kb, 
respectively (Figure 5.13). The plasmid construct was named pDPs2 (Figure 5.14). 
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Figure 5.12: Physical map of pMAD (Arnaud et al. 2004). This plasmid contains an 
ampicillin resistance gene (bla) for selection in E. coli and an erythromycin resistance gene 
(ermC) for selection in S. aureus. There is a replication sequence (ori) for replication of 
plasmid at low temperature. The plasmid also contains a hgaB gene, encoding a 
thermostable ß-galactosidase, which allows colorimetric blue/white selection of bacteria 
when plated onto X-gal. 
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Figure 5.13: 1% (w/v) TAE agarose gel analysis of restriction digests of pDPs2 from E. 
coli Top 10 transformants. Panel A, digestion with BamHl and EcoRl; Panel B, digestion 
with Ascl. Lane 1, molecular size marker; 2, clone 1; 3, clone 2; 4, clone 3. The correct 
sized fragments at 9.7 kb and 4.3 kb were seen for BamHl/EcoRl (filled arrows) and at 14 
kb for Ascl (unfilled arrow). 
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Figure 5.14: Physical map of pDPs2. The insert containing Pspac:: scal and tetracycline 
resistance marker was cloned into pMAD using BamHl and EcoRI. S. aureus sequence is 
highlighted by the inner purple lines. 
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5.2.1.3. Transfer of pDPs2 into S. aureus 
A midi preparation (Chapter 2.16.6) of plasmid pDPs2 was made and used to transform 
electrocompetent S. aureus RN4220 (Chapter 2.20.2). Transformants were selected on Bill 
agar containing tetracycline (5 pg/ml) at 30°C and positive clones were patched onto B111 
agar containing erythromycin (5 µg/ml) and lincomycin (25 µg/ml). Three clones resistant 
to both antibiotics were selected for plasmid preparation and restriction digestion. Upon 
digestion with BamHI and EcoRI, the correct sized fragments of 9.7 kb and 4.3 kb were 
seen for clones 1 and 2, and digestion with Ncol resulted in the expected fragments of 11.5 
kb and 2.5 kb for clones 1 and 2, confirming the presence of the plasmid in these strains 
(results not shown). 
Plasmid pDPs2 was transferred into S. aureus SH1000 by phage transduction (Chapter 
2.19). Transductants were selected on LK top agar containing tetracycline (5 µg/ml) at 
30°C and subsequently patched onto BHI agar containing erythromycin (5 pg/ml), 
lincomycin (25 µg/ml) and X-gal (80 µg/ml). Four transductants resistant to both 
antibiotics which were blue when grown on X-gal were selected for plasmid preparation 
and restriction digestion. Clones were digested with BamHIIEeoRl and Ascl and analysed 
by 1% (w/v) TAE agarose gel electrophoresis. Fragments of the expected sizes were seen 
for 3 of the 4 transductants, confirming the presence of pDPs2 in these strains (results not 
shown). 
5.2.1.4. Recombination of scaD:: Pspac into the S. aureus chromosome 
As pMAD cannot replicate at temperatures greater than 37°C, incubation of strains carrying 
the plasmid at high temperature leads to homologous recombination of the cloned gene 
region. Several attempts to isolate a clone in which a double crossover event had occurred 
were carried out. 
SHI000 pDPs2 was grown at 30°C overnight in 5 ml DUE containing tetracycline (5 
pg/ml). This culture was used to inoculate a fresh 5 ml of MR without antibiotic to 
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ODD,,,,, 0.01 and cultures were incubated at 30°C, 250 rpm for 2 h, followed by 6h at 
42°C. Cultures were serially diluted and plated onto BHI agar containing tetracycline (5 
µg/ml) and X-gal (80 gg/ml), before being incubated overnight at 42°C. Clones having 
undergone a single crossover event produced blue colonies due to integration of the vector. 
However, clones in which a double crossover event had occurred, resulting in loss of the 
pMAD vector, were seen as white colonies (Arnaud et al. 2004). Despite repeated attempts, 
no correct colonies were obtained. 
The next attempt involved passaging of strains at 42°C until white colonies were isolated. 
A single colony of SHI000 pDPs2 was streaked 20 times onto Bill agar containing 
tetracycline (5 µg/ml) and X-gal (80 pg/ml) and incubated at 42°C for 48 h. A single 
colony was then picked from each strain and streaked out again onto the same medium. 
Plates were incubated at 42°C for a further 48 h and the process repeated up to ten times. 
After several attempts, no white colonies were isolated by this method. 
As passaging of strains on medium containing tetracycline had failed, the method was 
repeated on BHI agar containing no antibiotics. After 5-6 passages white colonies were 
observed. However, when these strains were plated back onto medium containing 
tetracycline, they were unable to grow. Analysis of these colonies by PCR using primer 
pairs PsF1/PsR and PsF2/PsR (Table 2.6) did not result in bands of the expected sizes (3.7 
kb and 3 kb, respectively). Instead, bands were seen corresponding to that of wild-type 
DNA (1.5 kb and no product, respectively), indicating that these strains had lost the 
plasmid without undergoing homologous recombination. 
LB medium was also used in the hope that a less-rich medium may increase the chances of 
recombination and plasmid loss. However, no white colonies were isolated after up to ten 
passages at 42°C. Other attempts involved variation of temperatures and levels of 
antibiotic, however, no correct clones could be obtained. 
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5.2.1.5. Identification by Southern hybridisation 
No white colonies were identified from attempts to isolate strains in which the plasmid had 
resolved due to homologous recombination. To determine the identity of the strains, three 
clones (A, B and C) were analysed by Southern hybridisation (Chapter 2.18). Genomic 
DNA from S. aureus SHI000 and clones A, B and C was digested with EcoRI and 
separated by 1% (w/v) agarose gel electrophoresis, blotted onto a nylon membrane and 
probed with a digoxygenin labelled DNA fragment of the 0.8 kb Arm A (Figures 5.9,5.14). 
The possible restriction patterns are shown in Figure 5.15. Homologous recombination 
could occur in two locations, (1) and (2). Two outcomes for single crossover events are 
possible (I and 2), yielding fragments of 3.6 kb/14 kb and 5.8 kb/11.8 kb. A double 
crossover event would result in a single band at 5.8 kb (3) and SH1000 genomic DNA 
would result in a band at 3.6 kb. 
Analysis of the three clones by Southern hydridisation (Figure 5.16) demonstrated that 
clones A and B (Lanes 2 and 3) represented strains which had undergone a single crossover 
event, with hybridising bands at approximately 3.6 kb and 14 kb. Clone C demonstrated the 
same banding pattern as SHI000 wild-type DNA (Lanes 1 and 4), although the band is 
faint so cannot be fully verified. 
5.2.1.6. Transductions 
Transductional outcross to resolve the single crossover insertions by recombination was 
attempted using phage transduction with the strains that had undergone a single crossover 
event (Chapter 5.2.1.5). Lysates were made of strains A and B and were used to transduce 
SH1000 (Chapter 2.19). Transductants were selected on LK top agar containing 
tetracycline and resulting colonies were patched onto Bill agar plates containing 
tetracycline (5 pg/ml) and plates containing erythromycin (5 µg/ml) and lincomycin (25 
pg/ml). Colonies resistant to Tet but unable to grow on Ery/Lin represented putative clones 
with resolved plasmids, However, all 585 patched transductants demonstrated resistance to 
both antibiotics, indicating that homologous recombination via double crossover had not 
occurred. 
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Figure 5.15 (previous page): Homologous recombination of scab region from pl)Ps2 into 
SH 1000. Recombination could occur in two possible locations, (I) and (2). Single 
crossover events could lead to two possible outcomes, (1) and (2); double crossover would 
lead to the outcome in (3). Relevant EcoRI restriction sites and expected size of fragments 
hybridising to the probe during Southern blot analysis are shown. 
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Figure 5.16: Southern hybridisation analysis of clones A, B and C, resulting from attempts 
to induce homologous recombination of Pspac:: scaD into Sl I 1000. Lane I, DNA molecular 
weight marker 111; 2, SH 1000; 3, A; 4, B; 5, C. Results demonstrate hands at approximately 
3.6 kb and 14 kb (filled arrows) for clones A and B, indicating a single crossover. 
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5.2.2. Analysis of the role of ScaD 
The inability to place scaD under the control of the inducible Pspac promoter was not fully 
understood. Insertional inactivation of scaD was also attempted to determine if a mutation 
could be made and the gene was therefore not essential. 
5.2.2.1. Insertional inactivation of scab gene using a kanamycin cassette 
Construction of scaD mutation was carried out by amplifying two fragments of the scaD 
locus using SH1000 genomic DNA as the template. Primers were designed to amplify a 
fragment of 1.3 kb (A) consisting of 130 bp of the 5' end of scaD and 1.2 kb of upstream 
sequence. A second fragment of 0.8 kb (B) consisted of 340 bp of the 3' end of scaD and 
440 bp downstream sequence. This resulted in the deletion of 330 bp of scaD. Fragment A 
was amplified using primer pair Mutl/Mut2 (Table 2.6) and incorporated the restriction 
sites BamHl and Sall. Fragment B was amplified using primer pair Mut3/Mut4 (Table 2.6), 
which incorporated the restriction sites Xhol and EcoRJ, respectively (Figure 5.17). The 
kanamycin cassette (1.5 kb) was amplified from pGL433b (Garcia-Lara, unpublished) 
using primer pair KanF/KanR, which incorporated the restriction sites Sall and Xhol 
(Figure 5.18). 
The PCR products of fragments A, B and the Kan cassette were digested with Sall, Xhol 
and SalUXhol, respectively, before being gel purified and used in a series of ligation 
reactions. Three ligation reactions were carried out: 1, A+ Kan; 2, B+ Kan; 3, A+ Kan + 
B. The ligation reactions were precipitated with glycogen before being used as the template 
DNA in PCRs using primers Mutl/KanR, KanF/Mut4, Mutl/Mut4, respectively (Figure 
5.17). Products were analysed by 1% (w/v) TAE agarose gel electrophoresis and results 
demonstrated the successful amplification of the two shorter fragments, but failure to 
produce the full insert containing arms A, B and the Kan cassette (Figure 5.19). Fragments 
were named AK (Arm A+ Kan) and BK (Arm B+ Kan). 
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Fragments AK and BK were gel purified and digested with Sall and Xhol, respectively. 
These fragments were then ligated to Arm B and Arm A, digested with the same enzymes. 
Ligations were precipitated with glycogen and used as the template for a second PCR using 
primers Mutl and Mut4. Analysis of PCR products by 1% (w/v) TAE agarose gel 
electrophoresis demonstrated a fragment of approximately 3.6 kb, indicating that the full 
insert had been successfully amplified in both cases. Fragments were gel purified and 
digested with both Sall and XhoI to verify their identity (Figure 5.20). The resulting 
fragment was named ABK. 
Fragment ABK was digested with BamHIIEcoRI and ligated into pMAD, which had been 
digested with the same enzymes. Ligation reactions were precipitated with glycogen before 
being used to transform electrocompetent E. coli Top 10 cells. Transformants were selected 
on LB agar containing ampicillin (100 pg/ml) at 30°C and patched onto LB agar containing 
kanamycin (50 pg/ml). 135 transformants were patched onto kanamycin and of these, 8 
displayed resistance to both antibiotics. Plasmid DNA was prepared from these strains and 
digested with BamHI/EcoRI. All 8 strains contained the correct plasmid with bands at 9.7 
kb and 3.6 kb (Figure 5.21). The resulting recombinant plasmid was named pDMut1. 
5.2.2.2. Transfer of pDMutl into S. aureus 
A midi preparation (Chapter 2.16.6) of plasmid pDMutI was made and used to transform 
electrocompetent S. aureus RN4220 (Chapter 2.20.2) Transformants were selected on 131 11 
agar containing kanamycin (50 µg/ml) at 30°C, resulting in four colonies. These putative 
clones were then patched onto BHI agar containing erythromycin (5 µg/ml) and lincomycin 
(25 pg/ml), resulting in one transformant which was resistant to both antibiotics. A plasmid 
preparation from this clone was digested using BamHVEcoRI and Sall/XhoI, and analysed 
by 1% (w/v) TAE agarose gel electrophoresis. The correct sized fragments of 9.7 kb / 3.6 
kb, and 11.8 kb / 1.5 kb were seen for the clone, confirming the presence of the plasmid in 
this strain (results not shown). 
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Plasmid pDMutl was transferred into S. aureus SHI000 by phage transduction (Chapter 
2.19). Transductants were selected on LK top agar containing kanamycin (50 µg/ml) at 
30°C and subsequently patched onto BHI agar containing erythromycin (5 µg/ml), 
lincomycin (25 pg/ml), and X-gal (80 pg/ml). Four transductants resistant to both 
antibiotics which were blue when grown on X-gal were selected for plasmid preparation 
and restriction digestion. Clones were digested with Bamffllecolll and SWUM, and 
analysed by 1% (wlv) agarose gel electrophoresis. Fragments of the expected sizes were 
seen for all four transductants, confirming the presence of pDMutl in these strains (results 
not shown). 
5.2.2.3. Recombination of inactivated scaD into the S. aureus chromosome 
In order to isolate a mutant which had undergone homologous recombination of the 
inactivated scaD into S. aureus, SH1000 pDMutl was passaged at 42°C on Bill containing 
kanamycin (50 gg/ml) and X-gal (80 gg/ml), as described previously (Chapter 5.2.1.4). 
However, similarly to the plasmid pDPs2, after several attempts no colonies could be 
isolated in which a double crossover event had occurred. The scaD gene could therefore not 
be inactivated in S. aureus in this study. 
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Figure 5.17: Physical map of the disrupted scab gene region and kanamycin cassette tier 
insertional inactivation of scaD. Relevant primers are shown. 
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Figure 5.18: Physical map of pGL433b (Garcia-Lara, unpublished). A 1.5 kh region 
containing a kanamycin resistance gene (kan) was amplified from the plasmid using 
primers KanF and KanR (Table 2.6). 
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Figure 5.19: 1% (w/v) TAE agarose gel analysis of PCR products from amplification of 
scaD ligations. Lane 1, molecular size marker; 2, Arm A+ Kan (Primers Mut1/KanR); 3, 
Arm B+ Kan (Primers KanF/Mut4); 4, Arms A+B+ Kan (Primers Mut I /Mut4). Results 
indicate the successful amplification of Arms A and B each with the Kan cassette (hands at 
2.8 kb and 2.3 kb, respectively). The 3-way ligation (lane 4) failed to produce a product at 
the expected size of 3.6 kb. Correct fragments were named AK (Arm A+ Kan) and BK 
(Arm B+ Kan). 
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Figure 5.20: 1% (w/v) TAE agarose gel analysis of restriction digests of fragments ABK. 
Lanes 2-4) AK + Arm B; Lanes 5-7) BK + Arm A. Lane 1, molecular weight marker; 2 and 
5, undigested; 3 and 6, Sall-digested; 4 and 7, Xhol-digested. Results demonstrate the 
correct amplification of the insert with bands at the expected sizes of 3.6 kb (undigested), 
2.3 kb and 1.3 kb (Sall), and 2.8 kb and 0.8 kb (Xhol). 
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Figure 5.21: Panel A, Map of pDMut l; Panel B, 1% (w/v) TAE agarose gel analysis of 
pDMutl digested with BamHl and EcoRl. Lane 1, molecular size marker; 2, digested 
pDMutl. The pMAD vector is shown at 9.7 kb by the filled arrow, the 3.6 kb insert is 
shown by the unfilled arrow. 
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5.2.3. Putative identification of ScaD in the native cell walls of S. aureus 
Native cell wall material was prepared from S. aureus spa (Chapter 2.11.2) and proteins 
separated by 17.5% (w/v) SDS-PAGE together with rScaD. Proteins were stained with 
Coomassie blue, as well as being transferred onto a PVDF membrane for Western blotting 
using anti-rScaD serum. Antibodies reacted with rScaD and identified a protein 
corresponding to the size of ScaD within the native cell walls of S. aureus spa (Figure 
5.22), suggesting that ScaD is an ionically-bound protein. The anti-ScaD antibodies also 
cross-reacted with two other proteins in this fraction (shown by unfilled arrows). 
5.2.4. Analysis of expression of scab 
To determine when scaD is expressed during growth, whole cell lysates of S. aureus grown 
to different points were probed with anti-rScaD serum in Western blots. An overnight 
culture of S. aureus spa was used to inoculate 11 BHI to approximately OD6oo,,,,, 0.05. The 
culture was incubated at 37°C with 250 rpm shaking and samples removed every hour. The 
OD60o, » was measured and I ODD,,,,, unit of culture was centrifuged (5500 rpm, 10 min, 
4°C) to recover bacterial cells. Cells were resuspended in 15 µl sample buffer and proteins 
were separated by 17.5% (w/v) SDS-PAGE. Separated proteins were blotted onto PVDF 
membranes, which were probed with anti-rScaD antibodies in Western blots. Results are 
shown in Figures 5.23 and 5.24. A fragment was seen at the expected size for ScaD after 1 
h, indicating that ScaD was rapidly produced in the logarithmic phase of growth. 
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Figure 5.22: Western blot analysis using anti-rScaD antibodies. Proteins were separated by 
17.5% (w/v) SDS-PAGE and either stained with coomassie blue (Panel A) or Western 
blotted with anti-rScaD serum (Panel B). Lane 1, molecular weight marker; Lane 2, rScaD; 
Lane 3, native cell wall material of S. aureus spa. The size of rScaD is shown by the filled 
arrow. Anti-rScaD antibodies also reacted with other proteins in this fraction, shown by the 
unfilled arrows. 
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Figure 5.23: Growth of S. aureus spa. The strain was grown in I 113111 at 37°C, 250 rpm, 
and the OD&om measured every hour during the logarithmic phase of growth. 
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Figure 5.24: Western blot analysis using anti-rScaD antibodies. S. aureus spa was grown 
in II BH1 at 37°C, 250 rpm, and I OD6wm unit of culture removed at intervals shown 
below. Cells were recovered by centrifugation and whole cell lysates were separated by 
17.5% (w/v) SDS-PAGE. Gels were either stained with Coomassie blue (Panel A) or 
Western blotted with anti-rScaD serum (Panel B). Lane 1, molecular mass marker; 2,0 h; 
3,1 h; 4,2 h; 5,3 h; 6,4 h; 7,5 h; 8,6 h; 9, molecular mass marker; 10,7 h; 1 I, 8 h; 12,9 
h; 13,24 h; 14, rScaD. 
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5.2.5. Depletion of yycFG 
To verify whether scaD is controlled by the essential two-component system YycG/YycF, a 
mutant in which yycFG, the genes encoding these proteins, are under the control of an 
IPTG-inducible promoter, strain MS014 (Dubrac and Msadek, 2004), was tested in Western 
blots with anti-rScaD serum. Strain MS014 was grown overnight in BHI containing 1 mM 
IPTG. As YycF and YycG are essential for growth, IPTG must be included in the medium 
to induce expression from the Pspac promoter. This overnight culture was used to inoculate 
50 ml BHI containing 10 pM IPTG to approximately OD ,m0.05. Cultures were grown at 
37°C, 250 rpm, until the OD6oo was approximately 1.0. Cells were then washed three 
times with BHI containing no IPTG before being resuspended to ODD 0.05 in 25 ml 
BHI containing either no IPTG, 10 µM IPTG, 100 µM IPTG or 1 mM IPTG. Cultures were 
grown at 37°C, 250 rpm, and the OD600nn measured every hour for 3 h. Cells were then 
harvested (5500 rpm, 10 min, 4°C) and pellets resuspended in sample buffer. 1 OD60om 
unit of pelleted culture was separated by 17.5% (w/v) SDS-PAGE, along with rScaD 
protein. One gel was stained with coomassie blue and one was blotted onto a PVDF 
membrane which was probed with anti-rScaD antibodies in Western blots. 
Results are shown in Figures 5.25 and 5.26. Growth without IPTG rapidly ceased and little 
ScaD protein reacted with the antibodies. A small amount was seen in the Western blot 
analysis, however, this may be due to remaining protein from initial growth in 10 µM 
IPTG. The level of ScaD present increased as the amount of IPTG in the medium increased, 
as did growth. When MS014 was grown in 100 µM or 1 mM IPTG, growth rates were 
comparable to that of the wild-type and equivalent amounts of ScaD were present. 
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Figure 5.25: Growth of strain MS014 in depleting levels of IPTG (and wild-type RN4220). 
The strain was grown at 37°C, 250 rpm in IPTG concentrations of 0 -1 mM and the optical 
density at 600 nm measured every hour. Concentrations of IPTG are detailed in the key. 
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Figure 5.26: Western blot analysis of whole cell lysates of strain MS0I4 grown in 
depleting concentrations of IPTG. I OD6oom unit of whole cells were separated by 17.5% 
(w/v) SDS-PAGE along with rScaD. Panel A, Coomassie-stained gel; Panel 13, Western 
blot probed with rScaD antiserum. Lane 1, molecular weight marker; 2, no IPTG; 3,10 µM 
IPTG; 4,100 pM IPTG; 5,1 mM IPTG; 6, RN4220; 7, rScaD. The approximate size of' 
ScaD is highlighted by the arrows. 
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5.2.6. Complementation of the essential YycG/YycF two-component system with ScaD 
YycGIYycF has been shown to be essential in S. aureus (Martin et al. 1999). Although not 
proven in this study, if ScaD were essential for viability, it could be hypothesised that the 
essentiality of YycG/YycF is in fact due to its positive regulatory effect on ScaD. In order 
to see if the essentiality of YycG/YycF can be complemented with ScaD, a 
complementation construct was created using pMJ8426 (Jana et al. 2000) (Figure 5.27), in 
which scaD is constitutively expressed from the Ppcn promoter. 
5.2.6.1. Construction of complementation plasmid 
A1 kb fragment containing scaD was amplified from SH 1000 genomic DNA using primers 
CompF and CompR (Table 2.6). Primers were designed to allow the in-frame expression of 
scaD and BamHI and EcoRI restriction sites were engineered to facilitate cloning. Primer 
CompF was designed downstream of the YycFG binding sites and upstream of the 
ribosome binding site, allowing constitutive expression from the Ppcn promoter in the 
vector. 
The amplified product was separated by 1% (w/v) agarose gel electrophoresis and the 
correct sized band was seen (not shown). DNA was excised from the gel and purified 
before being digested with BamHI and EcoRl. Digested inserts were ligated into the 
pMJ8426 vector, which had been digested with the same enzymes. Ligations were then 
electroporated into electrocompetent E. cola ToplO cells and colonies containing the 
recombinant plasmids were isolated by selecting for spectinomycin resistance. Plasmid 
DNA was purified from transformants using Qiagen mini-prep kits (Chapter 2.16.5) and 
recombinant plasmids were digested with BamHI and EcoRl and separated by 1% (w/v) 
agarose gel electrophoresis to confirm the presence of the insert (Figure 5.28 B). The 
recombinant plasmid containing the scaD insert was named pDComp and is shown in 
Figure 5.28 A. 
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Figure 5.27: Map of pMJ8426 (reproduced from Jana et al. 2000). The plasmid contains a 
spectinomycin (spe) resistance gene for selection in E. coli and a tetracycline (tel) 
resistance gene for selection in S. aureus. A Iacl gene is also present under the control of 
the constitutive Ppcn promoter. 
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Figure 5.28: Panel A, Map of pDComp; Panel B, 1% (w/v) TAF, agarose gel analysis of 
pDComp digested with BamHl and EcoRl. Lane 1, molecular size marker; 2, digested 
pDComp. The pMJ8426 vector is shown at -10 kb by the filled arrow, the -1 kb insert is 
shown by the unfilled arrow. 
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5.2.6.2. Transformation of constructs into RN4220 
Recombinant pDComp and pMJ8426 plasmids were transformed into competent S. aureus 
RN4220 by electroporation (Chapter 2.20.2). Positive clones were identified by selecting 
for tetracycline resistance. To verify the overproduction of ScaD protein in the 
complementation plasmid, whole cell lysates of RN4220 and RN4220 pDComp were 
separated by 17.5% (w/v) SDS-PAGE and proteins blotted onto PVDF membranes. 
Membranes were then probed with anti-rScaD antibodies in Western blots. Results showed 
that more protein reacted with the anti-rScaD serum at the size expected for the strain 
carrying the complementation plasmid (Figure 5.29). Therefore, the overproduction of 
ScaD in pDComp was confirmed. 
5.2.6.3. Transduction of plasmids intoyycFG mutant 
Phage transduction (Chapter 2.19) was used to transfer pDComp and pMJ8426 into strain 
MS014, which contains yycFG under the control of the IPTG-inducible promoter Pspac 
(Chapter 5.2.5). Transductants were selected on LK top agar containing tetracycline and 
positive clones were verified by purification of plasmid DNA using Qiagen midi-prep kit 
and restriction digestion using BamHI and EcoRl. Digests were analysed by 1% (w/v) 
agarose gel electrophoresis (not shown). 
5.2.6.4. Complementation of YycG/YycF with ScaD 
To determine the ability of ScaD to complement the essentiality of YycG/YycF, MS014 
containing pMJ8426 and pDComp were streaked onto ßH1 agar plates containing 
tetracycline both with and without IPTG. Plates were incubated overnight at 37°C and the 
level of growth compared. Figure 5.30 demonstrates that MS014 containing the control 
plasmid is unable to grow in the absence of IPTG. However, when ScaD is overproduced 
via the plasmid pDComp, growth occurs independently of IPTG. 
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To further test the complementation, strains RN4220, MS014, MS014 pMJ8426 and 
MS014 pDComp were grown in BHI with and without IPTG. For strains carrying a 
plasmid, tetracycline was also included in the medium. Strains were grown overnight in 5 
ml BHI containing I mM IPTG and 5 pg/ml tetracycline, where appropriate. The overnight 
cultures were then used to inoculate 50 ml BHI containing 10 µM IPTG to approximately 
OD600.0.05. Cultures were grown at 37°C until OD600 0.5 and cells harvested by 
centrifugation (5500 rpm, 10 min, 4°C). Cells were washed three times with BHI, before 
being resuspended to OD6oo, m 0.01 in 50 ml BHI with and without 1 mM IPTG. Cultures 
were then incubated at 37°C for 5 hours and the ODooo, measured every hour. Figure 5.31 
demonstrates that growth of MS014 is comparable to that of wild-type (RN4220) in the 
presence of IPTG, but growth is rapidly arrested in the absence of the inducer, when no 
yycFG is expressed. The strain containing the control plasmid pMJ8426 exhibited a similar 
pattern, with growth only occurring in the presence of the inducer. However, strain MS014 
pDComp grew at a similar rate both with and without IPTG. The growth rate of this strain 
was lower than that of MS014 pMJ8426 in the presence of IPTG, however, the 
overproduction of ScaD in this strain complemented the essentiality of YycFG and allowed 
growth to occur independently of the inducer. 
After 5h growth, cells were harvested by centrifugation (5500 rpm, 10 min, 4°C) and 1 
OD6wtt, unit of each pelleted culture was resuspended in sample prep buffer. Whole cell 
lysates were then separated by 17.5% (w/v) SDS-PAGE. One get was stained with 
Coomassie-blue and one gel was transferred onto a PVDF membrane by electroblotting. 
The membrane was then probed with ScaD antiserum in a Western blot. Figure 5.32 shows 
that strain MS014 pDComp produced a larger amount of ScaD compared to RN4220, 
MS014 and MS014 pMJ8426. 
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Figure 5.29: Western blot analysis of ScaD complementation strains. Whole cell lysates of 
RN4220 and RN4220 pDComp were separated by 17.5% (w/v) SDS-PAGE, proteins were 
blotted onto membranes and probed with anti-rScaD antibodies. Lane 1, molecular weight 
marker; 2, RN4220; 3, RN4220 pDComp. ScaD was successfully overproduced in the 
strain carrying the plasmid (shown by the filled arrow). 
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Figure 5.30: Complementation of strain MS014 with ScaD. Strains containing the ScaD 
complementation plasmid (pDComp) and strains containing a control plasmid (pMJ8426) 
were streaked onto BHI containing tetracycline both in the absence and presence of IP'l'G, 
and incubated overnight at 37°C. 
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Figure 5.31: Analysis of complementation of the essential YycG/YycF in strain MS014 by 
overproduction of ScaD. Strains were grown in BHI both with (+) and without (-) IPTG. 
Strains RN4220, MSO14, MS014 pMJ8426 and MS014 pDComp are as detailed in the key. 
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Figure 5.32: Western blot analysis of the overproduction of ScaD in MS0I4. I OD(,, Nh, m 
unit of whole cells were separated by 17.5% (w/v) SDS-PAGE along with rScaD protein. 
Panel A, Coomassie blue-stained gel; Panel B, western blot probed with rScaD antiserum. 
Lane 1, molecular mass marker; 2, RN4220; 3, MS014 (+ IPTG); 4, MS0I4 (no IPTG); 5, 
MS014 pMJ8426 (+ IPTG); 6, MS014 pMJ8426 (no IPTG); 7, MS014 pDComp (+ IPTG); 
8, MS014 pDComp (no IPTG); 9, rScaD. The approximate size of Seal) is shown by the 
filled arrows. 
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5.2.7. Overproduction of ScaD in wild-type S. aureus 
5.2.7.1. Transduction of complementation plasmids into SHI000 
Phage transduction (Chapter 2.19) was used to transfer plasmids pMJ8426 and pDComp 
from S. aureus RN4220 (Chapter 5.2.6) into S. aureus SH1000. Transductants were 
selected on LK top agar containing tetracycline and positive clones were verified by 
plasmid preparation and restriction digestion using BamHI and EcoR1(results not shown). 
Overproduction of ScaD in SH1000 was verified by 17.5% (w/v) SDS-PAGE analysis and 
Western blotting with rScaD antiserum (Figure 5.33). 
5.2.7.2. Growth experiments 
Strains SHI000, SH1000 pMJ8426 and SH1000 pDComp were grown overnight in 5 ml 
BHI with antibiotics, where appropriate. 50 ml BHI was then inoculated to OD600m 0.01 
and cultures incubated at 37°C, 250 rpm. Growth was measured every hour for 12 h and 
results are shown in Figure 5.34. Growth of SH1000 pDComp displayed comparable 
optical densities to that of SH1000 pMJ8426 (Panel A), however, growth was notably 
lower when colony forming units were determined (Panel II). 
5.2.7.1. Transmission electron microscopy study 
Strains were assessed by transmission electron microscopy as described in Chapter 2.9.2. 
and results are shown in Figure 5.35. Cells containing only the control plasmid pMJ8426 
(Panel B) displayed a similar morphology to the wild-type SH1000 cells (Panel A). 
However, overproduction of ScaD via the pDComp plasmid (Panel C) led to disruption of 
cell division. Asymmetric septa were formed leading to irregular cell division. 
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Figure 5.33: Western blot analysis of overproduction of ScaD in S. aureus S[I1000.1 
ODbppnm unit of whole cells were separated by 17.5% (w/v) SDS-PAGE along with rScaD. 
Panel A, coomassie blue-stained gel; Panel B, western blot probed with rScaD antiserum. 
Lane 1, molecular weight marker; 2, SH 1000; 3, SH 1000 pMJ8426; 4, SH 1000 pDComp; 
5, rScaD. The approximate size of ScaD is highlighted by the filled arrow. 
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Figure 5.34: Overproduction of ScaD in S. aureus SH1000. Strains were grown in B111 and 
growth measured every hour. Panel A, optical density (OD6oo ); Panel B, CFU/mI. Strains 
are as detailed in the keys, standard error bars are shown. 
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Figure 5.35: The effect of overproduction of ScaD in S. uureu. º SII1000. Exponentially 
growing bacteria were analysed by transmission electron microscopy. Magnification is 
shown by the black bars. A) SH 1000; B) SH 1000 pMJ8426; C) SH 1000 pDComp. 
Asymmetric septa leading to irregular cell division are highlighted by the red arrows. 
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5.2.7.2. Role of ScaD in cell lysis of S. aureus 
To determine the effect of overproduction of ScaD on cell autolysis in S. aureus, strains 
SH1000, SHI000 pMJ8426 and SH1000 pDComp were analysed in duplicate for lysis 
using Triton X-100 (0.05% (w/v)), as described in Chapter 2.8. Lysis was followed 
spectrophotometrically over time of washed cells and is expressed as a percentage of the 
initial optical density (OD6oonm). 
Figure 5.36 demonstrates that SHI000 and SHI000 carrying the control plasmid pMJ8426 
displayed comparable autolysis profiles. Both stains lost approximately 90% of the initial 
OD6w. after 6 h, with loss of approximately 80% within the first 2 h. The rate of autolysis 
of the strain overproducing ScaD is considerably lower, with loss of only approximately 
75% initial OD6 ,. after 6h and only 45% within the first 2 h. 
5.2.7.3. Role of ScaD in peptidoglycan hydrolase activity 
Strains SH1000, SHI000 pMJ8426 and SH1000 pDComp were grown to OD60o. 1.0 in 
BHI. Cells were harvested by centrifugation and resuspended in sample buffer. Whole cell 
lysates, along with rScaD, were tested by zymogram analysis (Chapter 2.12.3) with 0.1% 
(w/v) S. aureus cell walls as substrate. Figure 5.37 shows the autolytic profiles of the three 
strains, with bands of clearing corresponding to Atl and its processed products seen. A faint 
band corresponding to the expected size of ScaD can be seen in the strain overproducing 
this protein (Lane 4). Notably, this strain appears to produce lower levels of Atl when 
compared to the strain carrying the control plasmid (Lane 3). This may account for the 
reduced rate of generalised cell lysis seen in Chapter 5.2.7.2. 
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Figure 5.36: Role of ScaD in generalised cell lysis using Triton X-100 (0.05% (w/v)). 
Strains are as described in the key and represent means of duplicate samples. 
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Figure 5.37: Zymography analysis of the effect of overproduction of ScaD in S. aureus 
SH 1000 on the autolytic profile. Whole cell lysates and rScaD were analysed by 17.5% 
(w/v) SDS-PAGE renaturing gel electrophoresis containing 0.1% (w/v) purified S. aureus 
cell walls as substrate. Lytic bands demonstrating autolytic activity are seen as bands of' 
clearing in the stained gel. Lane 1, molecular mass marker; 2, S111000; 3, Sl1I000 
pMJ8426; 4, SH1000 pDComp; 5, rScaD. Bands corresponding to the approximate size of 
ScaD are shown by the asterisks. 
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5.2.8. Creation of scaD mutant in strain complemented with ScaD 
It was demonstrated in Chapter 5.2.6 that overproduction of ScaD could complement the 
essentiality of the YycG/YycF two-component system which regulates scaD expression. 
This suggests that scaD may be an essential gene in S. aureus, however, attempts to verify 
this by placing the gene under the control of an inducible promoter have failed (Chapter 
5.2.1). If ScaD were essential, it could be proposed that overproduction of the protein in S. 
aureus may allow a mutant to be created in which the genomic copy of scaD is disrupted. 
In order to determine if this was feasible, phage transduction (Chapter 2.19) was used to 
transfer the plasmid pDMutl (Chapter 5.2.2) into SH1000 pDComp (Chapter 5.2.6), a 
strain overproducing ScaD. Transductants were selected on LK top agar containing 
tetracycline (5 pglml). Clones were then patched onto BHI plates containing kanamycin (50 
pg/ml) and neomycin (50 pg/ml) and plates containing erythromycin (5 pg/ml) and 
lincomycin (25 pg/ml). Colonies resistant to both Tet and Kan/Neo but sensitive to Ery/Lin 
would represent putative clones with a disrupted genomic copy of scaD. However, after 3 
independent attempts, scaD could not be inactivated in a strain overproducing ScaD. 
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5.3 Discussion 
In Chapter 4, the Sca family of amidases was characterised. One of these proteins, ScaD, 
was identified as being putatively important in S. aureus and its function was further 
elucidated. Molecular genetic approaches were used to attempt to determine the role of 
scab by replacement of its native promoter with an inducible promoter, and also by 
insertional inactivation of the gene using a kanamycin cassette. However, numerous 
problems were encountered during mutagenesis, the reasons for which are not fully 
understood, resulting in the inability to create these mutations. Therefore, other analyses 
were carried out to further determine the role of scaD. 
Western blot analysis using anti-rScaD antibodies and native cell wall material of S. aureus 
identified ScaD, suggesting that it may be ionically-bound. ScaD is expressed early during 
the logarithmic phase of growth. Protein corresponding to the expected size of ScaD was 
seen in cell lysate after just 1 hour of growth, suggesting that this enzyme is required by the 
cell early during the exponential phase. It has been described previously that the production 
of autolysins is predominantly during the logarithmic growth phase (Komatsuzawa et al. 
1995) and is most likely due to the high rate of cell division, requiring hydrolytic enzymes 
to cleave nascent septa allowing separation of daughter cells. The partially mutually 
compensatory autolysins IsaA and SceD are also produced maximally during exponential 
growth and these putative lytic transglycosylases are involved in cell separation (Stapleton 
et al. 2007). The amidase Aaa/Slel (ScaA) is involved in separation of daughter cells 
during cell division, along with the major S aureus autolysin AtIA (Sugai et at. 1994; 
Foster, 1995; Kajimura et al. 2005). The two products of at1A, a 62 kDa amidase and a 51 
kDa glucosaminidase form a ring structure on the cell surface and, following septum 
formation, these two autolysins digest the peptidoglycan connecting the two daughter cells, 
allowing the cells to separate (Yamada et al. 1996). 
The importance of autolysin activity during the exponential phase is further highlighted in 
E. faecalis, in which the enzymes AtIA and AtIB, which are responsible for digesting the 
septum during cell separation, are mutually compensatory only during the logarithmic 
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phase of growth (Mesnage et at 2008). This suggests that peptidoglycan hydrolase activity 
is most crucial during this time, hence strategies are employed by the bacteria to ensure that 
cell separation is carried out by at least one of these enzymes. The production of ScaD so 
early during growth suggests that this protein may have a key function in cell physiology 
and may be vital for viability. In order to further elucidate the function of this enzyme 
during the early stages of growth, subsequent work is required, including localisation of the 
protein and inactivation of scaD to determine its role. 
It has been reported previously that scaD is controlled by the essential two-component 
regulator YycG/YycF (Dubrac and Msadek, 2004). This was confirmed by Western blot 
analysis using anti-rScaD antibodies and a strain depleted for yycFG. Depletion of IPTG, 
resulting in reduced expression of the yycF and yycG genes, also resulted in decreased 
levels of ScaD being detected in Western blots. This demonstrates the direct effect of this 
regulator on production of ScaD. Indeed, Dubrac and Msadek (2004) identified two binding 
sites of the YycF regulator on the promoter region of scaD, indicating that scab 
transcription is directly controlled by this regulator. 
In addition to YycF, ScaD levels are also influenced by the two component system SaeRS 
(Rogasch et al. 2006). In S. aureus COL, SaeRS was shown to negatively influence the 
amount of ScaD, as mutation of saeS resulted in accumulation of ScaD. This effect most 
likely occurs at the post-transcriptional level, as transcription of scaD was not influenced in 
the mutant. Post-transcriptional regulation may occur via endonucleolytic enzyme activity 
which degrades mRNA or by binding of proteins to mRNA transcript to inhibit translation 
of the protein (Dubrac and Touati, 2002; Tang et al. 2004). 
YycG/YycF has been demonstrated to be essential in several species, including B. subtilis, 
S. aureus and S. pneumoniae (see Chapter 5.1). However, no single protein has been 
identified in any strain which is directly correlated with the essentiality of YycF. In B. 
subtilis, the endopeptidases LytE and YvcE (CwIO) were demonstrated to be controlled by 
YycFG and their activities were demonstrated to be essential for lateral cell wall synthesis 
and cell elongation during growth (Bisicchia et al. 2007). Whilst single mutants were 
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constructed for both IylE and yvcE, no double mutant could be obtained, demonstrating that 
the enzymes are mutually functionally redundant but together are required for growth. The 
essential nature of their endopeptidase activity may be explained by the proposed 
mechanism of peptidoglycan synthesis, in which three new murein strands are synthesised 
from a single docking strand and attached to cross-bridges whilst the original docking 
strand is degraded (Höltje, 1998). This "three-for-one" model is carried out by a multi- 
enzyme complex in E. coli, consisting of transpeptidases and transglycosylases to 
synthesise new bonds, and endopeptidase and lytic transglycosylase autolysins which 
degrade the original strand. As the synthase enzymes are in front of the hydrolase enzymes 
within this complex, new peptidoglycan strands are constructed before old strands are 
degraded, hence the stress-bearing cell wall structure and shape is maintained throughout. 
Whilst this model has been proposed for E. cola, it could be speculated that a similar 
mechanism in the Gram-positive B. subtilis may give reason for the essential nature of 
endopeptidase activity seen by Bisicchia et al. (2007). 
Despite the essentiality of LytE and YvcE in B. subtilis, it was concluded that YycFG- 
controlled expression of these genes was not the only reason for the essentiality of the two- 
component system (Bisicchia et al. 2007). Indeed, it has been proposed that the essentiality 
of the two-component system is more likely due to the global regulation of several proteins 
which, in combination, are essential for correct cell wall metabolism and hence viability 
(Dubrac et ad. 2007). 
Studies by Ng et al. (2004) originally attributed the essentiality of YycG/YycF in S. 
pneumoniae to its positive regulatory effect on production of the autolysin PesB, as YycF 
was not required when pcsB was constitutively expressed. I lowever, more recently, pcsB 
has been inactivated, confirming that it is not in fact essential for growth (Giefing et al. 
2008). Mutants demonstrated severely defective growth, with disrupted cell morphology 
and aberrent septum formation, indicating that PcsB is highly important during 
pneumococcal growth and division. This suggests that, whilst this enzyme is not uniquely 
responsible for the essentiality of YycFG, it most likely contributes significantly along with 
other enzymes involved in cell wall metabolism. 
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Bioinformatic analysis of PcsB revealed the presence of a C-terminal CHAP domain, which 
shares 32% identity to that of ScaD. As these proteins share significant homology in their 
C-terminal domains, ScaD was constitutively expressed in a conditional mutant, in which 
yycFG is under the control of an IPTG-inducible promoter. Overproduction of ScaD in this 
strain allowed it to grow independently of IPTG, hence complementing the essentiality of 
yycFG, similar to PcsB in S. pneumoniae. Further analysis to confirm whether constitutive 
expression of scaD would allow the disruption of yycF in S. aureus would provide further 
evidence towards the role of the regulation of this gene and its effect on the essentiality of 
YycFG. In addition, placing scaD under the control of the IPTG-inducible Pspac promoter, 
which was not possible during this study, would establish whether or not scaD itself is 
essential in S. aureus. 
As PcsB and ScaD are homologues, it could be speculated that they may have similar roles 
in the cell physiology. It has been demonstrated that severe depletion and inactivation of 
PcsB resulted in aberrant cell shapes and irregular septum formation, indicating an 
important role in cell wall biosynthesis (Ng et al. 2004; Giefing et al. 2008). 
Underexpression also led to the formation of long chains of cells, a phenotype commonly 
associated with strains deficient in cell wall hydrolase activity (De Las Rivas et at. 2002; 
Carballido-L6pez et al. 2006; Priyadarshini et al. 2007; Mesnage et al. 2008). 
The role of PcsB in cell wall dynamics is further supported in studies in S. agalactfae 
(GBS). Mutants lacking pcsB exhibited dramatically reduced growth rates compared to 
wild-type strains, and grew in irregular clumps with severely disturbed morphology 
(Reinscheid et al. 2001). Unequal septa formed in different planes without subsequent cell 
wall separation, leading to giant and irregular-shaped cells. These results indicated that 
PcsB is required for cell division in GBS, either responsible for placement of the septum at 
the midpoint of the cell or involved in splitting of the septum. Disruption of pcsB was also 
associated with an increased susceptibility to ß-lactam antibiotics, possibly due to increased 
uptake via a defective cell wall (Reinscheid et al. 2001,2003). A similar function has been 
assigned to scaD, which has been demonstrated to be associated with resistance to 
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macrolide-lincosamide-streptogramin B (MLSB) antibiotics (Martin et al. 2002), indicating 
a putative role in cell wall biosynthesis. 
Although overproduction of ScaD in strains depleted for yycFG complemented its 
essentiality and allowed growth, the rate of growth of this strain was reduced when 
compared to the control strain containing only the plasmid with no scaD insert. This 
suggests that although ScaD may provide a vital role within the cell, unregulated expression 
of this autolysin may also be detrimental. To further determine this effect, ScaD was 
overproduced in wild-type S. aureus SH1000. Growth experiments revealed a markedly 
lower growth rate of cells overproducing ScaD compared to cells containing just the control 
plasmid. This reduced growth rate was most prominent when CFUs were measured rather 
than optical density, suggesting that whilst cells may not have been viable, they did not 
necessarily lyse. Interestingly, cells depleted for YycG/YycF, which would also be depleted 
for ScaD, were shown to die without lysis (Dubrac et al. 2007). 
To determine the effect of ScaD overproduction on cell autolysis, strains were lysed using 
Triton X-100 and followed spectrophotometrically over time. Results demonstrated that the 
strain overproducing ScaD was more resistant to this lysis. This is again in contrast to 
previous studies, in which yycFG depletion (and hence reduction of scaD) led to increased 
resistance to lysostaphin-induced lysis (Dubrac et al. 2007). Although the specific role of 
scaD is unknown, it could be speculated that it is tightly regulated within the cell and that 
disruption of levels of the enzyme, whether increased or reduced, may lead to defective cell 
wall synthesis and hence result in the phenotypes seen here. Uncontrolled cell wall 
hydrolysis activity may lead to excessive breakage of bonds within the peptidoglycan, 
ultimately causing cell lysis (Chauhan et at 2006). Structural muropeptide analysis of the 
cell wall in strains with varying levels of ScaD may further elucidate the function of this 
enzyme in the dynamics of the peptidoglycan. 
Another possible explanation for the observed effects is that overproduction of ScaD affects 
production of other autolysins, disrupting the autolytic profile. When whole cell lysates of 
strains overproducing ScaD and control strains were analysed by zymography, it was 
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observed that the levels of AtRA were slightly reduced when ScaD was overproduced. The 
reason for this effect is not known, however, it could be speculated that excess ScaD 
enzyme bound to the cell wall may mean that less AtIA is able to do so. Alternatively, 
excess hydrolysis of peptidoglycan by ScaD may lead to the down-regulation of other 
autolysins. Indeed, it is speculated that a regulatory mechanism exists which down- 
regulates expression of autolysin genes when cell wall synthesis is disturbed (Antignac et 
al. 2007). Therefore, disruption of cell wall synthesis by excess ScaD enzyme may also 
have resulted in down-regulation of other autolysins, including AtIA, exacerbating the 
effect. At1A is the major autolysin of S. aureus and is involved in cell separation (Foster, 
1995; Biswas et al. 2006). This enzyme is also controlled by YycG/YycF, therefore, 
depletion of the two-component regulator in experiments by Dubrac et al. (2007) would 
also result in reduction of AtIA. The similarities of the observed phenotypes when ScaD is 
overproduced may hence be accounted for by the indirect effect on levels of AtIA. 
Cells overproducing ScaD were analysed by transmission electron microscopy and, whilst 
wild-type and control strains displayed cells of regular size and shape, with evenly placed 
septa, cells containing excess ScaD had misplaced septa leading to asymmetrical cell 
division. This phenotype has been seen previously, for example, E. coli lacking the 
amidases AmiA, AmiB and AmiC produced abnormal septa, indicating a role for these 
enzymes in the correct orientation of septa during cell division (Priyadarshini et al. 2007). 
The B. subtilis endopeptidase LytE has also been proposed to function in digesting 
peptidoglycan from the division septum to allow separation of cells, as strains lacking this 
enzyme were irregular in shape and formed long chains (Carballido-Lopez et al. 2006). 
Along with YvcE (CwIO), this endopeptidase activity is an essential function in B. subtills 
as no viable mutants could be obtained lacking both these autolysins (Bisicchia et al. 2007). 
In Mycobacterium tuberculosis, overproduction of the cell wall hydrolase Rv2719c led to 
reduced growth with severe clumping and cell lysis (Chauhan et al. 2006). Overproduction 
of Rv2719c also disrupted the assembly of FtsZ-rings, indicating a role in cell division. It 
was proposed that this murein hydrolase is needed for cell wall remodelling during active 
growth of mycobacteria and may have a specific role following stressful growth conditions. 
Furthermore, ScaA (SleI) of S. aureus, which shares 30% identity with ScaD, including 
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51% identity within the C-terminal CHAP domains, has been shown to be involved in cell 
separation after division (Kajimura et al. 2005). The homology of ScaA and ScaD may 
suggest that these proteins have similar functions in the cell. 
The observed effect on cell division may explain the inability to inactivate the 
chromosomal scaD in a strain overproducing ScaD via the plasmid pDComp. It was 
hypothesised that if scaD was constitutively transcribed via the Ppcn promoter in the 
plasmid pDComp, then the genomic copy of the gene may be inactivated, which was not 
possible by conventional mutagenesis. However, this could not be achieved during this 
study, which may be explained by the defective phenotype caused by overproduction of 
ScaD. As mentioned previously, the defects caused by overproduction of the protein are 
comparable to that seen in several studies where amidases were inactivated, suggesting that 
the uncontrolled expression of scaD is as hazardous to the cell as underexpression. 
Whilst the true role of scaD remains to be determined, it can be speculated that the function 
of this likely amidase is most likely implicated in the division and separation of cells, and 
in the biosynthesis of the cell wall. Further studies are required, including placing scaD 
under the control of an inducible promoter, to fully establish the role of this putatively 
important amidase. Analysis of the effects of levels of ScaD in an atM mutant would also 
resolve the question of whether any of the observed effects are due to indirect influence on 
the amounts of the major staphylococcal autolysin. 
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Chapter 5- Summary 
" ScaD is an Tonically bound cell wall protein produced early during logarithmic 
growth. 
" Expression of scaD is controlled by the essential two-component system 
YycF/YycG; depletion of this regulator leads to a decrease of ScaD. 
" The essentiality of YycF/YycG can be complemented by overproducing ScaD in a 
conditional yycFG mutant. 
" Overproduction of ScaD in S. aureus SH1000 resulted in a growth defect with 
asymmetical septum formation during cell division. 
" Cells overproducing ScaD demonstrated increased resistance to cell lysis. 
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Chapter 6 
General Discussion 
6.1 Vaccines against opportunistic pathogens 
Gram-positive pathogens cause significant morbidity and mortality world-wide, and are 
common causes of nosocomial disease, which constitute a significant economic burden 
due to increased costs of hospital care. In particular, patients undergoing surgery, 
immunocompromised individuals and the elderly represent key groups at risk of 
nosocomial infections. In Europe and the USA, 5-10% of patients develop infections 
during their hospital stay, and this rises to almost 50% in critically ill patients in intensive 
care units (Datamonitor, 2008). Therefore, development of vaccines to target these 
pathogens is highly desirable in order to reduce incidence of disease and associated 
healthcare costs. In particular, the potential emergence of strains of S. aureus which are 
resistant to all available antibiotics poses a serious threat, prompting the need for novel 
prophylactic and therapeutic measures. 
Immunological approaches based on vaccination or the use of prophylactic/therapeutic 
monoclonal antibodies are attractive alternatives to antibiotics. Current approaches for S. 
aureus have targeted specific antigens. For example, Aurexis0 (tefibazumab) consists of 
a humanised monoclonal antibody (MAb) that recognises the S. aureus MSCRAMM 
CIfA (Patti, 2004). This MAb was protective in animal models of S. aureus infection and 
was well-tolerated and effective in human trials (Domanski et at 2005; Weems et at 
2006). StaphVAXTM (Nabi) is a bivalent polysaccharide and protein-conjugated vaccine, 
directed against the two most prevalent S. aureus capsular polysaccharides, types 5 and 8 
(Jones, 2002). However, despite a significant decrease in S. aureus bacteraemia in the 
first 10 months after vaccination during phase III clinical trials, StaphVAXTM failed to 
elicit significant protection after one year (Fattom et at 2004). Aurograb® (NeuTec 
Pharma) is a recombinant antibody preparation against peptides based on the ATP 
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binding subunit of an ABC transporter associated with strains of MRSA (Burnie et at. 
2000). Antibodies were shown to reduce bacterial counts in mouse organs and further 
development of this prophylaxis by NeuTec Pharma is ongoing. It is proposed that this 
immunotherapeutic approach may be used in combination with vancomycin antibiotic 
therapy against MRSA infections (NeuTec Phan-na). 
In streptococci, prophylactic approaches primarily target the surface-located M protein 
(Fischetti, 1989; McMillan et al. 2004b). Whilst antibodies against the amino terminus of 
this protein have been both opsonic and protective, vaccines based on M proteins are 
hindered by the high antigenic variability, with over 100 emm-types reported (McMillan 
et al. 2004b). In order to circumvent these difficulties, vaccines have been developed 
which consist of several M protein serotypes. For example, a 7-valent conjugative 
vaccine (PVC-7), known as Prevnar, is currently in use in the USA and Europe to combat 
S. pneumoniae infections (Leibovitz, 2008). Although this vaccine has proved effective in 
reducing the incidence of invasive pneumococcal diseases, acute otitis media, 
community-acquired respiratory infections and nasopharyngeal colonisation, an increase 
in replacement serotypes of this pathogen has also occurred, creating concerns regarding 
the development of replacement disease against which Prevnar would be ineffective 
(McGee, 2007; Leibovitz, 2008). 
The ideal vaccine would induce antibodies to prevent the key stages in the bacterial 
infective process, including inhibiting bacterial adherence, promoting opsonophagocytic 
killing by leukocytes and neutralising the toxic exoproteins produced by the pathogen 
(Lee and Pier, 1997). Due to the complexity of staphylococcal and streptococcal 
infections and the multitude of virulence determinants produced by these organisms, a 
single-component vaccine, such as those described above, is unlikely to be effective. 
Incorporation of several peptises into a multi-v4lenl: vaccine can confer higher levels of 
protection and may also protect against mu! ljplo stns or specjQs (McMillan et al. 
2004a). 
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A single vaccine against a pathogen may provide significant benefits to those at risk. 
However, these benefits must also be commercially viable. Whilst a vaccine against S. 
aureus would be considered highly valuable for people undergoing dialysis or surgery, its 
use could be limited by effective alternative infection prevention methods, such as hand 
hygiene and patient screening. Therefore, a vaccine protective against several pathogens 
would have greater potential in a wider range of patient groups. Indeed, a single vaccine 
against S. epidermidis would be of limited use but could prove valuable for patients with 
prosthetic implants if combined with a S. aureus antigen (Datamonitor, 2008). Moreover, 
a vaccine targeted against several virulence components would be less likely to induce 
resistant strains, such as those observed during vaccination with the PCV-7 (Prevnar) 
(McGee, 2007; Leibovitz, 2008). 
Peptide based vaccines have the advantage of being able to choose minimal sequences 
necessary to generate an immune response, and peptides may be linked to carrier 
molecules to increase this immunogenicity (McMillan et al. 2004a). In my current study, 
putative immunogenic protein domains were identified which were cross-reactive 
between five pathogenic species, S. aureus, S. epidermidis, S. pneumoniae, S. agalactiae 
and S. pyogenes. Thirteen families of conserved domains were identified and alignment 
of these regions led to the identification of three domains which were particularly highly 
conserved within these species, IsdA-c (amino acids 215-310), SdrD-n (amino acids 30- 
200) and ScaB-c (amino acids 156-265). Further analysis demonstrated that antibodies 
against these domains were opsonic during infection by S. aureus and S. agalactiae, and 
that IsdA C-terminus polypeptide showed promise in protecting against infection by these 
pathogens in a mouse model of septic arthritis. 
SdrD is structurally related to C1fA, which has also been demonstrated to provide 
effective passive protection (Aurexis®) (Patti, 2004). Antibodies against full-length SdrD 
have also been identified previously to mediate complement-dependent phagocytosis of 
S. aureus (Stranger-Jones et al. 2006). Whilst IsdA is not essential for S aureus growth, 
its requirement for nasal colonisation is a predisposing factor for nosocomial infections, 
making it a suitable target for prophylactic development (Garcia-Zara et al. 2005; Clarke 
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et al. 2006). Furthermore, IsdA is associated with S. aureus infection and confers 
resistance to hydrophobic fatty acids, antimicrobial peptides of the host cell, thereby 
promoting survival of S. aureus on human skin (Clarke et at 2006; 2007). ScaB is a 
novel protein identified during this immunoscreen, which is part of a large family of 
surface proteins in staphylococci (Pourmand et at 2006). The conserved CHAP domain 
of this protein is also found in several species, including Streptococcus, Enterococcus, 
Lactococcus and Bacillus species (Rigden et al. 2003; Pourmand et al. 2006). Targeting 
the specific domains within these proteins which are antigenic and cross-reactive 
provides the opportunity to develop a specific vaccine which incorporates several 
antigenic polypeptides, thereby providing effective protection against this family of 
pathogens. Identification of further immunogenic targets within these Gram-positive 
pathogens may permit the development of an effective multi-valent vaccine which could 
successfully contribute to the decrease in incidence of disease. 
6.2 An essential autolysin in S. aureus? 
Peptidoglycan hydrolases represent a vast and diverse group of enzymes which are 
involved in some of the key processes of bacterial physiology, including cell separation 
during division. The importance of these enzymes in maintaining growth and physiology 
is highlighted by the defects seen when key peptidoglycan hydrolases are inactivated. For 
example, inactivation of pcsB in S. pneumoniae resulted in severely defective growth 
with disrupted cell morphology and aberrant septum formation, indicating that this 
enzyme plays a crucial role during pneumococcal growth and division (Giefing et al. 
2008). The key contribution of peptidoglycan hydrolases to bacterial survival is also 
highlighted by the functional redundancy of this group of enzymes. A process may be 
performed by several enzymes, and individual enzymes may be involved in numerous 
processes (Smith et al. 2000). This ensures that hydrolytic activity occurs when needed 
under all circumstances and conditions, and may provide a means of adapting to the 
various environments encountered by the bacteria during infection by being able to 
modify the peptidoglycan. 
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Whilst the importance of autolysins is evident, to date no single enzyme has been found 
to be essential. In B. subtilis, endopeptidase activity carried out by LytE and YvcE 
(CwIO) was demonstrated to be essential for lateral cell wall synthesis and cell 
elongation during growth (Bisicchia et al. 2007). This requirement may be attributed to 
the "three-for-one" mechanism of cell wall synthesis, in which transpeptidases and 
transglycosylases synthesise new bonds, and endopeptidase and lytic transglycosylase 
autolysins degrade the original strand (HÖltje, 1998). 
Gene products that are essential for cell growth under all conditions are primary targets 
for antimicrobial therapy because their inhibition would be fatal for the cell (Garcia-Lara 
et al. 2005). In particular, surface proteins represent promising vaccine targets as they 
have key roles in the interaction between pathogen and host cells. The identification of a 
cell wall-associated peptidoglycan hydrolase enzyme which was essential for viability 
would represent a promising candidate for prophylaxis due to its surface location and 
requirement for survival of the pathogen. Although not essential for viability, several 
important autolysins have been identified which are immunogenic during infection and 
represent putative vaccine targets, for example, PcsB of S. pneumoniae (Giefing et at 
2008), IsaA and SceD of S. aureus (Stapleton et al. 2007) and AtIE of S. epidermidis 
(Pourmand et al. 2006). 
Enzymes involved in peptidoglycan structural dynamics have previously been 
demonstrated to be essential for growth of S. aureus, for example, MurB, a UDP-N- 
acetylenolpyruvylglucosamine reductase which acts early during peptidoglycan 
biosynthesis (Matsuo et al. 2003). Several effective antibiotics have targeted 
peptidoglycan biosynthesis (e. g. glycopeptides, ß-lactams, phosphomycin), hence the 
essentiality of MurB during cell wall synthesis suggests it could be a suitable new target 
for drug development (Garcia-Lara et al. 2005). 
The use of a peptidoglycan hydrolase as a therapeutic agent against S. aureus infection 
has been demonstrated with the endopeptidase lysostaphin, which cleaves the cross- 
linking pentaglycine bridges in the cell walls of staphylococci. Application of lysostaphin 
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formulated in a cream was effective in eradicating S. aurcus nasal colonisation in a cotton 
rat model (Kokai-Kun et al. 2003). Furthermore, lysostaphin successfully treated aortic 
valve endocarditis in a rabbit model of infection (Climo et al 1998; Patron et al. 1999). 
In addition, phage-encoded peptidoglycan hydrolases, including the muramidase Cpl-1 
and the amidase Pal, have demonstrated effective treatment of S. pneumoniae infection, 
protecting mice from bacteraemia and death (Jado et al. 2003; Loeffler et al. 2003). 
Intraperitoneal therapy with the pneumococcal autolysin LytA was also shown be an 
effective treatment in reducing (3-lactam-resistant S. pneumoniae infection in a mouse 
peritonitis-sepsis model, suggesting a novel putative treatment regimen for antibiotic- 
resistant pathogens (Rodriguez-Cerrato et al, 2007). 
As the key roles of peptidoglycan hydrolases are further elucidated, it could be speculated 
that amongst this important group of enzymes there may indeed be one without which the 
bacteria cannot survive. As autolysins are involved in the fundamental processes of cell 
growth, their contribution to bacterial survival and pathogenicity is considerable. 
Aberrant cell separation due to lack of specific autolytic activity may result in impaired 
dissemination in the host and thus reduced virulence (Stapleton et al. 2007). However, 
whether a single essential autolysin does in fact exist in S. aureus, or any other species, 
remains to be determined. 
6.3 Future work 
The three conserved domains identified by immunoscreening displayed potential as 
immunogenic targets. Further work to determine their use is required, including 
assessment of the opsonophagocytic abilities of antiserum against each polypeptide in 
several bacteria. Protection studies using multiple proteins would also determine the 
protective capacity of these components in a multi-valent vaccine. Finally, identification 
of additional domains or proteins which may be immunogenic in the species studied 
through further screening would provide additional putative components for a vaccine 
targeted against a range of Gram-positive pathogens. 
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In order to establish the essential nature of ScaD, it is necessary to complete the 
mutagenesis attempted during this study, placing the scaD gene under the control of an 
inducible promoter. Once this is achieved, work to further elucidate the role of this 
peptidoglycan hydrolase is possible, including phenotypic analysis of strains depleted for 
ScaD. 
Further work to determine the overlapping functions of the Sca family of autolysins is 
required, including expression studies to confirm the conditions under which each gene is 
optimally expressed. Solubilisation of the recombinant proteins would allow more 
detailed analysis of the activity of these enzymes. 
As S. aureus is an opportunistic and ubiquitous pathogen carried either continuously or 
intermittently by up to 80% of the population (Foster, 2004), levels of antibodies against 
this pathogen are likely to be high. Therefore, it could be speculated that high levels of 
antibodies may not necessarily be protective. Indeed, despite inducing high levels of 
antibodies in patients after immunisation, against the two most common capsular 
polysaccharides of S. aureus, the vaccine StaphVAXTM (Nabi) failed to significantly 
protect against S. aureus bacteraemia (Fattom et al. 2004). Therefore, it may not be 
feasible to develop a vaccine in this manner, or it may be necessary to target very specific 
components in order to induce an effective level of protection. The organism itself does 
not want the host to develop an immune response, therefore, key proteins involved in 
virulence may not be immunogenic. This may give reason for the lack of reactivity seen 
for ScaD, as this protein failed to bind antibodies in human serum and displayed a 
relative lack of reactivity during rabbit immunisation. It could be speculated that 
monoclonal antibodies against ScaD may be more effective and ý further work to 
determine this is required. My study has identified putative vaccine components and 
further insight may lead to the rational development of immunogenic approaches for the 
control of S. aureus and other important human pathogens. 
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Appendix 
Appendix 
S aureus 
antigen 
Species Homologous 
proteins 
% 
identity 
% 
similarity 
Homologous 
protein (aa 
length) 
Region of 
S. aureus 
protein with 
homology (an 
length) 
SA0609 S. e idermidis SE0750 25 47 43-238 (195) 45-204 159 
SdrD ATCC 12228 27 45 35-159 124 70-184 114 
27 47 676-723 (47) 637-683 (46) 
33 48 1137-1163 26 715-741 26 
29 45 1118-1163 45 915-962 47 
SE0245 29 48 1-190(190) 16-199 183 
21 43 130-354 224 45-274 229 
25 45 96-259 163 27-204 177 
35 54 618-654 (36) 959-992 (33) 
31 45 304-335 (31) 698-732 (34) 
SE0331 60 74 601-825 (224) 902-1123 (221) 
27 44 54-1025 (971) 47-1039 (992) 
30 58 1-203(203) 1-201(201) 
SE0185 28 46 4-185(181) 17-185 168 
36 48 187-226 39 1024-1062 38 
SE2319 25 41 9-82 73 36-108(72) 
37 54 34-69(35) 685-721 (36) 
S. neumoniae SP 0648 23 47 7-171(164) 18-196 (178) 
TIGR4 32 52 672-708 (36) 390-429 39 
30 44 676-718 (42) 542-580 (38) 
20 46 1879-1917 38 1044-1082 38 
50 62 963-978 (15) 187-202(l 5 
46 61 252-264 12 451-463 14 
SP 1174 21 41 232-312 (80) 46-126(80) 
SP 2190 22 41 330-474 144 49-184 131 
33 46 628-672 (44) 986-1028 (42) 
43 68 627-642 15 875-890 15 
SP 2216 23 43 7-184(177) 33-204 171 
30 51 348-388 (40) 528-570 (42) 
S. a alactiae GBS0016 21 44 15-182 167 29.198 169 
NEM316 GBS 1529 21 42 134-597 463 60-521 460 
45 46 1259-1278 19 975-994(12) 
S. o eves SP1937 23 47 88-179(91) 58-150(92) 
MGAS8232 44 55 420-437 (17) 1009-1026 (17) 
SA0856 S. epidermidis SE0750 26 45 3-199 (196) 12.204 192 
(CIfA) ATCC 12228 26 42 849-996 147 173-321 148 
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SE0245 28 44 1-114(114) 3-102(99) 
26 37 158-202 (44) 163-207 (44) 
28 44 589-638 (49) 229-270 (41) 
SE0331 28 44 225-597 (372) 163-542 (379) 
38 54 1003-1055 52 881-932 51 
SE0185 27 44 3-110(107) 2-105 103 
S. newnoniae SP 0057 33 51 1111-1137 26 186-211 25 
TIGR4 SP 2190 43 60 669-691 (22) 498-518 20 
37 44 81-109(28) 256-284 (28) 
S. agalactiae GBS0016 23 42 70-215 145 29-178 147 
NEM316 GBS1356 26 42 461-521 (60) 393-459 66 
28 44 777-812 (35) 256-293 (37) 
25 50 1297-1328 31 416-447 31 
27 48 690-724 (34) 276-304 (28) 
30 46 623-659 (36) 373-411 38 
GBS1529 25 46 319-597 278 229-491 262 
SA2511 S. e idermidis SE0331 46 62 1011-1053 (42) 976-1017 41 
FnbA ATCC 12228 33 45 729-790 (61) 28-93(65) 
40 54 42-63(21) 842-862 (20) 
S. pneumoniae SP 0648 30 59 2176-2221 (45) 961-1007 (46) 
TIGR4 22 43 1805-1919 
(114) 
196-310 (114) 
21 43 1826-1902 (76) 605-678 (73) 
22 51 1812-1856 (44) 823-867 (44) 
SP_0057 26 43 1021-1162 
(141) 
151-300 (149) 
30 50 1263-1312 (49) 964.1015 51 
50 61 958-975 17 521-538 17 
SP 2190 24 41 565-693 128 344-463 119 
30 44 239-286 (47) 146-194 48 
S. p yo genes SP1937 25 50 196-257 (61) 405-464 59 
MGAS8232 32 58 481-510 29 714-744 (30) 
SA2150 S. e idermidis SE0750 27 48 1092-1124 (32) 1076-1108 (32) 
SasB/FmtB ATCC 12228 27 41 531-580 (49) 1823.1872 49 
22 42 26-243 217 1301.1524 223 
25 44 28-183 155 1631-1801 170 
22 43 24-211 (187) 488-664176 
32 50 1091-1139 (48) 887-936 (49) 
30 41 934-986 (52) 1346-1396 50 
27 37 608-705 (97) 2261-2360 99 
26 56 191-220 29 2141-2170 29 
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SE0245 23 42 31-216 (175) 1565-1747 182 
25 45 44-177 133 909-1030 121 
23 43 50-249 199 1302-1516 214 
29 48 148-346 198 1849-2047 198 
SE0185 27 41 165-245 (80) 2243-2326 (83) 
25 44 42-183 141 1301-1452 151 
30 50 96-134(38) 2142-2181 (39) 
25 45 442-510 (68) 1604-1682 (78) 
SE0331 25 40 314-562 (248) 205-468 (263) 
21 41 49-242 193 1349-1539 190 
24 46 146-271 (125) 2240-2358 (118)- 
26 41 395-447 (52) 902-954 (45) 
23 45 67-173 106 1910-2030 120 
22 41 15-125 110 1911-2015 104 
47 70 786-802 (16) 1242-1258 (16)- 
31 48 779-807 (28) 1342-1370 (28) 
26 51 984-1031 (47) 1912-1960 48 
39 51 737-769 32 271.302 31 
S. pneumoniae SP 0648 30 47 58-148(90) 710-795 (85) 
TIGR4 22 46 1230-1382 
(152) 
1788-1940 (152) 
25 47 67-175 108 806-919 113 
25 41 47-174 127 1161.1302 141 
21 41 54-180 126 1462-1591 (129) 
32 46 524-583 (59) 1240-1299 59 
27 48 464-506 (42) 562-602 (40) 
26 41 335-436 101 273-373 100 
27 50 98-156(58) 1591.1650 59 
28 42 274-325 51 1192.1242 50 
29 50 471-512 41 1358-1400 42 
40 59 1820-1841 21 1183.1201 21 
29 44 297-371 (74) 204-264 (60) 
42 57 2169-2195 (26) 1289-1316 27 
22 50 2145-2199 (54) 1437-1494 57 
32 44 1559-1592 33 2059.2092 33 
23 45 2068-2118 50 1981-2031 50 
SP 0057 25 40 73-309 (236) 2240-2459 219 
25 43 548-664 116 1308-1424 116 
27 45 975-1131 (156) 539-695 156 
22 46 549-658 109 1770-1884 114 
30 44 550-658 (108) 1921.2037 116 
23 41 40-250 (210) 1325.1531 206 
23 44 96-270 174 1607.1781 174 
27 45 56-193 (137) 1657.1799 142 
25 41 120-312 192 1607-1801 (194) 
28 53 585-639 (54) 1190-1243 53 
21 43 43-207 164 577-731 154 
28 50 104-181 (77) 785.860 75 
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24 42 43-160 117 909-1027 118 
27 45 546-639 (93) 917-1012 95 
23 47 539-634 95 1631-1732 101 
27 50 270-337 (67) 897-960 (63) 
32 52 602-663 61 1597-1665 68 
38 53 1143-1168 (25) 2274-2299 25 
28 46 1217-1266 (49) 1334-1381 (47) 
27 37 154-193 39 1069-1108 39 
34 60 128-150 (22) 1140-1162 (22) 
SP 2216 25 42 13-241 (228) 509-746 (237) 
23 42 11-225 (214) 797-1025 (228) 
22 42 36-234 198 1673-1873 (200) 
SP 2190 24 43 243-438 195 1596-1791 (195) 
23 41 396-494 98 1596-1697 (99) 
28 42 466-528 (62) 1604-1666 (62) 
SP 1282 25 42 200-345 (145) 1750-1884 (134) 
S. agalactiae GBS0016 21 41 19-277 258 1271-1528 257 
NEM316 22 45 19-154 (135) 1932-2069 (137) 
GBS1356 35 60 1413-1440 27 1903-1930 (27) 
29 62 1524-1558 (34) 828-864 (36) 
28 50 1563-1594 31 2140-2171 (31) 
25 37 659-745 (86) 2278-2362 84 
31 46 785-825 40 1203-1240 37 
Sc B 25 44 1029-1119 (90) 2240-2339 (99) 
23 42 18-160 142 1373-1505 132 
39 60 592-619 (27) 2150-2177 (27) 
GBS1529 22 44 118-370 252 433-680 247 
35 60 48-67(19) 1447-1466 19 
S. o eves SP1937 24 48 32-127(95) 936-1030 94 
MGAS8232 28 48 68-131(63) 2298-2361 (63) 
541806 S. epidermidis SE0750 23 43 35-287 252 1609-1842 (233) 
SasC/FmtB ATCC 12228 24 44 41-209 168 1101-1263 162 
6omolo ue 22 42 1111-1210 99 1985-2086 101 
29 49 532-580 (48) 1903.1952 (49) 
29 54 1107-1142 35 1339-1375 36 
23 42 759-822 (63) 1088-1149 (61) 
SE0245 22 41 95-344 (249) 1522-1782 260 
28 42 295-346 (51) 1094-1150 (56) 
27 45 503-542 (39) 1405-1442 (37) 
37 58 688-710 (22) 320-343 23 
SE0185 25 41 96-142(76) 38-117(79) 
31 60 469-508 (39) 820-864 (44) 
40 63 486-507 (21) 1121-1142 (21) 
37 66 470-496 26 1451.1476 (25), 
SE0331 23 41 70-196 126 1139.1264 125 
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26 40 85-172 87 33-122 (89) 
24 54 1001-1033 (32) 276-308 (32) 
26 45 445-482 37 317-358 41 
S. pneumoniae SP 0648 21 44 2079-2213 
(134) 
1134-1260 (126) 
TIGR4 21 43 71-156(85) 1796-1882 86 
21 41 295-387 92 1076-1171 (95)- 
21 52 85-145(60) 1191.125564 
41 76 859-875 16 680-696 16 
SP 0057 24 48 548-638 (90) 1522-1609 87 
24 43 1116-1251 
(135) 
557-701 (144) 
24 44 530-628 98 1622-1717 (95) 
33 71 35-55(20) 250-270 (20) 
21 41 499-621 (122) 714-841 (127) 
25 40 1008-1080 72 1127-1197 70 
31 63 135-156 21 1284-1305 21 
SP 2216 25 47 25-276 (251) 1661-1916 255 
26 40 39-245 (206) 1339-1550 211 
SP 2190 21 41 104-353 (249) 675-917 242 
S. a alactiae GBS0016 24 42 39-301 (262) 1569-1827 258 
NEM316 24 41 45-322 (277) 1734-2005 (271) 
22 41 46-315 (269) 1400-1667 267 
GBS1356 26 42 108-245 137 776-909_(133) 
25 42 792-913 121 435-561 126 
26 40 177-319 142 733-861 128 
22 46 273-383 (110) 1580-1695 118 
23 43 792-855 63 1668-173263 
30 50 1125-1166 41 1178.1219 41 
GBS1529 24 45 198-283 85 29412_J83) 
35 57 1269-1310 41 2146-2185 39 
23 50 706-810 (104) 20-126 106 
22 46 1094-1198 
101 
20-126 (106) 
23 45 838-942 (106) 20-126 (106) 
22 48 934-1042 108 20.126 106 
24 41 453-643 190 348-533 185 
22 51 115-193 (78) 48-126(78) 
28 48 447-481 34 1120-1154# 3.1 
28 43 54-137(83) 393468(75) 
SA2668 S. e idermidis SE0750 23 42 11-240 (229) 19-246 (227) 
(SasF) ATCC 12228 SE0331 27 51 605-633 (28) 440-468 28 
S. pneumonlae SP 0648 21 46 21.196 175 16-1 t; 6 170 
TIGR4 26 41 2034-2153 205-3201115) 
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(119) 
S. o enes SP 1937 25 40 50-174 124 86-223 137 
MGAS8232 
SA2676 S. epidermidis SE0185 29 49 35-88(53) 1350-1406 56 
SasA AT-CC 12228 27 48 497-549 (52) 580-629 49 
SE0750 21 46 55-310 (255) 1326-1582 256 
30 45 41-192 151 81-226 145 
21 43 145-326 181 97.270 200 
SE0245 22 41 106-241 (135) 85-215 130 
23 51 272-346 74 83-162(79) 
26 40 282-371 (91) 521-613 (92) 
57 64 504-517 13 2200-2213 (13) 
S. pneumoniae SP 0057 21 43 1111-1311 
(200) 
2062-2249 (187) 
TIGR4 25 40 22-117(95) 63-154(91) 
26 43 28-117(89) 116-216 100 
25 48 31-117(86) 733-828 (95) 
36 50 682-716 34 254-289 35 
22 49 34-117(83) 1320-1406 86 
24 41 270-339 69 492-563 (71) 
22 41 52-117(65) 1464.153066 
25 45 236-275 (39) 1014-1053 (39) 
38 77 1109.1126 17 1038-1055 17 
29 51 236-266 30 253-283 (30) 
S. agalactiae GBS1356 25 43 533-607 74 1507-1585 78 
NEM316 GBS1529 32 54 638-697 59 684-743 (59) 
25 47 113-190 77 490-568 78 
25 53 139-199 (60) 686-749 63 
30 49 500-550 50 688-740 52 
SA1138 S. e idermidis SE0185 28 52 62-113(41) 564-616 42 
Sas l/lsdB ATCC 12228 SE0750 21 45 39-213 (174) 445-622 177 
S E0245 21 41 2-418(416) 6-423(417) 
SE2272 21 51 650-682 32 587.619 32 
32 48 22-96(74) 225-300 (75) 
36 57 230-262 32 387-4181 31 
S. neumoniae SP 0648 34 46 1-154(154) 1.153 153 
TIGR4 40 48 805.830 15 578-604 26 
31 63 882-903 21 344-365 21 
SP 2190 33 57 145.175 20 55.87 22 
S. a alactiae 013S0016 23 46 64-183(119 492406 114 
NEM316 23 50 70-148(78) 288.363 75 
GBS1356 26 42 119-262(143) 446.597 151 
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Sc B 22 45 12-162(150) 19-159 140 
31 55 595-618 23 238-266 28 
27 51 693-721 (28) 495-523 (28)-- 
SA 1140 S. e idermidis SE0185 22 45 2-98(96) 9-100(91) 
SasE/IsdA ATCC 12228 30 50 164-205 (41) 278-316 48 
SE0750 25 48 51-150(99) 215-312 (97)-- 
34 46 123-215 92 222-305 83 
24 44 102-216 114 37-157 (120)- 
32 41 608-663 (55) 241-298 (57) 
SE0245 25 45 2-159(157) 11-163 (152)- 
34 57 178-225 (47) 259-309 (50) 
21 48 276-332 56 256-315 59 
SE0331 31 50 170-236 (66) 254-326 (72) 
35 56 985-1021 (36) 279-317 38 
S. neumoniae SP 0648 24 42 57-171 (114) 205-309 (104) 
TIGR4 SP 0057 27 42 29-94(65) 258-316 58 
S. a alactiae GBS0016 30 42 247-329(82 252-326 (74) 
NEM316 GBS1356 31 45 131-207 (76) 253-326 (73) 
S. pyogenes SP1745 29 48 1111-1184 (73) 252-352 100 
MGAS8232 23 47 341-382 41 69-110(41) 
SA2509 S. e idermidis SE0750 21 41 4-144 140 6-146 144 
FnbB ATCC 12228 SE0245 27 44 4-133(129) 2-136 134 
22 43 405-485 80 424.497 73 
SE0331 23 42 148-853 (705) 33-751 (718) 
26 50 109-218 109 30-136 106 
44 60 1011-1053 42 898-939 41 
40 54 42-63(21) 778-798 (20) 
SE0185 23 46 138-243 105 28-144(1I6) 
22 44 148-214 66 493-559 (66 
S. neumoniae SP 2216 28 54 338-371 (33) 652-6861 34 
TIGR4 25 41 60-145(85) 31-117(86) 
SP 0648 29 48 2136-2187 51 466-519(53) 
21 49 916.1040 124 22-135 113 
30 59 2176-2221 45 883.929 46 
23 53 1798.1858 60 376-436 60 
25 58 1687.1739 52 221-271 50 
25 59 801.827 26 717-743 26 
58 75 421432(it) 446-457 11 
28 56 803-827 (24) 681.705 24 
42 52 890-910 20 565.585 20 
SP 0057 27 43 8.148 140 6-146(140) 
27 48 1097-1125(281 331-359f28) 
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SP 1174 26 45 685-793 (108) 28-144 (116) 
SP 2190 25 43 386-480 94 33-120(87) 
21 41 298-390 (92) 49-142 (93) 
S. agalactiae GBS1356 35 48 616-716 100 772-869 97 
NEM316 21 45 111-256 145 45-189(l44)_ 
Sc B 28 44 24-117 93 50-140(90) 
33 48 476-520 44 316-355 39 
GBS0016 26 42 240-322 82 34-117 83 
23 41 138-227 89 33-119 86 
30 51 397-428 31 654-686 32 
39 57 277-309 32 341-370 29 
GBS1529 23 45 1188-1281 (93) 16-110(94) 
21 44 809-908 (99) 35-135 100 
SA2418 S. neumoniae SP 0648 25 46 43-157 114 198-304 106 
SBI TIGR4 28 53 2042-2073 31 353-384 (31) 
SP 0057 21 41 755-862 107 274-386 112 
28 43 532-628 (96) 159-239 80 
27 60 552-581 (29) 233-265 32 
30 53 258-283 (25) 105-130 25 
SP 1174 30 53 688-767 79 243-316 73 
28 47 670-761 (91) 202-290 88 
29 49 456-525 (69) 162-233 (71) 
SP 1282 22 43 221-343 122 111-235 124 
S. a alactiae GBS0016 26 51 125-218 93 212-305 93 
NEM316 
S. o eves SP1937 26 40 88-173 (85) 147-230 83 
MGAS8232 
SA1781 S. e idermidis SE0185 25 47 48-149 (101) 278-365 87 
SasI ATCC 12228 29 52 191-245 (54) 278-331 (53) 
21 46 129-175 46 656-702 (46) 
SE0750 25 42 158-247 (89) 656-738 82 
SE0245 25 47 243-305 (62) 643-701 (58) 
21 44 145-222 77 282.363 81 
SE0331 30 53 606-644 38 591-628 37 
32 48 87-161(74) 652-721 (69) 
22 52 971.1017 46 285-334 49 
31 43 378-409 31 139-170 31 
23 47 147-237 (90) 277.358 81 
27 46 60-111(51) 284.335 51 
23 48 247-310 (63) 288-348 (60) 
S, pneumoniae SP 0648 23 45 1823.1956 
133 
288422 (1361) 
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TIGR4 30 52 1795-1864 (69) 679-743 64 
33 44 2188-2232 44 850-893 43 
27 50 1458-1493 35 435470(35) 
S. o eves SP1937 29 43 25-106(81) 681-763 (82) 
MGAS8232 33 51 78-132(54) 278-336 58 
SA2666 S. epidermidis SE0750 28 48 1185-1328 
(143) 
326-482 (156) 
ATCC 12228 46 57 688-715 (27) 179-204 (25) 
SE2319 26 44 55-323 (268) 338-616 (278) 
SE0433 40 55 162-265 (103) 508-616 108 
SE0331 31 47 689-827 138 376-505 (129)- 
25 45 105-216 111 234-340 (106)- 
34 53 545-570 25 111-136 25 
33 44 193-225 (32) 173-206 (33) 
S. neumoniae SP 2216 32 44 282-389 107 503-616 113 
TIGR4 27 44 1367-1449 (82) 362-439 (77) 
29 45 249-296 (47) 164-206 (42) 
26 50 1813-1866 53 384-439 55 
26 52 1678-1715 (37) 408-445 (37) 
SP 2190 30 46 141.221 80 238-307 69 
S. a alactiae GBS0016 34 47 330-444 114 497-616 119 
NEM316 24 41 26-134 108 338-445 107 
35 45 272-308 (36) 164-200 36 
GBS1306 26 44 44-137(93) 721.813 92 
S. o enes SP1937 31 47 247-532 285 . 
349-622 273 
MGAS8232 
Table A. 1: Families of cross-reactive antigens, based on sequence homologies and representation of 
each screened genome. 
